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Numerous drug-drug interactions have been reported with oral anticoagulant warfarin. 
It is subject to many drug interactions leading to serious consequences because of the 
fact that it possesses a narrow therapeutic index and its enantiomers vary in 
pharmacokinetic properties. Many reported warfarin-drug interactions come from 
isolated incidences and their underlying mechanisms are not clearly understood. Since 
there is a realistic limit to the number and scope of clinical drug interaction studies 
that can be performed due to the ethical constraints and other limitations, alternative 
approaches have to be used to verify prospectively the interaction with warfarin and 
probe its mechanism in greater depth. 
 
The first “life style” drug, Viagra® (sildenafil citrate) is consumed by millions of men 
suffering from erectile disfunction (ED). Previous studies show that sildenafil citrate 
can potentiate anticoagulant action of warfarin and also possesses inhibitory action on 
platelet aggregation. Due to the fact that ED is considered as an early sign of 
cardiovascular disease, there is need to probe the mechanism of the potential 
interactions and between warfarin and sildenafil citrate.  
 
Our present study was mainly designed to investigate the in vitro drug interaction 
between these two agents. The in vitro drug interaction study was carried out using 
both rat and human liver microsomes. Moreover, the interaction of these drugs in 
serum and liver microsomal binding was also investigated. 
 
 X
No significant interaction of warfarin and sildenafil in pooled rat serum protein 
binding was noted. However, based on concentration of warfarin and sildenafil, the 
either displacement or positive allosteric effect was observed in rat liver microsomal 
protein binding. The in vitro data indicated that sildenafil inhibits the formation of 
phenolic metabolites of both (S)-and (R)-warfarin, but its inhibitory effect is selective 
towards (R)-warfarin either in rat or human liver microsomes.  
 
Finally, based on the either in vitro metabolism data or in vivo data retrieved from the 
literature, the magnitude of drug interactions between warfarin and sildenafil was 
quantitively predicted. Overall findings of the present study suggest that the increase in 
the anticoagulant activity of warfarin in patients taking both warfarin and sildenafil 
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Cardiovascular disease (CVD) is a global leading killer of death and it is predicted to 
be the number one killer of people by 2010 [1]. The information from WHO shows 
17.5 million people died from CVD in 2005, representing 30% of all global deaths 
[2].  Moreover, the statistics based on international death rate for cardiovascular 
disease, which was revised in 2006 indicates that the death rates of CVD per 100,000 
populations in United State are 289 for men and 150 for women [3]. CVD is any of a 
number of specific diseases which affects the heart itself and/or the blood vessel 
system, especially the veins and arteries leading to and from the heart. The formation 
of thrombi and emboli in the result of the interaction between blood platelets and 




Figure 1.1. Diagram of all global death due to relating disease [2] 
 1
Anticoagulants are agents which reduce the risk for CVD and blockage of the blood 
vessels by preventing formation of blood clot in the body. Heparin which is from 
animal origin, and warfarin which is from plant origin are most widely used 
anticoagulants [4]. The chief advantage of warfarin over heparin is that warfarin can 
be given orally while heparin can be administered only parentally [4, 5].  The 
anticoagulant, dicoumarol, was introduced to the drug discovery in 1939 from the 
finding of hemorrhage in animals feeding on spoiled sweet clover. It was first utilized 
as a rat poison because of its high hemorrhaging activity in rats.  In 1948, the more 
otent synthetic compound, namely warfarin was developed at University of 
le under the brand names of Coumadin, Waran, Jantoven, Marevan [12].  
p
Wisconsin to use it for the treatment of hemorrhage disorder in man but it was not 
widely used because of the fear on its unfavorable toxicity. Warfarin was 
commercially introduced as human anticoagulant agent in 1952 and was approved by 
FDA in 1954 [4, 6, 7].  
 
Warfarin has the predictable onset and duration of action as well as the excellent 
bioavailability [8-10]. Furthermore, warfarin is available in tablet form as well as 
injection form while heparin is only available in injection form [5].  For these reasons, 
warfarin is currently the most widely used oral anticoagulant drug and it was the 57th 
most prescribed drug in USA based on data from NDC health, 2002 [11]. Warfarin is 
also availab
It is prescribed in the prophylaxis and/or treatment of acute deep vein thrombosis, 
pulmonary embolism, and venous thromboembolism associated with orthopedic or 
gynecological surgery. Additionally, it is also taken to prevent systemic embolism 
with acute myocardial infarction, prosthetic heart valves, or chronic atrial fibrillation 
[4, 6, 13].   
 2
Despite warfarin has excellent evidence for clinical application, it has very narrow 
therapeutics index and thus tight monitoring is necessary.  The most commonly 
occurred side effect of warfarin is fatal or nonfatal bleeding from tissues or organ 
[13]. The study of warfarin-related hemorrhage at Brigham and Women’s Hospital 
shows that the annual incidence of warfarin related bleeding increased by 22% 
between two time periods (January 1995 to October 1998 and November 1998 to 
August 2002) [14]. In addition, necrosis of skin and other tissues, 
hypersensitivity/allergic reactions, chest pain, fatigue, lethargy, malaise, asthenia, 
headache, dizziness, loss of consciousness, nausea, vomiting, loss of appetite, 
stomach/abdominal bloating or cramps may occur as less common side effects[13, 
15]. Therefore, warfarin should be taken under well therapeutics control which carried 
out by the measurement of the International Normalized Ratio (INR), a ratio of the 
prothrombin time in the patient to that in normal person.  PT, which is the time taken 
 clot the liquid portion of blood in the normal person is around 11~15 seconds. INR 
h included anticoagulant is 
nger in twice than that of the blood without anticoagulant (i.e., PT = 22~30 seconds 
rystalline warfarin is a white odorless powder and discolored by light. It is highly 
to
of 2 indicated that the clotting time of the blood whic
lo
[5]). But, there is significant interindividual variability in daily dose requirement. 
Hence, the dosage should be adjusted based on INR of patients [13, 16, 17].  
 
1.1.2 Physical and Chemical Properties of Warfarin 
 
C
soluble in water and alcohol but slightly soluble in chloroform and ether. It is a weak 
acidic compound and its pKa is 5.1. A single ring coumarin derivative; warfarin is 
 3
chemically named by 3-α-acetonylbenzyl-4-hydroxycoumarin and its molecular 
formula is C19H16O4 with the molecular weight of 308.34 [13] Figure 1.2.  
 
The commercially available warfarin is in the form of a racemic mixture with the 
asymmetrical carbon at position 9 which gives rise to two optical isomers, namely (R) 
- and (S)-warfarin Figure 1.3. The drug used in anticoagulation therapy composed of 
roughly equal amount of enantiomers (R)- and (S)-warfarin in the racemic mixture bu
 4
t 
e isomers are different in the anticoagulant potency, metabolism, elimination and 
e interaction with other drugs [6]. Generally, (S)-warfarin has 2 ~ 5 times more 
nticoagulant activities than (R)-warfarin but it has a more rapid clearance. Thus, the 
harmacokinetics of warfarin must be investigated in the characteristics of 
nantiomers. The injection form of sodium warfarin is also available as a sterile, 





































1.1.3. Mechanism of Action 
 
As shown in Figure 1.4, Vitamin K is the necessary participant in the formation of 
coagulation factors II (Prothrombin), factor VII (Proconvertin), factor IX 
(Antihemophilic B factor) and Factor X (Stuart factor) and naturally occurring 









Figure 1.3. Three–dimensional structures of warfarin isomers [10] 
 
 
er extension of formed thrombus and 
econdary thromboembolic complications [13]. Therapeutics doses of warfarin reduce 






reductase and vitamin K1 epoxide reductase are the essential enzymes which catalyze 
the interconversion of vitamin K1 (active form) and vitamin K1 2, 3-epoxide (inactive 
form). Reduced form of vitamin K1 is the essential cofactor in the carboxylation of 
clotting factors to its activated form. Warfarin achieves its anticoagulation activity by 
inhibiting the reductase enzyme, thereby reducing the formation of vitamin K1 
dependent coagulation factors. (Figure 1.3) Generally, warfarin has no direct effect on 
the established thrombus. But it prevents furth
s
reduced 10% to 40% of biological activity [6, 7]. After warfarin administration, it 
chieves its anticoagulation activity within 24 hours but its peak effect may be 
elayed from 72 to 96 hours. However, the anticoagulant action lasts 2 to 5 days for 















Figure 1.4 Vitamin K cycle and Inhibition by warfarin. [18] 
 
1.1.4. Pharmacodynamic of Warfarin 
 
The anticoagulant effect of warfarin will not be obvious in coagulation tests such as 
the prothrombin time (PT test) until the normal factor already present in the blood are 
catabolized because warfarin does not alter the degradation rate of clotting factors 
already in circulation. Therefore, the onset of anticoagulation which is induced by 
warfarin is delayed. The latency is determined in part by the time required for the 
absorption of warfarin and, in part by the half-lives of the vitamin K1-dependent 
 6
haemostatic proteins, i.e., prothrombin (factor II), factors VII, IX and X and proteins 
C and S [19] . After administration of warfarin, the vitamin K-dependent clotting 
factors decline according to the increasing order of their half-lives, i.e., factor VII, 6 
hour; IX, 24 hours; X, 40 hours; II, 60 hours [20]. The reduced activity of these 
factors shows the generation of thrombin and fibrin, thereby reducing haemostatic 
effectiveness, although without affecting platelet function. Moreover, the onset of the 
action of warfarin is not dependent on the route of administration.  In man, after 
intravenous administration of single doses of warfarin, hypoprothrombinemia is still 
ot detectable for 8 hours and not maximal for one or two days [21, 22]. On the other 
on of the 
ariation factors by the intersubject differences; including the high variation in the 
n
hand, larger loading doses of warfarin (0.75 mg/kg) can only hasten the onset of 
anticoagulation up to a certain level, beyond which the speed of onset is independent 
of the dose size [23]. Nonetheless, the principal result of a larger loading dose is a 
longer duration of the hypothrombinemia [19].  
 
The PT/INR response to initial dosing of warfarin is complex for the reas
v
pharmacodynamic and pharmacokinetics responsiveness to warfarin, the rate of 
disappearance of functional vitamin K-dependent clotting proteins. Differences in the 
binding affinity of warfarin to the receptor site on the epoxide reductase and in the 
amount of vitamin K1 in the liver influence the sensitivity to warfarin [24].  
 
Moreover, several diseases are associated with increased pharmacodynamic 
sensitivity to warfarin, particularly liver disease, congestive heart failure, and 
hyperthyroidism [25, 26]. Cirrhosis and severe congestive heart failure decrease the 
production of vitamin K dependent factors II, VII, IX, and X with the greater extent of 
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factor VII, but, compensated heart failure is not associated with dynamic response. 
Cholestasis and acute cholecystitis disorders may lead to a decrease in vitamin K-
absorption from the gut. Patients with hyperthyroidism are more sensitive and who 
with hypothyroidism are less sensitive to warfarin than euthyroid patients. Because of 
vitamin K-dependent clotting factors are metabolized more quickly in hyperthyroid 
atients and more slowly in hypothyroid patients. Salicylates in gram doses prolongs 
ip and 
C50 concentration of (S)-warfarin is 16ng/ml [27]. Nonetheless, the sigmoidal effect 
In man, the anticoagulant activity of (S)-warfarin is 2~5 fold more 
otent than (R)-warfarin. In rats, the hypoprothrombinemic effect of (S)-warfarin is 
p
the prothrombin time significantly by inhibiting thrombus formation and increasing 
whole blood fibrinolytic activity. Heparin has very little effect on the PT/INR when 
the plasma concentration is in the low range of 0.2 ~ 0.5 units/ml, which is 
approximately therapeutic range.  
 
Regarding the disturbing of warfarin on the vitamin K cycle, it has been observed that 
the microsomal warfarin binding sites and the activity of microsomal enzymes called 
vitamin K1 2,3-epoxide reductase are closely correlated [27, 28].  It has been observed 
that under the steady state in rat, the relationship between S-warfarin and the 
inhibition of vitamin K1 reductase has a steep sigmoidal response relationsh
I
relationship for S-warfarin plasma concentration and the inhibition of clotting factor 
synthesis has shown a relatively greater IC50 of 210ng/ml [27]. Before vitamin-K-
dependent carboxylation of the clotting factors becomes compromised, at least 70% of 
the hepatic vitamin K1 2, 3-epoxide reductase activity must be inhibited [29].  
 
The potencies of anticoagulant activity of warfarin isomers are different in both man 
[30] and rats [31]. 
p
 8
2~3 times more potent than that of the (R)-enantiomer [31, 32] and LD50 of the (S)-
arfarin is 8.5 times greater than that of antipode [33]. Moreover, the warfarin 
nticoagulant activity but are considerably less potent than the 
arent drug [34].   
].  However, its 
nticoagulation action will be occurred within 24 hours after dose. The presence of 
elay warfarin absorption, yet do not affect on its bioavailability. 
he different brands of warfarin are different in absorption rate due to variation of 
w
alcohols also have a
p
 




Warfarin is rapidly and almost completely absorbed when it is given either orally or 
rectally. Its bioavailability is more than 90% [4, 35]. In man, warfarin reaches its peak 
plasma concentration in 2~8 hours after oral administration [6, 35-38] while in rat its 
peak concentration occurred in 4 hours postdosing [39]. Different studies observed 
that the times for peak concentrations are different [6, 35
a
food in GI tract may d
T
dissolution by different preparation of warfarin [4, 6]. Some concurrent use of drugs 




Warfarin is extensively bound to human serum protein 97.4~99.9% [4, 41-46] and rat 
serum protein 98.3~99.8% [41, 46, 47]. It is especially bound to albumin, which has 
primary and secondary binding sites for warfarin [48].  The fractions of drug which 
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bound to serum protein are not pharmacologically active and are protected from 
biotransformation and excretion [49]. Warfarin isomers have different binding 
ffinities to their binding sites [46, 47]. S-warfarin has higher binding affinity for the 
eless, some researchers reported 
at there is no significantly difference in isomer binding [52, 53].  
4, 13] but it crosses 
e placenta into fetal tissues [4].  The volume of distribution of warfarin varies from 
.09 to 0.17 L/kg in man [4, 13, 35, 54] whereas that ranges from 0.10 to 0.32 L/kg in 
t [55]. Some studies have reported that there is no isomeric difference in distribution 
f warfarin in both man and rats [31, 32] but another study observed that (R)-warfarin 






primary binding sites [50, 51] while R-warfarin has greater binding affinity for the 
secondary binding sites [52]. The serum protein binding affinity of (R)-warfarin is 
lower than that of (S)-warfarin [4, 35, 46]. Neverth
th
 
Many studies have investigated the serum/plasma protein binding of either racemic 
warfarin or warfarin isomers. A list of serum protein binding studies of warfarin and 
related information are summarized in Table (1.2).  
 
The volume of distribution values for single dose of warfarin after oral and 
intravenous administrations are not different [13, 52]. Warfarin is distributed to the 








Table 1.1. Serum/pla  protein binding of warfarin 
Concentration F  
bo ) 

















warfarin 1.0 Serum 98.9 RED [46] 
 1.0 Serum 98.26-99.75 RED [47] 
 1.5 Serum 99.48 RED [47] 
  







    
 
 .7-23.0 Serum 99.41 HPLC [57] 
      
(S Serum 99.16 RED [46] 
 4.0- 0.1 Plasma 15-98. RED [58] 
 7.7-23.0 Serum 99.1 PLC [57] 




arfarin 11.0 HSA 97.4 RED [59] 
 5.0 HSA 99.13 RED [60] 
 1 H  99. RED [6 ] 
2
4  
2  HSA 99 SPF [4 ] 
0 Plasma 99.15 SIST [56] 
HSA 99.41 HPLC [43] 
   
(S)-warfarin 1.0 Serum 99.99 RED [62] 
0 Plasma 99.47 SIST [56] 
0.0 SA 12 0
 .0-8.0 Plasma 99.4 RED [42] 
 .6-9.2 Serum 98.91 SPF [61] 
 55.0 HSA 99 SPF [44] 
 .0 4
 1.0 Serum 99.99 RED [46] 
 7.0 HSA 98.92 HPLC [43] 
      
(R)-warfarin 1.0 Serum 99.98 RED [46] 
 10.
 7.0 
   
 10.
 7.0 HSA 99.42 HPLC [43] 
HSA= Human Serum Albumin; RED=Radioisotope Equilibrium Dialysis; 




1.1.5.3. Metabolism and Excretion 
 
The anticoagulant activity of warfarin is entirely terminated by metabolism in both 
man [63] and rats [64]. Warfarin is extensively metabolized in the smooth 
endoplasmic reticulum of liver by the hepatic microsomal enzyme. The inter-subject 
variation of warfarin dose-response relationship is caused by variability of warfarin 
metabolism in different stereoselective pathways [4, 21, 54, 63]. Warfarin is 
metabolized into inactive phenolic metabolites by oxidation which catalyzed by the 
cytochrome P450 (CYP450) system, as well as into alcoholic metabolites by 
duction which catalyzed by liver cytosolic ketone reductases [13]. The warfarin 
oselectivity [66, 67]. 
re
alcohols have slight pharmacological activity [4, 13]. The warfarin metabolites which 
excreted into the urine and feces include 4-hydroxywarfarin, 6-hydroxy warfarin, 7-
hydroxy warfarin, 10-hydroxy warfarin, dehydroxywarfarin and two pairs of 
diastereomeric warfarin alchohols [13, 65]. 
 
The metabolism of warfarin isomers involve the stereospecific pathways which 
catalyzed by CYP isozymes [4, 13, 35, 65]. From the standpoint of chemistry, 
steroselectivity refers to those reactions in which one stereoisomer is either formed or 
converted preferentially to the other stereoisomers. Two basic types of 
stereoselectivity are substrate stereoselectivity and product stere
The substrate stereoselectivity occurs when the stereoisomers are metabolized 
differentially (in quantitative and/or qualitative terms) by the same biological system 
under the identical condition. Product stereoselectivity occurs when stereoisomeric 
metabolites are generated differentially (in quantitative or qualitative terms) from a 
single chiral, prochiral, or pronon-stereospecific substrate [67].  
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The product stereoselectivity in the warfarin metabolism is different with the 
interspecies variation [64, 68]. In man, the predominant metabolite of (S)-warfarin is 
(S)-7-hydroxywarfarin which transformed by hydroxylation of (S)-warfarin with the 
help of  hepatic cytochrome P450 (especially by CYP2C9) [69-71]while that of R-
warfarin is R,S-warfarin alcohol; which transformed from (R)-warfarin by reduction 
of the carbonyl group of the side chain by liver cytosolic ketone reductases [72]. Only 
a small amount of (R)-warfarin is metabolized into 6-hydroxywarfarin by several 
r route of (S)-warfarin metabolism undergoes via CYP2C9 while 
)-warfarin is mainly degraded by CYP1A2. CYP3A4 is involved in the metabolism 
f both (S)-and (R)-warfarin as a minor metabolic pathway [4, 35]. Warfarin is highly 
etabolized and its metabolites are mainly excreted into the urine and bile [13]. Only 
-5% of unchanged dose occur in human urine [9, 30, 77] while 3 % of the dose occur 







CYP450 isozymes, such as CYP1A2 [71, 73, 74], CYP3A4 [75] and CYP2C19 [76]. 
In rat, 7-hydroxylation is the major pathway for the metabolism of R-isomer whereas 
4-hydroxylation is for S-isomer. Keto reduction is also found in rats with relative 
substrate stereoselective for the (S)-enantiomer to produce S, S-warfarin alcohol [64].   
 











Figure 1.5 Sites of hydroxylation of (S) - and (R)-warfarin catalyzed by human P450s 
to yield the hydroxylated metabolites of warfarin. [78] 
 




The elimination half-lives of warfarin enantiomers are also different. In man, half-life 
for racemic warfarin varies from 36 to 45 hours [4, 5, 42, 79]and that for (S)-and (R)-
warfarin is from 27 to 36 hours [4, 13, 35, 42, 79]  and from 36 to 89 hours [4, 13, 35, 
80] respectively. In rat, elimination half-life of (S)-warfarin is approximately 25.5 
hours while that of (R)-warfarin is 17.5 hours [39]. Compared to (S)-warfarin, the 
elimination half-life of (R)-warfarin is longer in man, but shorter in rats. 
 
It has been shown that the clearance of warfarin decreases with the increasing of age 
while its clearance increases in smoking people [81]. Renal dysfunction is not the 
major determinant for anticoagulation activity of warfarin [13]. However, hepatic 
dysfunction potentiates the risk of hemorrhage due to impaired synthesis of clotting 
factors and decreased metabolism of warfarin [4, 13, 35].   
 
In recent decades, the predictions of the in vivo metabolic clearance based on the in 
vitro intrinsic clearance are successfully done using well-stirred model and parallel 
tube model. [82]. It has been recognized that nonspecific binding in the in vitro 
metabolic assay medium can significantly affect the observed kinetics of metabolism 
and hamper the accurate prediction of clearance [83, 84]. Non-specific binding of 
several drugs has been fairly well studied using either rat or human liver microsomal 
protein. To our knowledge, only one research group has investigated the microsomal 
protein binding of racemic warfarin to human liver microsomal protein [83].  They 
observed that the microsomal protein binding of racemic warfarin is dependent on 
both drug and microsomal protein concentration. The binding of warfarin increases 
from 1 to 53% with the increase of microsomal protein concentration from 0.1 to 10 
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mg/ml. Because of the increasing of warfarin concentration from 1 to 100 µM, the 











Figure 1.6. Binding of warfarin  at concentration of 10 µM were dialyzed vs human 
liver microsomes (0.1~10mg/ml) for 5 hours. Points represent the mean±SD of 











Figure 1.7. Binding of warfarin  at concentration ranges of 1.0~100 µM were 
dialyzed vs human liver microsomes (1mg/ml) for 5 hours. Points represent the 
mean±SD of triplicate determination. [83] 
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1.1.6. Drug interactions with Warfarin 
 
Many studies regarding interaction of warfarin with food, herbals and drugs have 
been published. Its unfavorable properties of narrow therapeutic index, high protein 
binding and cytochrome P450 dependent metabolism can lead to unexpected 
outcomes of warfarin drug interactions. The interactions are mediated by either 
pharmacokinetics or pharmacodynamic mechanism. The factors, which influence the 
pharmacokinetics and pharmacodynamic of warfarin, include patient’s genetics 
polymorphism in CYP450, diet, disease states, lifestyle and drug combination [40, 
85].  
 
With respect to the pharmacodynamic drug interaction of warfarin, the exogenous 
substances alter pharmacodynamic profile of warfarin by interfering the platelet 
function, synthesis and clearance of vitamin K1 dependent clotting factors. The 
pharmacodynamic mechanism is associated with the changes in the response to 
warfarin such as antagonistic, synergistic or additive.  As for examples, 
cholestyramine reduces the absorption of vitamin K1 from the intestine, thereby 
indirectly affecting the clinical response to warfarin [86, 87]. Clofibrate can augment 
the anticoagulant effect of warfarin by increasing the affinity of warfarin to its action 
site, i.e., vitamin K1 epoxidase [52, 88, 89].  Some drugs enhance the anticoagulant 
activity of warfarin by independently affecting on the amount and the activity of 
circulating coagulant protein, e.g., quinidine [90-92]. Some drugs reduce the warfarin 
activity indirectly by increasing the circulating coagulant protein activity, e.g. 
disopyramide [93, 94]. Drugs which have also anticoagulative activity can cause 
bleeding when concurrently used with warfarin, e.g. heparin [95]. Drugs that inhibit 
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the platelet function also prolong the bleeding time, thereby inducing the risk of 
anticoagulation action of warfarin, e.g. aspirin [96]. 
 
Regarding to the pharmacokinetic drug interaction with warfarin, the exogenous 
substances either potentiate or inhibit pharmacokinetic profile of warfarin by altering 
its protein binding, absorption, metabolism and elimination. The pharmacokinetic 
interaction is associated with the alteration in plasma concentrations, area under the 
curve, onset of action, elimination half-life, which may lead to a reduced or 
potentiated therapeutic activity of warfarin.   
 
Drugs which significantly influence the absorption of warfarin are cholestyramine 
[87], ascorbic acid (high dose) and sucralfate [97, 98]. Warfarin is highly protein 
bound drug and large changes in circulating unbound drug may be occurred even 
small changes in protein binding.  Some drugs induce warfarin activity by displacing 
its albumin binding site which could lead to increase free concentration of warfarin. A 
number of weakly acidic drugs, such as aspirin[96], chloral hydrate [99-101], 
phenylbutazone [52, 102-104], nalidixic acid [100, 105-107]and sulfinpyrazone [56, 
108-110], are capable of competing with warfarin for the protein binding site. Among 
them, sulfinpyrazone [56] and phenylbutazone [52, 56] displace (S)-warfarin from its 
protein binding site to a greater extent than (R)-warfarin.  
 
Most of clinically warfarin drug interactions result from the induction or inhibition of 
warfarin metabolism, particularly metabolized by cytochrome P450. Some drugs, 
such as barbiturates [111-114], carbamazepine [115-117], glutethimide [111, 112, 
118], griseofulvin [119-121], increase the metabolic rate of warfarin enantiomers, and 
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decreases its plasma half-life, thereby reducing its anticoagulant effect. Long term 
ethanol consumption may also induce and yet moderate ethanol intake does not affect 
warfarin metabolism.  
 
Some drugs potentiate anticoagulant activity of warfarin by inhibition of warfarin 
metabolic enzymes which cause the increase the plasma concentration of warfarin. 
Generally, there are two types of inhibition-based interactions on the metabolism of 
warfarin, namely non-specific inhibition [122, 123] and stereospecific inhibition [124, 
125].  Drugs, which non-specifically inhibit the metabolism of both warfarin isomers, 
include amiodarone [122, 126-128], erythromycin [129, 130], fluconazole [123], 
ketoconazole [131] and so on. Although amiodarone does not alter the volume of 
distribution of warfarin isomers [70], it reduces the total clearance of both warfarin 
isomers which lead to prolong prothrombin time (PT) [122, 126-128], by inhibiting 
the reduction of (R)-warfarin to R, S-warfarin alcohol as well as the hydroxylation of 
both (R) - and (S)-warfarin enantiomers. Fluconazole has been reported to inhibit the 
hydroxylation of warfarin metabolism thereby increasing the anticoagulant effect of 
warfarin [123]. It mainly inhibits on the (S)-6- and (S)-7- hydroxylation as well as on 
the (R)-6-, (R)-7-, (R)-8- and (R)-10 hydroxylation pathways [79]. 
 
Some drugs stereospecifically prolong the PT of warfarin by inhibiting the 
metabolism of warfarin enantiomers, such as phenylbutazone, sulfinpyrazone, 
metronidazole, miconazole. It has been reported that phenylbutazone selectively 
inhibits the metabolism of more potent isomer of warfarin; (S)-warfarin rather than 
that of (R)-warfarin. Thus, the (S)-warfarin is slowly cleared out from the body and its 
effect is prolonged [102]. Likewise, sulpinpyrazone causes the prolonged PT time due 
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to its effect on the protein binding of warfarin and platelet aggregation [132], as well 
as its also selective inhibition of CYP2C9 which is responsibility for the metabolism 
of more potent (S)-warfarin[133]. Some of the previous studies of warfarin-drug 
interactions are summarized in Table 1.1.  
 
The interactions of some of natural substances and foods with warfarin had been 
studied. According to reported clinical data in man, garlic [134], ginkgo[135], 
coenzyme Q10 [136], danshen [39, 137], devil’s clam [136], dong quai [138], 
ginseng[138], vitamin E and papaya [40] are some of natural products which may 
potentiate the anticoagulant action of warfarin while green tea and St. John’s wort are 
antagonist warfarin action [40]. One of in vitro studies has shown that coenzymes 
Q10 has a selective activation effect on the 4’hydroxylation of (S)-warfarin as well as 
the 6-and 7-hydroxylation of (R)-warfarin at low concentration and the 4’-
hydroxylation of (R)-warfarin at high concentration in rat liver microsomes. However, 
coenzyme Q10 is a selective activator for the 7-hydroxylation of both (S)-and (R)-




























Antibiotics   
Erythromycin Decreases the warfarin metabolism by inhibiting CYP-450 enzyme activity [129, 140] 
Fluconazole Reduces the metabolism of warfarin by inhibiting the activity of CYP-450 enzyme [79, 123] 
Metronidazole Prolong the half-life of (S)-warfarin, decreases P-450 microsomal activity 
[124, 141, 
142] 
Miconazole Decreased P-450 microsomal activity, (S)-warfarin [77, 143-146] 
Tetracycline Induce the absorption of warfarin [146] 
Nalidixic acid Inhibit protein binding of warfarin [100, 105-107] 
Cardiac   
Amiodarone 
Inhibit the protein binding and clearance of warfarin, 




Clofibrate Inhibit protein binding of racemic warfarin, lower the fibrinogen, reduce platelet aggregation. 
[52, 88, 
89] 
Propafenone Inhibit the metabolism [147] 




Synergistic action with warfarin by depressing the 
synthesis of Vitamin-K dependent clotting factors, 
Induce the absorption of warfarin 
[90-92] 
Anti-
inflammatory   




Aspirin Inhibit platelet aggregation and  prolong bleeding time [148] 
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continue   
CNS   
Chloral hydrate Inhibit the protein binding [99, 100, 113] 
Disulfiram Induce the absorption of warfarin [150-152] 
GI   
Cimetidine 
Increase the plasma AUC of warfarin, Inhibit the 




Omeprazole Inhibit the metabolism of R-warfarin [155, 156] 






Drugs which inhibit anticoagulant activity of warfarin 
 
Interacting Drug Mechanism Reference 
Antibiotics   
Griseofulvin Act as P-450 enzyme inducer and increase the metabolism of warfarin [119, 120] 
Nafcillin Induce the metabolism of warfarin [157-159] 
Rifampin Increase the metabolism of warfarin by inducing CYP-450 enzyme activity [160-163] 
Cardiac   
Cholestyramine Inhibit the absorption of warfarin and enterohepatic reabsorption of intravenous warfarin [86, 87, 164] 
CNS   
Carbamazepine Increase the plasma clearance of S-warfarin, reduce the PT and induce the warfarin metabolism [115, 116] 
Barbiturates Induce the metabolism of warfarin [111, 112] 
GI   
Sucralfate Inhibit the absorption of warfarin and reduce bioavailability [97] 
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Sildenafil citrate (Viagra®) is the first line oral medication for men with erectile 
dysfunction (ED). It is the selective inhibitor of cyclic guanosine monophosphate 
(cGMP)-specific phosphodiesterase type 5 (PDE5). Viagra was discovered from the 
original desire on new antihypertensive and angina pectoris through a rational drug 
design programme [165]. It was originated in 1996 and approved by FDA to use it for 
ED in 1998[166].  
 
Erectile dysfunction (ED) is a significantly occurred health problem in over 50 year 
old men [167].  It can occur at any age but it is treatable disease.  ED is a medical 
condition with a remarkably negative impact on quality of life due to lack of the 
ability to get erection or to sustain an erection to achieve sexual intercourse [168-
170]. ED not only affects on the lives of men but also affects on their partners [170].  
ED can be caused due to physical factors which disrupt the blood flow to the penis 
and nerve. Some of underlying physical conditions, which are associated with ED, 
include vascular disease, diabetes, medication (e.g. antidepressant, ACE inhibitor, β 
blocker), hormone disorders, neurologic conditions, pelvic trauma, surgery, radiation 
therapy, peyronie’s disease, venous leak and life styles (drinking alcohol and 
smoking).  Psychological conditions of stress, anxiety, depression are also causes of 
ED [171, 172].  
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It has been estimated in 1992 that thirty million of men from US and hundred million 
men from over the world suffer ED [173]. A survey carried out in 1985 by 
Ambulatory Medical Care Survey (NAMCS) indicated that 7.7 men suffer ED out of 
1000 men in the United States. The result based on the survey performed by the 
Massachusetts Male Aging Study has shown that ED is a worldwide health problem 
which affects almost 50% of the men over the age of 40 [174].  Similar findings have 
also been reported in Singapore that 51.3% male in the ages of 30 and above have 
some degree of ED and the degree of ED is increased with age [167]. The studies on 
Asian males with ED observed that sildenafil is effective and safe medicine for the 
patient with ED and co-morbidities such as diabetes, cardiovascular disease [175, 
176].  
 
1.2.2. Physical and Chemical Properties of Sildenafil  
 
Sildenafil Citrate, a white to off-white crystalline powder, is manufactured as blue, 
film-coated rounded-diamond-shaped tablet (Viagra) with the equivalent amount of 
sildenafil 25mg, 50mg and 100mg. Sildenafil has molecular weight of 666.7 with a 
solubility of 3.5 mg/ml in water. It is relatively lipophilic (Log D7.4 = 2.7) with a 
weakly basic centre in the piperazine tertiary amine (pKa=6.5) chemically named as 
1-[[3-(6, 7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4, 3-d] pyrimidin-5-yl)-4-













   Figure 1.8. Viagra tablet                         Figure 1.9. Structure of sildenafil citrate 
 
1.2.3. Mechanism of Action 
 
During sexual stimulation, mechanism of penile erection is resulted through the 
release of nitric oxide in the corpus cavernosum. Nitric oxide then activates 
guanylatecyclase, which results in increased level of cGMP. This produces smooth 
muscle relaxation in the corpus cavernosum, which allows inflow of blood. 
Phosphodiesterase type 5 (PDE-5) is responsible for the degradation of cGMP in the 
corpus cavernosum. Sildenafil is a selective inhibitor of PDE5, thus increasing the 
cGMP level in the corpus cavernosum. It has no direct relaxant effect on human 
corpus cavernosum and has no effect in the absence of sexual stimulation at 







   




1.2.4. Pharmacodynamic of Sildenafil Citrate 
 
Viagra (sildenafil) is the first oral agent to be introduced for the treatment of ED 
which was approved by FDA in 1998 [166]. Other PDE-5 inhibitors include tadalafil 
and vardenafil were emerged around 2003 and 2004. They are also used for the 
treatment of ED [178]. The case report to US FDA (11/2007) indicates that a few 
patients who were under the treatment of ED and pulmonary arterial hypertension, 
suffered sudden hearing loss following the use of PDE-5 inhibitors such as sildenafil, 
levitra, cialis and revatio. In some patients, the sudden hearing loss was temporary but 
it was ongoing in some patients [179]. Therefore, FDA investigated all the cases of 
hearing loss either from post marketing report or clinical trials. The information 
shows that the hearing loss is related to the dosing. Pfizer updated sildenafil labeling 
that the sudden hearing loss is one of side effect of sildenafil [180].  
 
Some of ex-vivo data suggests that sildenafil prolongs bleeding time, which was 
evaluated by the clotting time of blood from the skin wounds incised by a lancet 
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before and after administration of sildenafil, due to its inhibitory action on collagen-
induced plate aggregation. The bleeding time is prolonged (167±16s) within 1 hour of 
post-oral administration of sildenafil (100mg) but it is back to normal bleeding time 
of 98 ± 16s after 4 hours of administration [181]. Some case report have showed that 
prolong epistaxis [182], hemorrhoidal bleeding [183], intracerebral hemorrhage [184, 
185] have been reported in patients with ED or those without ED taking medication 
such as nifedipine, aspirin, after taking sildenafil. 
 
The efficacy of viagra has been determined in the patients with either organic or 
psychogenic erectile dysfunction.  The effect of viagra such as sexual stimulation 
which results in improved erection is conducted by the measurement of hardness and 
duration of erections compare to the placebo. The effect of viagra is generally 
increased with the increasing of sildenafil dose and plasma concentration. The 
duration of the action is up to 4 hours [177].  
 
The blood pressure decreases (mean maximum decrease in systolic/diastolic blood 
pressure of 8.4/5.5 mmHg) within 1~2 hours after single oral dose of sildenafil 
(100mg) in healthy volunteers, but the effect of viagra (sildenafil) on the blood 
pressure is not related to the dose or plasma levels within the range of 25-100mg.  
However, sildenafil can cause a dramatic decrease in blood pressure when it is 
concurrently administered with anti-hypertensive medication such as nitrate. [177, 
186, 187].  
 
Although single oral doses of sildenafil up to 100mg produce no clinically relevant 
changes in the ECGs of normal male volunteers, the result from the study of ischemic 
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heart disease patients who administered total dose of 40mg by intravenous infusion 
indicates the mean resting systolic and diastolic blood pressure decreased by 7% and 
10% compared to baseline in these patients. Mean resting values for right atrial 
pressure, pulmonary artery pressure, pulmonary artery occluded pressure and cardiac 
output are decreased by 28%, 28%, 20% and 7%, respectively. The mean peak plasma 
concentration of sildenafil in heart disease patients is 2~5 times higher than that in 
healthy male volunteers, receiving the same single dose of 100mg [177]. 
 
In the treatment of daily dose up to 60mg/kg in male and female rats, there was no 
treatment related effect on the reproduction parameters, such as changes in the weight 
of testes or ovaries, mating behavior, pregnancy success, disturbances of fertility. 
However, slight or minimal maternal toxicity was observed at 200mg/kg of sildenafil 
in inseminated rats and rabbits, yet no fetotoxicity was occurred. There was no 
mortality difference between control and treated rats by daily dose of up to 60mg/kg 
for 24 months. Thus, sildenafil is not carcinogen to mice and rats [188].  
 
1.2.5. Pharmacokinetics of Sildenafil Citrate 
 
Sildenafil is rapidly absorbed after oral dose with absolute bioavailability of about 38-
41. Food not significantly reduces the absorption rate [189]. However, maximum 
plasma concentrations reach within the range of 30 to 120 minutes (median 60 
minutes) after oral dose in the fasted state, but the absorption rate is reduced with a 
mean delay in Tmax of 60 minutes when taken with high fat meal [177]. The first order 
absorption rate constant (Ka) is 2.6 ± 0.176 h-1 based on the population 
pharmacokinetic analysis in the patients with ED [190].  
 28
The pharmacokinetics of sildenafil following single dose of intravenous and oral 
administration has been determined in mouse, rat and dog. After the single dose of 
oral sildenafil administration, the low bioavailability was occurred in any species of 
mouse, rat, rabbit, dog and man. It was due to the pre-systemic hepatic first-pass 
effect of sildenafil [191-193]. Sildenafil and its major metabolite; N-desmethyl 
metabolite (UK-103, 320) are highly bound to plasma protein but the binding is 
independent on the concentrations over the range of 0.01-10 µg/ml. The mean 
proportion of plasma protein binding in rats and man are 95% and 96-97% 
respectively [177, 191, 194].  After given intravenous (IV) single dose (1mg/kg), the 
volume of distribution is 1.1L/kg in rats and 1.21 ~ 1.5L/kg in man [191, 194]. The 
mean steady-state volume of distribution (Vss) of sildenafil in man after IV 
administration is 105 L [189], which greatly exceeds the total volume of body water 
(approximately 42 L), indicating a possible distribution into the tissues and binding to 
extravascular proteins [195]. However, according to a population pharmacokinetic 
study of patients with ED, the apparent volume of distribution (V/F) after oral 
administration is 3.5L/kg [190]. The report of Pfizer to FDA has shown that the 
percentage bioavailability values of sildenafil in male rats and man are 15-23% [191, 
194] and 41 % respectively [189, 194].  
 
Sildenafil is cleared primarily via the metabolism [177, 191]. It is metabolized by 
CYP2C9 (major route) and CYP3A4 (minor route) and converted mainly to its active 
metabolites N-desmethylated sildenafil (UK-103, 32), which has a similar property on 
PDE-5 with the potency of around 50% of the parent drug. In the case of intravenous 
administration, it has the same elimination half-life with its parent drug at ~ 0.3 hours 
in male rat and ~ 2.4 hours in man [191]. After oral administration, sildenafil and its 
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metabolite are eliminated with the half-life of ~ 0.4 hours in male rat [191] and ~ 4 
hours in man [177, 190, 191].  
 
Sildenafil is excreted as metabolites predominantly in the feces (approximately 73-
88% of administered oral dose) to a lesser extent in the urine (approximately 6-15% 
of administered oral dose) [177, 196]. Studies in rat, mouse and dog show the action 
of sildenafil is mainly terminated by the metabolism and less than 10% of the 
unchanged parent drug is recovered in the feces of these animals [192]. However, 
there is no recovery of radioactivity of sildenafil from the feces of man [191]. The 
clearance of sildenafil is reduced in the elderly patients (age >65) with severe renal 
impairment (CLcr ≤ 30ml/min) or hepatic cirrhosis [177, 197].  
 
1.2.6. Drug interactions with Sildenafil  
 
Drug interaction studies conducted by Pfizer research group have indicated that 
concomitant use of sildenafil (50mg) with 800mg of cimetidine (nonspecific CYP 
inhibitor) increase plasma sildenafil concentration. In addition, erythromycin (potent 
inhibitor of CYP3A4) and ritonavir (potent P450 inhibitor) also extensively increase 
plasma sildenafil level in healthy male [177] and modify other pharmacokinetics 
parameters; such as AUC, Cmax, Kel, by inhibiting its CYP3A4-mediated first-pass 
metabolism [198].  However, the substrates of CYP2C9 (tolbutamide, warfarin) have 
no effect on pharmacokinetics profile of sildenafil [177].  
 
To date, only limited in vitro studies have been performed. It has been shown that 
sildenafil is cleared by NADPH-dependent metabolism [191] with the major pathway 
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of CYP3A4 (79%) and minor pathways of CYP2C9, CYP2C19 and CYP2D6 (20%) 
[177]. Sildenafil itself is a weak inhibitor of the cytochrome P450 system with 
IC50>150µM [177]. In vitro metabolic drug interactions of sildenafil (36µM) with 
omeprazole (10µM), quinidine (10µM), sulfaphenazole (10µM) and ketoconazole 
(2.5µM) have been carried out using either human liver microsomes or human liver 
microsomes containing heterologously expressed human cytochromes. The 
metabolism of sildenafil to its metabolite, UK-103, 320 is completely inhibited by 
ketoconazole and ritonavir whereas no such an inhibition is occurred when co-
incubated with sulfaphenazole, omeprazole and quinidine [199].  
 
1.3. Possible Drug Interaction between Warfarin and Sildenafil Citrate in 
Related Reports 
 
Both warfarin and sildenafil are extensively metabolized in liver via CYP3A4 and 
CYP2C9. A serious case reports in the use of sildenafil were observed. The case study 
in “Canadian Adverse Drug Reaction Newsletter” shows that the concomitant use of 
sildenafil and warfarin increases the international normalized-ratio (INR) in man, but 
the detail information is not included in this report [200].  
 
Another case report in 2003 showed that INR of the patient, who is on oral 
anticoagulant therapy with warfarin and concurrently using of sildenafil (once a 
week), was increased [201]. Severe bleeding was also reported in 61-year-old atrial 
fibrillation patient on chronic warfarin treatment, possibly caused by change of 





HYPOTHESIS AND OBJECTIVES 
 
Warfarin is widely used in the treatment of hemorrhage disorder due to its relatively 
predictable onset and duration of action as well as due to its excellent bioavailability. 
However, careful monitoring is needed due to its unfavorable properties including 
very low therapeutic index, high protein binding and cytochrome enzyme dependent 
metabolism. These undesired properties predispose it to numerous life threatening 
drug-drug interactions. Extensive studies of warfarin-drug interactions have been 
documented and most of them are based on the changes in pharmacokinetics of 
warfarin such as displacement of plasma protein binding, induction or inhibition in 
metabolism of warfarin.  The anticoagulant activity of warfarin is terminated by 
metabolic mechanism. The commercially available warfarin is in racemic nature and 
the warfarin isomers are cleared from the body in different metabolic pathways. Some 
drugs which go through the same metabolic pathway cause the impaired clearance of 
warfarin which may lead to increase an INR.  
 
Sildenafil, a potent phosphodiesterase type 5 inhibitor, is the first prescribed oral 
medications for erectile dysfunction. Similar to warfarin, it is highly bound to plasma 
protein and mainly metabolized in liver. The displacement of warfarin protein binding 
by sildenafil citrate would result in an increase in unbound warfarin plasma 
concentrations, and subsequently could lead to an enhanced warfarin response. One 
study indicates that sildenafil itself has the inhibitory property on platelet aggregation 
by blocking cGMP metabolism [181]. Some case reports have shown that INR 
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increases in the patient who is on warfarin therapy and periodically uses sildenafil for 
erectile dysfunction [200, 201]. In addition, both of warfarin and sildenafil are 
metabolized in the liver mainly by CYP2C9 and CYP3A4 and both are among the top 
300 prescribed drugs. Half of the men over 40 years old have erectile dysfunction 
(ED) and the populations on warfarin therapy are mostly elderly patients with atrial 
fibrillation, the presence of artificial heart valves, deep venous thrombosis, pulmonary 
embolism, antiphospholipid syndrome and, occasionally, after myocardial infarction 
[203]. Moreover, ED is often associated with common chronic diseases such as 
hypertension, heart disease and diabetes. There is a chance for patients who are on 
warfarin anticoagulation are also taking sildenafil for erectile dysfunction [203]. It 
was, thus, hypothesized that a potential drug interaction may occur in patients 
receiving both warfarin and sildenafil due to the inhibition of metabolism of the 
former by the latter through CYP isozymes. 
 
The primary objective of the present in vitro study is to investigate the effect of 
sildenafil on the hydroxylation of warfarin enantiomers in both rat and human liver 
microsomes. In addition, the effect of sildenafil on the in vitro serum and/or liver 
microsomal protein binding of warfarin would be explored to investigate if the protein 
displacement would be a source of interaction between warfarin and sildenafil.  
Finally, attempt was made to evaluate the extent to which the in vitro data is 
predictive of the actual pharmacokinetic interaction between warfarin and sildenafil 








3.1 NON-STEREOSPECIFIC REVERSED PHASE HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR 
DETERMINATION OF WARFARIN METABOLITES IN LIVER 
MICROSOMAL SAMPLES 
 
3.1.1. Introduction  
 
Warfarin is the most frequently used anticoagulant for the treatment of hematological 
disorder. However, it displays a narrow therapeutics index and causes a fatal 
hemorrhage from tissues and organs as well as has highly protein binding property. 
Therefore, appropriate laboratory monitoring is needed to prescribe warfarin 
effectively and safely. The increasing concerns have developed over the various 
studies on useful but unsafe anticoagulant called warfarin since it was introduced as 
clinically effective oral anticoagulant. Various analytical methods, namely 
spectrophotometry [54], fluorometry [204], high performance thin-Layer 
chromatography (TLC) [63, 205], gas chromatography (GC) [206], high performance 
liquid chromatography [207, 208]; have been used for investigation of warfarin and 
its metabolites in biological samples such as serum, urine, liver microsomes.  
 
Out of these methods, warfarin metabolites in liver microsomal sample were usually 
determined by HPLC [207-210]. To analyze the polar nature of warfarin, reversed 
phase high performance liquid chromatography method has been used [210-212]. For 
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analyzing metabolites of warfarin enantiomers from different isomer incubations, 
non-stereospecific reversed-phase HPLC method with fluorescent detection could be 
used to determine phenolic metabolites (4’-, 6-and 7-hydroxywarfarin) of (R)- or (S)-
warfarin. However, the available reversed-phase HPLC methods require relatively a 
long running time to complete each analysis (about 16~27 mins) [211, 213].  
 
The shorter running time is one of advantages when analyzing a large amount of 
samples. Therefore, a rapid and reliable non-stereospecific HPLC method with 
fluorescent detection was developed to quantify phenolic metabolites of (R) - or (S)-
warfarin in liver microsomal samples obtained from in vitro warfarin–sildenafil 
interaction studies. As sildenafil peak is not eluted under fluorescent detector, no 
interference of sildenafil would be expected when performing analysis of the warfarin 
metabolites.  
 
3.1.2 Materials and Methods 
 
3.1.2.1 Chemicals and Reagents 
 
Our research group had previously prepared warfarin isomers and isomers of its 
metabolites for research purpose. The optically pure (R) - or (S)-warfarin (optical 
purity > 99%) were prepared from racemic warfarin by fractional crystallization 
method [214]. The 4’-, 6- and 7-hydroxylated metabolites of (R) - or (S)-warfarin (4’-
OH, 6-OH, 7-OH) were synthesized using modification of previously reported 
methods [215, 216].  
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Analytical grade of dibasic sodium phosphate and monobasic sodium phosphate were 
purchased from Merck KGaA (Schuchardt, Germany). Diethyl ether was obtained 
from Tedia (Fairfield, Ohio, US), acetone of HPLC grade from Labscan (Dublin, 
Ireland), acetonitrile of HPLC grade (for HPLC analysis) from Fisher Scientific (PA, 
USA) and methanol of HPLC grade (for HPLC analysis) from Tedia (Fairfield, Ohio, 
US) were purchased. All solutions were prepared using eighteen MΩ water generated 
by Milli-Q RG Millipore water purification system (Millipore Corporation, Bedford, 




The HPLC system composed of a solvent delivery system (LC-10AT, Shimadzu, 
Japan), a fluorescent detector (RF-10AXL, Shimadzu, Japan), an auto injector (SIL-
10AT, Shimadzu, Japan), a system controller (SCL-10A, Shimadzu, Japan), a 
degasser (DGU-14A, Shimadzu, Japan) and a C18 column (XTerraTM RP18, 150mm 
X 4.6mm, serial no. PN 18600492 W22901K 005) packed with particles with a 
diameter of 5µm and a guard column (Water® XTerra® RP18 5µm Part No.: 
186000662) was used to analyze the samples.  
 
The shaking water bath (GFL-1083, Gesellschaft fur Labortechnnik mbH, Burgwedel, 
Denmark) was used for the incubation of microsomal samples. The pH of a buffer 
solution was measured with pH meter (EcoMet, Istek, Seoul, Korea) and the solution 
was filtered through a 0.20µm hydrophilic polypropylene membrane filters (Pall 
Corporation, Michigan, USA) and degassed in ultrasonic bath (Transsonic T460, 




3.1.2.3.1. Sample Preparation  
 
Accurately weighed amounts of metabolites were dissolved with a few drops of 3M 
sodium hydroxide solution (NaOH) and diluted with 0.1M Tris buffer at pH 7.4 to 
prepare stock solution of the concentrations of warfarin phenolic metabolites 
(10mg/ml for 4’-OH, 10mg/ml for 6-OH and 1mg/ml for 7-OH). 
 
Working solutions were prepared by mixing the stock solution with 0.1M Tris buffer 
at pH 7.4 to obtain desired concentrations. The calibration standards in liver 
microsomes, over the ranges of 0.08 to 15 µM for 4’-and 6-hydroxywarfarin and 
0.005 to 3.5 µM for 7-hydroxywarfarin were freshly prepared on each analysis day by 
diluting the working solution with 0.1M Tris buffer at pH 7.4. 
 
The low, medium and high concentrations of standards in liver microsomes (226.9, 
2268.7 and 3889.2 ng/ml of 4’- or 6-hydroxywarfarin and 9.72, 226.8 and 388.8 
ng/ml of 7-hydroxywarfarin) were used as the quality control (QC) samples. 
 
The calibration curve establishment and assay validation were carried out using the 
sample preparation procedures as described in in vitro metabolism study (Section 
6.2.5). Briefly, an appropriate amount of 0.1M Tris buffer (pH 7.4) was added to 
make the final volume of 500µl including 1.6 mg of rat liver microsomes and the 
desired standard concentrations for the respective calibration range. The microsomal 
 37
samples were pre-incubated in 37°C shaking water bath (GFL-1083, Gesellschaft fur 
Labortechnnik mbH, Burgwedel, Denmark) with the shaking speed of 150rpm for 3 
minutes.  
 
To calibration samples, 500 µl of 0.1 M Tris Buffer (pH 7.4) was added instead of 
500µl of NADPH generation system and mixed thoroughly. The mixture was allowed 
to proceed in the 37°C shaking water bath for 30 minutes. 600 µl of iced-cooled 
acetone was then added to the incubation mixture and mixed well.  
 
3.1.2.3.2. Liquid-liquid Extraction 
 
Samples preparation by liquid-liquid extraction was done prior to HPLC. The 
extraction method was adopted from a previously reported method with modification 
[211]. Briefly, 10µl of chlorowarfarin (2mM in pH 7.4 of 0.1M Tris buffer, which 
was used as an internal standard) and 2 ml of 1 M monobasic potassium phosphate 
(~pH 4.5) were added to incubation mixture.  The aqueous layer was extracted two 
times with 8ml of peroxide free ether by shaking horizontally at 200rpm for 30 mins. 
The mixture was centrifuged at 3,000 rpm for 10mins. Subsequently, the upper 
organic layer was collected into a clean test tube. A few granules of antibumping 
agent were added to the test tube of organic mixture and then evaporated on a heating 
block at 55ºC. The wall of the test tube was washed with 1ml of peroxide-free ether 
by three times, allowing ether to evaporate to dryness between each wash. Finally, the 
extract was reconstituted with 50µl of mobile phase solution. 20µl of aliquots were 
then uploaded to HPLC for analysis.  
 
 38
3.1.2.3.3. Chromatographic Condition 
 
To determine the quantity of the phenolic metabolites of (R) - or (S)-Warfarin (4’-, 6- 
and 7-OH) which were formed in the microsomal incubation mixture, a non-
stereospecific reversed-phase HPLC system with fluorescence detector was 
employed. The isocratic elution mode was carried out at ambient temperature of 25ºC 
under the chromatographic conditions, being consisted of a flow rate of 1.0 ml/min 
with a mobile phase composition of 20mM sodium phosphate buffer (pH 3.5), 
acetonitrile and methanol (50:40:10, v/v/v).  The eluents were monitored at an 
excitation wavelength and an emission wavelength of 313 and 370nm, respectively. 
 
3.1.2.3.4. Quantification of Warfarin Metabolites in Liver Microsomal Samples 
 
For the quantitative determination of warfarin metabolites in the samples, the 
calibration plots were constructed based on the peak area ratio of metabolites (4’-OH 
or 6-OH or 7-OH) to internal standard (chlorowarfarin) versus the known metabolite 
concentration in liver microsomes. 
  




The Linearity of the method was evaluated over the respective concentration ranges of 
warfarin metabolites (0.08 to15 µM for 4’-hydroxywarfarin, 0.08 to15 µM for 6-
hydroxywarfarin, 0.005 µM to 3.5 µM for 7-hydroxy warfarin). The calibration 
 39
standards were freshly prepared on each analysis day using boiled liver microsomes 
spiked with five concentrations of the phenolic metabolites over the respective ranges. 
 
3.1.3.2. Intraday and Interday Accuracy and Precision 
 
Intraday and interday accuracy and precision of the assay were assessed by 
performing replicate analyses of three QC sample concentrations. To investigate 
intraday repeatability, the assays of QC samples were performed triplicate on the 
same day. The assays of QC samples were assessed on 3 different days on the spiked 
standards to determine interday repeatability.  
 
3.1.3.2. Limit of Detection and Limit of Quantitation  
 
In order to evaluate the limit of detection (LOD) and limit of quantitation (LOQ) of 
the assay, a series of standard concentrations of warfarin metabolites were prepared 
according to the sample preparation and assay procedures described in Sections 
3.1.2.3.1 and 3.1.2.3.2, prior to the HPLC analysis. The LOD was determined as the 
analyte concentration at which its signal to noise ratio is 3 while LOQ was determined 
as the lowest calibration at which the intra-and inter-day coefficient of variation is not 
greater than 20%.  
 
3.1.4. Results  
 
In order to develop a non-stereospecific reversed-phase HPLC with fluorescence 
detection, the phenolic metabolites were extracted from a liver microsomal sample 
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followed by the analysis of metabolites using the above mentioned non-stereospecific 
HPLC assay under four different compositions of mobile phase. The relationship 
between the composition of mobile phase and the retention time of the phenolic 
metabolites and internal standard is shown in Table 3.1. The results were based on the 
mean value of triplicate samples.   
 
Table 3.1. The relationship of mobile phase composition and retention times of 
warfarin metabolites, warfarin and internal standard (chlorowarfarin). 
Mobile Phase Composition 
(%)  Retention Time (minutes) 
Buffer a ACN b MeOH c  4'-OH 6-OH 7-OH War d Cl-War 
58 42 0  5.3 6.3 7.4 12.2 21.9 
55 40 5  4.2 4.8 5.6 8.7 14.3 
50 40 10  4 4.5 5.2 6.6 11.6 
48 40 12  3.4 3.8 4.4 5.9 9.4 






The mobile phase composition (50:40:10) of 20mM sodium phosphate buffer (pH 
3.5), acetonitrile and methanol was found as the optimal condition for the analysis of 
in vitro metabolism samples. Figure 3.1 shows the entire running time for each 
sample assay was 18 mins, as 4’-, 6- , 7- hydroxywarfarin and chlorowarfarin are 
eluted at 4, 4.5, 5.2 and 11.6 minutes, respectively, with baseline resolution (Figure 
3.1.C).  The resolution between two adjacent peaks was calculated based on the 
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equation 3.1. The resolution values between 4’-OH and 6-OH, 6-OH and 7-OH under 






−•=       3.1 
 
Table 3.2. The resolution values between two adjacent peaks under different mobile phase 
composition. 
Mobile Phase Composition (%)  Resolution between peaks (RS) 
Buffer (a) ACN (b) MeOH (c)  RS(4'- & 6-OH) RS(6- & 7-OH)
58 42 0  1 0.9 
55 40 5  0.9 0.9 
50 40 10  1.2 1 
48 40 12  0.9 1 













































Figure 3.1. Chromatogram resulting from in vitro metabolism study (a) blank rat 
liver microsomal sample, (b) blank rat liver microsomal sample spiked with internal 
standard, (c) blank rat liver microsomal sample spiked with phenolic metabolites of 
warfarin and internal standard, (d) formation of phenolic metabolites of (S)-warfarin  
from the control rat liver microsomal sample, (e) formation of phenolic metabolites of 
(R)-warfarin from the control rat liver microsomal sample, (f) formation of phenolic 
metabolites of (S)-warfarin  from the control human liver microsomal sample, (g) 













Linearity was evaluated based on the coefficient of determination (i.e. r2) and visual 
inspection of the residual plots of the data points. Figures 3.2 show the linear 
calibration plots for 4’-OH, 6-OH and 7-OH, the linear equation for each with the r2 
value being close to the unity. The intraday and interday accuracy was evaluated by 
means of percentage error, while the precision was presented as relative standard 
deviation (R.S.D). The results of intraday and interday precision and accuracy, 
obtained for the three phenolic metabolites of warfarin are shown in Table 3.3 while 
those of LOD and LOQ values of the assay for those warfarin metabolites are 
presented in Table 3.4. 
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Calibration curve for 4'-OH 





















Calibration curve for 6-OH 




















Calibration curve for 7-OH   
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Figure 3.2. The linear calibration plots for the phenolic metabolites of warfarin (a) 
















Table 3.3 A. Intra-day and Inter-day precision and accuracy of the assay for the 
determination of 4’-hydroxywarfarin 
Concentration Determined concentration RSD Accuracy 
(ng/ml) (ng/ml) a (%) (error %) 
Intraday 
226.9 231.1 ± 18 0.08 0.2 
2268.7 2243.8 ± 177.4 7.7 1.3 
3889.2 3762.8 ± 189.5 4.9 -0.8 
Interday 
226.9 218.6 ± 7.6 3.5 -3.6 
2268.7 2268.6 ± 140.2 6.2 -0.002 
3889.2 3896.3 ± 170.8 4.4 0.18 
a: the presented values are Mean ±SD 
 
 
Table 3.3.B. Intra-day and inter-day precision and accuracy of the assay for the 
determination of 6-hydroxywarfarin 
Concentration Determined concentration RSD Accuracy 
(ng/ml) (ng/ml) a (%) (error %) 
Intraday 
226.9 232.6 ±  1.7 0.7 2.5 
2268.7 2332.9 ± 53.6 2.3 2.8 
3889.2 3834 ± 49.5 1.3 -1.4 
Interday 
226.9 240.4 ± 6.5 2.7 5.9 
2268.7 2262.1 ± 62.3 2.8 -0.3 
3889.2 3774.2 ± 52.7 1.4 -2.9 
a: the presented values are Mean ±SD 
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Table 3.3 C. Intra-day and inter-day precision and accuracy of the assay for the 
determination of 7-hydroxywarfarin 
Concentration Determined concentration RSD Accuracy 
(ng/ml) (ng/ml) a (%) (error %) 
Intraday 
9.72 9.1 ± 0.36 4 -6.8 
226.8 244.7 ± 2.9 1.2 7.9 
388.8 372.9 ± 20.8 5.6 -4.1 
Interday 
9.72 9.5 ± 0.85 9 3.2 
226.8 233.1 ± 10.6 4.5 4.2 
388.8 387.6 ± 14 3.6 1.7 




Table 3.4. Limit of detection (LOD) and limit of quantitation (LOQ) of the assay for 
the determination of phenolic metabolite of warfarin. 
 
 LOD  (ng/ml) 
LOQ  
(ng/ml) 
4’-hydroxywarfarin 6.5 25.9 
6-hydroxywarfarin 3.2 9.7 





A rapid and reliable non-stereospecific HPLC method was optimized and validated to 
quantify the three phenolic metabolites of (R) - or (S)-warfarin in liver microsomal 
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reaction samples obtained from different incubation studies. The peaks were eluted 
with longer retention times when methanol was absent in the mobile phase, in 
particular chlorowarfarin peak with retention time of around 22 minutes. For the 
analysis of larger amount of samples, the running time of the sample was a very 
important factor.  In the presence of methanol, the peaks were observed with shorter 
retention times. Therefore, different methanol compositions of mobile phase were 
used to optimize the chromatographic assay conditions.   
 
Our finding shows that the peaks were eluted faster with a higher composition of 
methanol in mobile phase (Table 3.1). The presence of 12% (the highest concentration 
used) instead of 10% of methanol in the mobile phase reduced the retention time of 
chlorowarfarin peak by about 2 minutes. However, the metabolites’ peaks were 
overlapped at the baseline for the former condition. Therefore, 10% methanol in 
mobile phase was the optimal composition with respect to shorter retention time and 
better baseline resolution. Hence, the mobile phase composition of (50:40:10) for 
20mM sodium phosphate buffer (pH 3.5), acetonitrile and methanol was employed to 
analyze warfarin metabolites in the microsomal reaction mixtures.  
 
In the present study, liquid-liquid extraction was involved for samples preparation and 
was sufficient enough to produce a clean chromatogram. The intraday accuracy was 
from -0.8 to 1.3, from -1.4 to 2.8 and from -6.8 to 7.9 while the interday accuracy was 
from -0.002 to 0.18, from -2.9 to 5.9 and from 1.7 to 4.2 for 4’-, 6- and 7-
hydroxywarfarin, respectively. The intraday and interday precision was adequate as 
the RSD values obtained were all less than 10%.  
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Moreover, the LOD values for 4’-, 6- and 7-hydroxywarfarin are 0.02µM (6.5ng/ml), 
0.01µM (3.2ng/ml) and 0.0005µM (0.16ng/ml), respectively. Therefore, the present 
HPLC assay method had better recovery and sensitivity as well as shorter running 
time than the reported method [208]. Thus, the former is possible to analyze the 
phenolic metabolites of warfarin in a reaction mixture when the metabolism study of 
warfarin was performed with weak inhibitor of cytochrome P450 (CYP). For the 
metabolic reaction study of warfarin in the presence of strong CYP inhibitor, the more 
sensitive assay, such as LC/MS or GC/MS, would be required to detect very low 
concentration of warfarin metabolites in microsomal samples.  
 
3.2 REVERSED PHASE HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHIC METHOD FOR DETERMINATION OF 
SILDENAFIL CITRATE IN RAT SERUM AND LIVER MICROSOMAL 




Sildenafil is widely prescribed oral drug to treat male erectile dysfunction with an 
effective, licensed preparation. It was introduced to drug discovery to use for the 
treatment of angina pectoric and hypertension by Pfizer research group. Some of 
clinical studies suggested that the compound is more effective for ED rather than for 
angina [165, 217]. Therefore, in 1996 Pfizer patented sildenafil for the treatment of 
ED and approved by FDA in 1998 [218].Subsequently a few comparative alternative 
drugs for ED are also available such as vardenafil, and tadalafil [219].  It was the most 
popular prescribed drug in USA at the position of 40th in 2003 [220-222], and at the 
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position of 62nd in 2006 [223], based on dispended prescriptions in USA. As sildenafil 
is a relatively new medication, only a few analytical methods have been published to 
determine sildenafil. Some used LC or GC/MS to analyze it in plasma and hair 
samples of rats and man [222, 224], whereas others used HPLC to quantify it in 
pharmaceuticals [225] and in plasma samples [226]. In the reported reversed-phase 
HPLC assay under ultraviolet (UV) detection [226], sildenafil was eluted around 11 
mins after direct solid phase extraction on poly (divinylbenzene-co-N-
vinylpyrolidone) cartridge. In the present study, a modification of the established 
HPLC assay method was employed to investigate sildenafil in serum and liver 
microsomal samples with a shorter running time after one step protein precipitation in 
the sample preparation. 
 
3.2.2 Materials and Method 
 
3.2.2.1. Chemicals and Reagents 
 
Sildenafil was obtained from Zhejiang Jiayuan Pharmaceutical Industry Co., Ltd, 
China. Analytical grade of dibasic sodium phosphate and monobasic sodium 
phosphate were purchased from Merck KGaA (Schuchardt, Germany). Acetonitrile of 
HPLC grade (for HPLC analysis) from Fisher Scientific (PA, USA) was employed in 
this study. Isotonic 0.067 M sodium phosphate buffer; PBS (pH 7.4) was bought from 
National University Medical Institute (NUMI), National University of Singapore. All 
solutions were prepared using eighteen MΩ water generated by Milli-Q RG Millipore 
water purification system (Millipore Corporation, Bedford, MA, USA).  
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3.2.2.2. Apparatus  
 
The HPLC system composed of a solvent delivery system (LC-10AT VP, Shimadzu, 
Japan), a UV detector (SPD-10A VP, Shimadzu, Japan), a communications bus 
module (CBM-101, Shimadzu, Japan), a mixer (FCV-10AL VP, Shimazu, Japan) and 
a degasser (DGU-14A, Shimadzu, Japan) together with C18 column (XTerraTM RP18, 
150mm X 4.6mm, serial no. PN 18600492 W22901K 005) packed with particles with 
a diameter of 5µm, a guard column (Water® XTerra® RP18 5µm Part No.: 
186000662) was employed to analyze sildenafil either in rat serum or liver 
microsomes. The pH of a  buffer solution was measured with pH meter (EcoMet, 
Istek, Seoul, Korea) and the solution was filtered through a 0.20µm hydrophilic 
polypropylene membrane filters (Pall Corporation, Michigan, USA) and degassed in 
ultrasonic bath (Transsonic T460, Singen, Germany) prior to its use. 
 
3.2.2.3. Method  
 
3.2.2.3.1. Sample Preparation 
 
To prepare stock solutions of sildenafil (1mg/ml), accurately weighed amount of 
sildenafil was dissolved in the mixture of acetonitrile and Milli-Q water (1:1 v/v). For 
method validation, working solutions were prepared by appropriate dilution of stock 
solution with the mixture of acetonitrile and Milli-Q water (1:1 v/v). Calibration and 
quality control samples for investigation of unbound sildenafil in rat serum and liver 
microsomal protein were prepared in 1 ml of isotonic 0.067 M sodium phosphate 
buffer; PBS (pH 7.4) containing 10µl of appropriate concentrations of working 
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solution of sildenafil. However, those samples for determination of total sildenafil 
concentration were prepared in rat serum and liver microsomal protein instead of 
using PBS.  
 
For the measurement of total concentration of sildenafil, a single protein precipitation 
method was involved. Briefly, a 50 µl of serum sample was pipetted into 1.5 ml of 
polypropylene Eppendorf micro test-tube and vigorously mixed with 50 µl of 
acetonitrile for 1 minute, followed by centrifuging at the speed of 5000 rpm for 10 
minutes. The supernatant was transferred into another clean micro test-tube, and 20 µl 
of aliquot was injected into the HPLC system for qualitative determination of 
sildenafil. 
 
3.2.2.3.2. Chromatographic Conditions 
 
To determine the quantity of sildenafil in PBS, a non-stereospecific reversed phase 
HPLC system with ultraviolet (UV) detector was employed. The HPLC system was 
composed of a solvent delivery system (LC-10AT VP, Shimadzu, Japan), a UV 
detector (SPD-10A VP, Shimadzu, Japan), a communications bus module (CBM-101, 
Shimadzu, Japan), a mixer (FCV-10AL VP, Shimazu, Japan) and a degasser (DGU-
14A, Shimadzu, Japan). The isocratic elution mode was carried out at ambient 
temperature of 25ºC under the chromatographic condition consisted of C18 column 
(XTerraTM RP18, 150mm X 4.6mm, serial no. PN 18600492 W22901K 005) packed 
with particles with a diameter of 5µm, a guard column (Water® XTerra® RP18 5µm 
Part No.: 186000662), a flow rate of 0.7 ml/min with a mobile phase composition of 
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50mM sodium phosphate buffer (pH 8): acetonitrile (50:50, v/v).  The ultraviolet 
(UV) detection was set at the wavelength of 300nm.  
 
3.2.2.4. Quantification of Sildenafil in Rat Serum and Liver Microsomal Samples 
 
The standard sildenafil samples over the concentration range of 0.1 to 25 µM were 
used to analyze free concentration while those of 1 to 65 µM were prepared to 
determine total concentration in rat serum and liver microsomal protein. The 
calibration plots were constructed based on the peak area of sildenafil versus the 
known sildenafil concentration either in PBS or in rat serum protein or liver 
microsomal protein. 
 




The Linearity of the method was evaluated over the concentration ranges of sildenafil 
(0.07 to 10 µM). The calibration standards were freshly prepared on each analysis day 
using the PBS solution spiked with eight concentrations of phenolic metabolites over 
the respective ranges. 
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3.2.3.2. Intraday and Interday Accuracy and Precision 
 
Accuracy and precision of intraday and interday of the assay were assessed by 
performing replicate analyses of three QC sample concentrations. To investigate 
intraday repeatability, the assays of QC samples were performed triplicate on the 
same day. The assays of QC samples were assessed on 3 different days on the spiked 
standards to determine interday repeatability. The sildenafil concentrations of 800, 




Figure 3.3 (a~j) show the chromatograms of blank PBS, blank rat serum or liver 
microsomal protein, blank rat serum or liver microsomal protein spiked with 
sildenafil, unbound and total sildenafil in rat serum or liver microsomal protein. The 
entire running time for one sample was within 9 min and the sildenafil was eluted 




























































































































































Figure 3.3. Chromatograms resulting from protein binding study of sildenafil (a) 
blank PBS, (b) blank sample from rat serum protein binding study, (c) blank sample 
from rat liver microsomal protein binding study, (d) PBS spiked with sildenafil, (e) 
unbound fraction of sildenafil in rat serum protein, (f) unbound fraction of sildenafil 
in rat liver microsomal protein, (g) blank rat serum protein, (h) blank rat liver 
microsomal protein, (i) blank serum protein spiked with sildenafil, (j) total sildenafil 
in rat serum protein, (k) blank rat liver microsomal protein spiked with sildenafil, (l) 






Linearity was evaluated based on the coefficient of determination (i.e. r2) and visual 
inspection of the residual plots of the data points. Figure 3.4 shows the linear 
calibration plots for free and total sildenafil in rat serum and liver microsomal protein, 
linear regression equations for each with the r2 value being close to the unity.  
 
 Calibration curve for sildenafil




















Figure 3.4.  The linear calibration plot for sildenafil in rat serum or liver microsomes 
 
The intraday and interday precision was presented by relative standard deviation 
(R.S.D) and accuracy was evaluated by percentage error. Table 3.5 lists the intraday 
and interday precision and accuracy for sildenafil at 3 concentrations of 800, 3000 and 
5000 ng/ml. The limit of detection (LOD) and limit of quantitation (LOQ) of the 









Table 3.5. Intraday and Interday precision and accuracy of the assay for the 
determination of sildenafil. 
Concentration Determined concentration RSD Accuracy 
(ng/ml) (ng/ml) a (%) (error %) 
Intraday 
800 790.6± 9.3 1.2 -1.2 
3000 2813.8±35.8 1.3 -6.2 
8000 7976.8±186.9 2.3 -0.3 
Interday 
800 835.3± 41 4.9 4.4 
3000 2865.7± 113.4 4 -4.5 
8000 8219.6 ± 396.5 4.8 2.8 




A published reversed phased HPLC method of Guermouche et al. [226] for 
quantitative determination of sildenafil in rat serum was adopted with some minor 
modification to investigate the protein binding of sildenafil in rat serum and 
microsomal protein. Instead of solid phase extraction procedures [226], a simple one 
step protein precipitation method was presently involved in the sample preparation for 
the subsequent determination of total concentration of sildenafil in serum and 
microsomal protein samples. It is not necessary to use the complicated extraction 
method to clean up any potential interference from biological samples.  The direct 
deproteinization method was found to produce effectively clean chromatographic 
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backgrounds (Figure 3.3 g and h) for subsequent measurement of the total 
concentration of sildenafil in rat serum and liver microsomal protein. 
 
Additionally, in this study, the separation was carried out on a shorter C18 column 
than that used previously [226]. Hence, a mobile phase composition of 50mM 
phosphate buffer (pH 8): acetonitrile (50:50 v/v) at the flow rate of 0.7ml/min was 
employed instead of using the composition of 45:55 v/v of the same mobile phase 
solution at the flow rate of 1ml/min [227]. Sildenafil was eluted faster around 6 min in 
this analysis instead of 11 min reported previously.  
 
In this study, the intraday and interday coefficients of variation were all less than 7% 
at the three QC concentrations of sildenafil with the accuracy varied from -6.2 to 4.4. 
LOQ of the present assay (50 ng/ml) was higher than that of the previous assay (10 
ng/ml). This may be due to the fact that simple one step precipitation method of 
sample preparation was employed in this study instead of using solid-phase extraction 
method previously [226]. However, the present assay method was adequately to 
quantify free concentration of sildenafil in all our serum and microsomal binding 
samples because a relatively high concentration of sildenafil was used in the present 




3.3. NORMAL PHASE HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHIC METHOD FOR DETERMINATION OF WARFARIN 





As commercially available warfarin is a racemic nature, the chiral separation methods 
of warfarin have also been developed to determine warfarin isomers and the isomers 
of its metabolites. To date, various stereospecific analytical methods namely 
supercritical fluid chromatography (SFC), gas chromatography (GC) and high 
performance liquid chromatography (HPLC) methods have been employed to carry 
out the enantiomeric separation [227].   
 
Additionally, some isomeric separations were also carried out by the capillary 
electrophoresis (CE) system. In the reported CE chiral separation method to date, 
several kinds of chiral selectors have been used such as alkyl glycoside surfactants 
[228], human serum albumin as buffer additives [229], maltodextrin [230, 231] and β-
cyclodextrin derivatives [231-233] under UV detection [234] . Some isomers 
determinations with HPLC involved either the application of chiral column in HPLC 
system [234, 235] or the pre-column derivatization of enantiomers using chiral 
derivatising agents prior to analyzing with normal phase HPLC system [210]. Out of 
these methods, HPLC is the most commonly used analytical method. 
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The stereospecific HPLC assay method of Banfield et al [210] was developed to 
analyze simultaneously warfarin enantiomers and its metabolites in biological fluids 
within the running time of 60mins. However, it was noted that some separation was 
not base-line resolution. As only (R) - and (S)-warfarin need to be investigated in rat 
serum and liver microsomal protein binding sample in the present study,  some 
modification of this stereospecific HPLC assay method [210] was adopted to measure 
warfarin enantiomers with baseline resolution. The method involved liquid-liquid 
extraction, followed by formation of warfarin enantiomers, using derivatizing agents. 
Hence, the chiral separation was done using silica stationary phase. 
 
3.3.2. Materials and Methods 
3.3.2.1 Chemicals and Reagents 
 
Racemic warfarin sodium salt and chlorowarfarin were obtained from Sigma 
Chemical Co. (St.Louis, MO, USA). 1, 3-dicyclohexylcarbodiimide, 99% (Cat.: D8, 
000-2) purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). 
Carbobenzyloxy-L-proline, 99% (Cat.: C8601) was purchased from Aldrich Chemical 
Company (Milwaukee, USA). Carboxymethyl-cellulose sodium salt (CMC-Na) (C-
5678) was purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany).  
Isotonic 0.067 M sodium phosphate buffer; PBS (pH 7.4) was bought from NUMI, 
National University of Singapore. For HPLC analysis, of HPLC grade, methanol, 
diethyl ether and n-hexane from Tedia (Fairfield, OH, USA), ethyl acetate from 
Fisher (Loughborough, Leics, UK) and of analytical grade, n-butylamine from Merck 
(Schuchardt, Germany) were purchased. All the solvents were degassed in ultrasonic 




The HPLC system for the assay of warfarin enantiomers consisted of a solvent 
delivery module (Shimadzu LC-10ATVP, Japan), an auto injector (Shimadzu, SIL-
10ADVP, Japan), a fluorescence detector (Shimadzu RF-10AXL, Japan), a system 
controller (Shimadzu, SCL-10AVP, Japan), a computer and workstation (Shimadzu 
Class-CR10, Japan). A stainless steel column (250 × 4 mm) packed with silica 
(MAXSIL 10 silica, 10 micron, Phenomenex, USA) maintained at 23°C (column 
temperature), was used for the separation of warfarin enantiomers. Bed reactor 
(stainless steel column 3 mm i.d., 25 cm) packed with glass beads (40 µm), was used 
for the post column aminolysis.  
 
The equilibrium dialysis system consisted of a Spectrum equilibrium dialyzer 
(Spectrum Laborztories Inc., USA) with teflon dialysis cells (type Semi-Micro) and 




3.3.2.3.1. Sample Preparation 
 
To prepare stock solutions of warfarin enantiomers, accurately weighted amount of 
racemic warfarin was dissolved with a few drops of 3M sodium hydroxide solution 
(NaOH) and diluted with Milli-Q water to obtain the concentration of 1000µg/ml. 
Working solution was prepared by mixing the stock solution with Milli-Q water to 
obtain desired concentrations.  
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The linear standard curves were constructed using PBS spiked with five 
concentrations of racemic warfarin, over the ranges of 1 - 18 µM. The calibration 
standards were freshly prepared on each analysis day by diluting 10µl of the working 
solutions with 100 µl PBS to obtain appropriate concentrations. The concentrations of 
1, 10 and 18 µM were selected as the quality control (QC) samples. 
 
3.3.2.3.2. Liquid-liquid Extraction 
 
200 µl of PBS sample (for determination of free drug) or serum/microsomal samples 
(for determination of total drug) was pipetted to a clean culture tube including 20µl of 
chlorowarfarin (10µg/ml) as internal standard. The samples were acidified with 500 
µl of 3 M hydrochloric acid. The mixture was extracted with 8 ml of perioxide free 
ether by horizontally shaking in the shaker (Gerhardt Bonn, Germany) at 200 rpm for 
45 minutes and centrifuged at 3000 rpm for 10 minutes. The upper ether layer was 
transferred to a clean nipple culture tube. A few granules of antibumping agent were 
added to each culture tube. The ether layer was evaporated on a heating block at 
45°C. The inside wall of the culture tube was then rinsed with 300 µl of peroxide free 
ether for 3 times. The ether was allowed to evaporate between each addition. Finally, 
the insider of the tube was washed with 200 µl of acetonitrile to concentrate the 
extracts. 
 
To a sample extract, 10 µl each of N, N-dicyclohexylcarbodiimide (DCHCDI) 
(200mg/ml acetonitrile) and carbobenzyloxy-L-proline (CBP) (200mg/ml acetonitrile) 
was added. Hence, the mixture was vortexed for 10 seconds, during which time the 
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precipitation was formed. Then, the tubes were uncapped and acetonitrile was let to 
evaporate overnight at room temperature. The residue was reconstituted with 100 ml 
of ethyl acetate and the mixtures were then vortexed for 10 seconds, followed by 
centrifuged at 3000 rpm for 10 minutes. The supernatant collected was subjected to 
HPLC analysis.  
 
3.3.2.3.3. Chromatographic Condition 
 
The analysis of warfarin enantiomers was carried out using stereospecific normal-
phase HPLC with the fluorescent detection at isocratic elution mode. The peaks were 
eluted at the pre-column mobile phase composition of ethyl acetate: hexane (26.5: 
73.5) with the flow rate of 1ml/min and post-column composition of methanol: 
butylamine (1:1) with the flow rate of 0.4ml/min. Methanol and butylamine were pre-
mixed before delivering to the HPLC system. The fluorescent detection was set at the 
excitation and emission wavelengths of 310 nm and 370nm respectively.  
 
3.3.2.4 Quantification of Warfarin Enantiomers in Rat Serum and Liver 
Microsomal Samples. 
 
Standard samples were obtained from blank samples (PBS, rat serum or liver 
microsomal protein) spiked with five different known concentrations of (RS)-
warfarin. For quantification of warfarin enantiomers in rat serum and liver 
microsomal protein binding samples, the standard calibration plots were constructed 
based on the peak area ratio of (R)-or (S)-warfarin to respective internal standard (R-
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or S-chlorowarfarin) versus the known (R)- or (S)-warfarin concentration (one half of 
the (RS)-warfarin concentration) in samples.  
 




The Linearity of the method was evaluated over 0.08 to 20 µM of the concentration 
ranges of warfarin enantiomers. Calibration standards were freshly prepared in every 
day during ongoing analysis.  
 
3.3.3.2. Intraday and Interday Accuracy and Precision 
 
Intraday and Interday accuracy and precision of the assay were assessed by 
performing replicate analyses of three QC sample concentrations (308.34, 3083.4 and 
5550 ng/ml). To investigate intraday repeatability, the assays of QC samples were 
performed triplicate on the same day. The assays of QC samples were assessed on 




Figure 3.5(a-h) show the chromatograms of blank rat serum, blank rat serum spiked 
with internal standard, blank rat serum spiked with (RS)-warfarin and internal 
standard, unbound warfarin enantiomers from the control serum protein binding 
sample and internal standard, blank rat liver microsomal protein, blank rat liver 
 67
microsomal protein sample spiked with internal standard, blank rat liver microsomal 
protein spiked with (RS)-warfarin and internal standard and  unbound warfarin 
enantiomers from the control liver microsomal protein binding sample and internal 
standard, respectively. The entire running time for one sample was within 38 min. The 
peaks were eluted in order of (S)-warfarin, (S)-chlorowarfarin, (R)-warfarin and (R)-
chlorowarfarin at the retention times of 21, 25, 28 and 33 mins, respectively. No 
interference was found in the analysis of isomers of warfarin and chlorowarfarin 











Figure 3.5. Chromatograms resulting from protein binding study of warfarin (a) 
blank rat serum,(b)blank rat serum spiked with internal standard,(c) blank rat serum 
spiked with (RS)-warfarin and internal standard,(d) unbound warfarin enantiomers 
from the control serum protein binding sample and internal standard, (e) blank rat 
liver microsomal protein, (f) blank rat liver microsomal protein sample spiked with 
internal standard, (g) blank rat liver microsomal protein spiked with (RS)-warfarin 
and internal standard, (h) unbound warfarin enantiomers from the control liver 
microsomal protein binding sample and internal standard .  
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Linearity was evaluated based on the coefficient of determination (i.e. r2) and visual 
inspection of the residual plots of the data points. Figure 3.6 shows the linear 
calibration plots for (R)-and (S)-warfarin, the linear equation for each with the r2 
value being close to the unity. The intraday and interday precision was presented by 
relative standard deviation (R.S.D) and accuracy was evaluated by percentage error. 
Table 3.6 presents the intraday and interday precision and accuracy for warfarin 
enantiomers at three quality control concentrations of 1, 10 and 18 µM. The limits of 
detection (LOD) and quantitation (LOQ) were 0.02 µΜ and 0.08 µM,   evaluated as 
warfarin molar concentrations of 3 × baseline noise and 10 × baseline noise, 
respectively, for each warfarin enantiomers.  
a 
Calibration curve for (S)-warfarin


















Calibration curve for (R)-warfarin 




































Table 3.6A. Intraday and Interday precision and accuracy of the assay for the 
determination of (S)-warfarin. 
Concentration Determined concentration RSD Accuracy 
(ng/ml) (ng/ml) a (%) (error %) 
Intraday 
308.34 324.8 ± 19.8 6.1 5.3 
3083.4 3050.5 ± 43.2 1.4 -1.1 
5550 5591.2 ± 64.2 1.1 0.74 
Interday 
308.34 316.6 ± 0.8 3.7 2.7 
3083.4 3103.3 ± 25.9 1.6 0.64 
5550 5567 ± 65.3 1.2 1 
a. the presented values are Mean ±SD 
 
Table 3.6.B. Intraday and Interday precision and accuracy of the assay for the 
determination of(R)-warfarin 
Concentration Determined concentration RSD Accuracy 
(ng/ml) (ng/ml) a (%) (error %) 
Intraday 
308.34 323.8 ± 18.8 5.8 5 
3083.4 3042.3 ± 116.7 3.8 -1.3 
5550 5545 ± 105 1.9 -0.1 
Interday 
308.34 317.2 ± 9.5 3 2.9 
3083.4 3104 ± 54.4 1.8 0.67 
5550 5538.8 ± 60 1.1 -0.2 





The reported normal-phase HPLC method of Banfield et al [210] was used with some 
modification for the quantitative analysis of warfarin enantiomers in serum or 
microsomal protein binding samples.  The method involved an extraction from 
acidified plasma or microsomes, removal of basic substances, and re-extraction into 
peroxide-free ether. The sample extraction was performed followed by derivatization 
of warfarin enantiomers.  
 
Several methods [213, 236-238] have been reported for the analysis of warfarin; each 
has some disadvantage in terms of specificity, sensitivity, reproducibility, or 
convenience. Fluorescence techniques often offer greater specificity, as well as 
enhanced sensitivity, over UV methods [234, 239]. Therefore, the normal-phase 
HPLC assay method coupled with fluorescence detection [210] was adopted in this 
study.  
 
This assay method [210] was validated to analyze warfarin enantiomers and its 
metabolites within 60 mins.  However, it was found that the two adjacent peaks (i.e., 
(S)-warfarin and (S)-chlorowarfarin, (R)-warfarin and (R)-chlorowarfarin), were not 
separated well at the baseline. As only the enantiomers of warfarin and chlorowarfarin 
(i.s) peaks were measured a simple modification of the mobile phase composition was 
performed to get better separation between the enantiomers of warfarin and 
chlorowarfarin with good reproducibility and accuracy. In this study, separations with 
baseline resolution were achieved using the mobile phase composition of ethyl acetate 
and hexane (26.5:73.5), the flow rate of 1 ml/min and the 250 mm x 4 mm i.d silica 
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column) instead of using a mixture of ethyl acetate, hexane, methanol and acetic acid 
(25 : 74.75 : 0.25 : 0.3), the flow rate of 0.8 ml/min and the 250 mm x 5 mm i.d silica 
column in the previous assay method [210].  
 
Furthermore, the reproducibility of the present study for both (R) - and (S)-warfarin 
was from 1.1 to 6.1% comparable to that 1.7 to 8.7% of the reported assay method 
Regarding the accuracy, the present study was slightly better with percentage error of 
0.64 to 2.9% compared to the reported values of 2.6 to 8.7%. . Moreover, LOD and 
LOQ of the assay method were 0.02µM and 0.08 µM, respectively. Hence, the present 
improved assay method was sensitive enough to measure quantitatively the unbound 










PROTEIN BINDING STUDY OF WARFARIN AND SILDENAFIL CITRATE 




Drug-protein binding is one of the important factors which influence the absorption, 
distribution, metabolism and excretion (ADME) related properties as well as 
pharmacodynamic properties of drugs. It is widely believed that only unbound drugs 
can penetrate into the blood vessels and exhibit the pharmacological effect while the 
protein bound drug cannot [240, 241]. 
 
In the case of serum protein binding, drugs commonly bind to serum albumin, 
lipoprotein, glycoprotein, α, β and γ globulin [242]. As more than half of the plasma 
protein is albumin, most of drugs bind to the albumin. However, some drug binds to 
single or multiple proteins due to its nature of either a weak or strong acid or base, or 
neutral [243]. Albumin is the major binding protein for acidic and neutral drugs while 
globulin is for basic drugs [243].  
 
The binding of a drug to the serum protein can be altered by the quality and quantity 
of serum protein, the serum concentration of the drug in the body, impaired renal or 
liver function and hypoalbuminaemia. Once two or more drugs are administered 
concurrently, the binding of one drug to serum protein may be inhibited by other 
drugs either competitively or non- competitively. The free fraction of one drug may 
be increased by displacement of serum binding site by other drug (s). Hence, the 
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displacement to the serum binding site can be a possible mechanism for drug-drug 
interaction [243]. The unfavorable drug interaction may be emerged when the drug is 
administered concurrently with highly protein bound drug which has long duration of 
action.  
 
Moreover, plasma protein has stereoselective binding capacity on a racemic drug. 
Therefore, the binding of isomers of the chiral drug to serum protein is different, as an 
example; warfarin. The previous study observed that warfarin is highly bound to rat or 
human serum albumin approximately 97~99 % [42, 59-61] and (S)-warfarin has more 
potent protein binding capacity than (R)-warfarin either in rat or human serum [46].  
 
According to the report of Pfizer, sildenafil is also highly bound to plasma protein and 
the protein binding is not dependent on the total drug concentration [177]. The finding 
of Walker et al [191] has shown that sildenafil is approximately 95 and 96 % bound to 
rat and human plasma protein, respectively and the binding is not dependent on the 
sildenafil concentration over the range of 0.01~10 µg/ml studied. The following 
factors are associated with increased plasma levels of sildenafil: age>65 (40% 
increase in AUC), hepatic impairment (e.g.; cirrhosis, 80%), severe renal impairment 
(creatinine clearance <30ml/min, 100%) [177], and concomitant use of sildenafil with 
potent cytochrome P450 3A4 I inhibitors such as ketoconazole, itraconazole, 
erythromycin, saquinavir) [177, 244]. However, insofar there is a lack of any reported 
study on the protein binding interaction between warfarin and sildenafil. 
 
In the recent years, the interest of in vitro metabolism study is increasing during new 
drug development [245, 246]. The drug metabolism and clearance are some of 
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influencing factors which maintain the action and duration of drug activity [247]. 
Hence, in drug discovery, the qualitative and quantitative prediction of in vivo 
metabolism and clearance are important to develop a new drug with optimal 
pharmacokinetic data [248].  
 
Successful prediction of in vivo pharmacokinetic parameters of the drug substance 
from in vitro data is not only saving animals, time and expense [249] but also 
reduction of potential risks involved in conducting human (in vivo) studies [250]. 
Human or rat liver microsomes are generally selected to study in vitro metabolism of 
drugs, because drug metabolism extensively take place in the liver [251]. The 
determination of intrinsic clearance which is the ratio of the maximal velocity and 
Michaelis-Menten constant (Vmax/Km) is critical to evaluate the metabolic pathway. 
Moreover, the nonspecific binding of drug to liver microsomal protein or membrane 
can alter its intrinsic clearance [83, 84, 252]. Prediction of in vivo pharmacokinetic 
parameters from in vitro metabolic assay data based on unbound fraction of substrate 
is more accurate than that based on observed total substrate [83, 84].  
 
In order to get the accurate prediction of metabolic interaction of warfarin and 
sildenafil, information on the microsomal protein binding of both drugs either given 
alone or in combination is required. To our knowledge, there is no published report on 
the binding of sildenafil to liver microsomal protein. However, liver microsomal 
protein binding of racemic warfarin to human liver microsomes [83, 84] as well as to 
rat liver microsomes have been reported [253]. 
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It has been shown that the microsomal protein binding of racemic warfarin is 
dependent on both the microsomal protein and warfarin concentrations. The 
microsomal protein binding of racemic warfarin increases from 1 to 53% with an 
increase of the former from 0.1 to 10 mg/ml, but declines from 27 to 5 % as the latter 
is increased from 1 to 100 µM [254].  
 
In this study, the serum and liver microsomal protein binding of warfarin enantiomers 
and sildenafil were investigated in undiluted pooled rat serum and rat liver 
microsomal protein at the concentration of 1.6 mg/ml which was the same protein 
concentration used in in vitro metabolism study (Section 6.2.5).  
 
There are many established methods to determine the protein binding of the drugs 
such as equilibrium dialysis, ultrafiltration, ultracentrifugation and high-performance 
liquid chromatography [255]. Among them, equilibrium dialysis and ultrafiltration 
methods are most commonly used. The equilibrium dialysis was employed to 
determine the serum protein binding of warfarin and sildenafil in the present study. 
  
4.2. Materials and Methods 
 
4.2.1. Chemicals and Reagents 
 
Racemic warfarin sodium salt and chlorowarfarin were purchased from Sigma 
Chemical Co. (St.Louis, MO, USA). Sildenafil was obtained from Zhejiang Jiayuan 
Pharmaceutical Industry Co., Ltd, China. The undiluted serum and liver from young 
male Sprague-Dawley rats, which were supplied by Laboratory Animal Center 
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(National University of Singapore), was employed in this study. 1, 3-
dicyclohexylcarbodiimide (DCHCDI), 99% (Cat.: D8, 000-2) from Sigma-Aldrich 
Chemie GmbH (Steinheim, Germany). Carbobenzyloxy-L-proline (CBP), 99% (Cat.: 
C8601) from Aldrich Chemical Company (Milwaukee, USA) and   carboxymethyl-
cellulose sodium salt (CMC-Na)(C-5678) from Sigma-Aldrich Chemie GmbH 
(Steinheim, Germany) were purchased.  
 
Of HPLC grade, acetonitrile from Fisher (PA, USA) and ethyl acetate from Fisher 
(Loughborough, Leics, UK) were purchased. Of analytical grade, n-butylamine from 
Merck (Schuchardt, Germany), methanol, diethyl ether and n-hexane from Tedia 
(Fairfield, OH, USA), dibasic sodium phosphate and monobasic sodium phosphate 
were purchased from Merck (Schuchardt, Germany). All solutions were prepared 
using eighteen MΩ water generated by Milli-Q RG Millipore water purification 




The HPLC system for the assay of warfarin enantiomers consisted of a solvent 
delivery module (Shimadzu LC-10ATVP, Japan), an auto injector (Shimadzu, SIL-
10ADVP, Japan), a fluorescence detector (Shimadzu RF-10AXL, Japan), a system 
controller (Shimadzu, SCL-10AVP, Japan), a computer and workstation (Shimadzu 
Class-CR10, Japan). A stainless steel column (250 × 4 mm) packed with silica 
(MAXSIL 10 silica, 10 micron, Phenomenex, USA) maintained at 23°C (column 
temperature), was used for the separation of warfarin enantiomers. Bed reactor 
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(stainless steel column 3 mm i.d., 25 cm) packed with glass beads (40 µm), was used 
for the post column aminolysis.  
 
The equilibrium dialysis system consisted of a Spectrum equilibrium dialyzer 
(Spectrum Laborztories Inc., USA) with teflon dialysis cells (type Semi-Micro) and 
dialysis membranes (Spectra/Por 3, 3500 MWCO). The pH of a buffer solution was 
measured with pH meter (EcoMet, Istek, Seoul, Korea) and the solution was filtered 
through a 0.20µm hydrophilic polypropylene membrane filters (Pall Corporation, 
Michigan, USA) and degassed in ultrasonic bath (Transsonic T460, Singen, Germany) 
prior to its use. 
 
4.2.3. In Vitro Protein Binding Study in Rat Serum or Liver Microsomes 
 
The serum or liver microsomal protein binding of warfarin in the absence and the 
presence of sildenafil as well as that of sildenafil in the absence and the presence of 
warfarin was studied by equilibrium dialysis. An appropriate amount of (RS)-warfarin 
was dissolved in a few drops of 3M sodium hydroxide solution and diluted with Milli-
Q water to prepare the desired final concentrations. Sildenafil solution was prepared 
in acetonitrile: milli-Q water (1:1 v/v) and it was diluted with the mixture of 
acetonitrile and water to prepare the desired concentrations.  
 
For warfarin serum binding study, 10 µl of known amount of warfarin at various 
concentrations and either 10 µl of acetonitrile and water mixture for control study or 
10 µl of known amount of sildenafil solution for combination study, were added to 1 
ml of rat blank serum/liver microsomal protein. Likewise, for the serum binding study 
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of sildenafil, 10 µl of known amount of sildenafil at various concentrations and either 
10 µl of milli-Q water for control study or 10 µl of known amount of warfarin 
solution for combination study, were added to 1 ml of rat blank serum/liver 
microsomal protein. The final concentrations of warfarin and sildenafil for the serum 
and liver microsomal protein binding studies are presented in Table 4.1.  
Table 4.1. Final concentrations of (RS)-warfarin and sildenafil in serum and liver 
microsomes. 
 Final concentration (µM) 
 In Serum In Liver Microsomes 
For the protein binding study of warfarin 
(RS)-warfarin 25, 50 , 100 1.25, 10, 20, 50 
Sildenafil 100 10, 100 
   
For the protein binding study of sildenafil 
Sildenafil 25, 100 5, 50 
(RS)-warfarin 10, 100 1, 10, 100 
   
 
The dialysis membrane tubing was soaked in distilled water for about 15 mins. It was 
then opened and cut into two equal pieces (~ 1.5 inches). These membrane pieces 
were treated for use by several washing with distilled water and subsequently soaking 
in 30% of ethanol, distilled water and 0.067 M sodium phosphate buffer (pH 7.4). 
Then, each piece of dialysis membrane was placed between two half dialysis cells. 
The samples were placed in one half of the dialysis cells and equilibrated against 1 ml 
of isotonic 0.067 M sodium phosphate buffer (pH 7.4) which was placed in the other 
half cell. The dialysis system was immersed in 37°C temperature control water bath 
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and rotated for 4 hours by which the equilibrium was achieved. At the end of 
experiment, the samples from both buffer and serum/liver microsomal protein sides 
were collected and stored at -20°C until being subject to HPLC analysis. 
 
Prior to measurement of warfarin using HPLC analysis, the samples obtained from 
both the buffer and serum/liver microsomal protein sides were extracted using liquid-
liquid extraction method, followed by formation of warfarin diastereoisomeric esters 
with the derivatizing agents (OCHCDI and CBP). The method was briefly described 
in Section 3.3.3.2. 
 
To determine free serum or liver microsomal concentration of sildenafil, sample from 
buffer side (20µl) was directly submitted to HPLC system. For the measurement of 
the total concentration of sildenafil in serum or liver microsomes, a single protein 
precipitation method briefly described in Section 3.2.2.2 was involved. 20µl of aliquot 
was uploaded to HPLC to determine total concentration of sildenafil. 
 
The extent of volume shift during dialysis of serum samples was assessed by 
measuring pre- and post-dialysis protein concentrations in serum, which were 
determined using Bradford’s standard method with bovine serum albumin as a 
standard calibrator [256]. The fractional increase in the volume of the protein 
compartment (δ) was determined using the following equation [257]. 
 




where P is the protein concentration. The observed unbound fraction (fu,obs) was 
corrected for volume shift to calculate the true unbound fraction (fu,true) using the 








ff −++= δ      (4.2) 
 
Unlike dialysis experiment with undiluted serum protein, the volume shift might not 
take place significantly in the compartment of liver microsomal protein as the osmotic 
force in latter with lower protein concentration was weaker than that in the former 
[259]. Therefore, no adjustment with respect to volume shift was made for the 
determination of free and bound drugs fraction. The percent of unbound fraction of 
drug was estimated as follows [260]. 
 
( ) 100%, •=
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4.2.4. Analytical Methods for Warfarin and Sildenafil Measurement. 
 free or total concentration of sildenafil in rat serum and liver 
icrosomes.  
.2.5. Statistical Analysis  
dent 
ariables. A p-value of less than 0.05 was considered as statistically significant.  
.3. Results 
.3.1 Interaction of Warfarin and Sildenafil in the Rat Serum Protein Binding  
 
Normal phase high performance liquid chromatography method, as described in 
Section 3.3.2.3.3, was used to measure the free and total concentrations of warfarin in 
rat serum and liver microsomes, while reversed-phase high performance liquid 






Statistical analyses were performed using SPSS 12.0 (SPSS Inc. Chicago, IL, USA). 
Data were expressed as mean ± standard deviation (SD). Comparison of means of 
related samples from two independent groups were made using the respective 
Student’s paired-samples and independent-samples t test. In case of multiple 
comparisons (control and interaction groups) was performed using one-way analysis 
of variance (ANOVA). Nonparametric correlation analysis (Spearman rank 









enantiomers was observed (P>0.05), though the unbound fraction values of both (R)-
and (S)-warfarin were slightly higher, in the presence of sildenafil. 
The determination of the effect of sildenafil on the serum protein binding of warfarin 
enantiomers was carried out in pooled rat serum and the relatively high concentration 
of sildenafil was chosen (100µM) because of highly protein binding property of 
warfarin. The finding of this study confirmed that warfarin is ~99% bound to pooled 
rat serum protein concentration of 75 mg/ml estimated in the present study. As 
presented in Table 4.2 and Figure 4.1, the unbound fraction values of warfarin 
enantiomers appeared to be consistent over the range of racemic warfarin serum 
concentrations studies of (25, 50 and 100 µM). Thus, the serum binding of warfarin 
was not concentration-dependent. The unbound fraction of (R)-warfarin was 
significantly higher than that of (S)-warfarin (P<0.01). The ratio of unbound fraction 
of (R) - and (S)-warfarin (R/S) for control study ranges from 1.75 to 1.79, while that 
for combination study ranges from 1.71 to 1.73 (Table 4.2 and Figure 4.1).  But, the 
R/S ratio for combination group tended to be lower when compared to the control 
group. No statistically significant change in the fraction unbound of warfarin 
Group Unbound fraction of (S)-warfarin (%)  Unbound fraction of (R)-warfarin (%) 
 25µM    50µM 100µM  25µM 50µM 100µM 
Control  0.5 ± 0.014 (3) 0.52 ± 0.008 (3) 0.51 ± 0.008 (3)  0.91 ± 0.02 (3)+++ 0.92± 0.003 (3)+++ 0.91 ± 0.01 (3)+++
R/S ratio 1.79 ± 0.05 (3) 1.75 ± 0.03 (3) 1.77 ± 0.03 (3)     
Total 0.51 ± 0.012 (9)    0.91 ± 0.01 (9)+++   
       
  
R/S ratio 1.77 ± 0.04 (9)       
 
Sildenafil (100µM) 0.54 ± 0.01 (3) 0.54 ± 0.02 (3) 0.54 ± 0.03 (3)  0.9 ± 0.01 (3)+++ 0.92 ± 0.01 (3)++ 0.94 ± 0.01 (3)++
R/S Ratio 1.71 ± 0.073 (3) 1.73 ± 0.12 (3) 1.71 ± 0.035 (3)     
Total  0.54 ± 0.02 (9)    0.93 ± 0.01 (9)+++
R/S Ratio 1.73 ± 0.06 (9)       
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Values presented are mean ± SD. Figures in parentheses indicate the number of determinations. ++P<0.01, +++P<0.001 as compared with the 
corresponding unbound fraction values of the (S)-enantiomer.








































































































































Figure 4.1 Graphs for in vitro effect of sildenafil on the rat serum protein binding of 
(a) (S)-warfarin, (b) (R)-warfarin and (c) the ratio of unbound fraction of R/S 
warfarin.  Data presented are the mean±SD of 3 determinations. 
 
 
The serum protein binding of sildenafil in the absence and the presence of warfarin 
was examined in pooled rat serum protein with the concentrations of sildenafil at 10 
and 100 µM. As shown in Table 4.3 and Figure 4.2, sildenafil was highly bound to the 
pooled rat serum (~95%). The fraction unbound of sildenafil was concentration-
independent over the range of sildenafil serum concentration studied (10~100 µM). 









Table 4.3. In vitro effect of warfarin on the protein binding of sildenafil in pooled rat 
serum.  
Group Unbound fraction of sildenafil (%) 
  25µM 100µM 
Control  5.06 ± 0.08 (3) 5.07 ± 0.06 (3) 
Total 5.07 ± 0.06 (6)  
   
Warfarin (10µM) 5.08± 0.37 (3) 5.1 ± 0.1 (3) 
Total  5.09 ± 0.24 (6)  
   
Warfarin (100µM) 5.05± 0.12 (3) 5.27 ± 0.17 (3) 
Total  5.16 ± 0.18 (9)  
      














































Figure 4.2 Graph for in vitro effect of warfarin on the rat serum protein binding of 




4.3.2 Interaction of Warfarin and Sildenafil in the Rat Liver Microsomal 
Protein Binding 
 
The determination of the effect of sildenafil on the rat liver microsomal protein 
binding of warfarin enantiomers was carried out in pooled rat liver microsomes and 
the two concentrations of sildenafil were chosen (10 and 100µM).  As presented in 
Table 4.4 and Figure 4.3, with an increase of racemic warfarin concentrations from 
1.25µM to 50 µM, the unbound fraction of (S)-warfarin enantiomer increased from 
61.8 to 70.7% while that of (R)-warfarin enantiomer increased from 84.6 to 88.9% in 
the absence of sildenafil, a statistically significant correlation (Spearman rank 
correlation) was found between the concentrations of (RS)-warfarin and the unbound 
fraction of (S)-warfarin (P<0.01) and (R)-warfarin (P<0.05). The unbound fraction of 
(R)-warfarin was significantly higher than that of (S)-warfarin (P < 0.01). The ratio of 
unbound fractions of (R) - and (S)-warfarin (R/S) decreased from 1.37 to 1.32 with an 
increase of warfarin concentration in the control studies (Figure 4.3.c). As shown in 
Table 4.4, there was no change in R/S ratio over the concentration range of (1.25~50 
µM) of warfarin concentration, indicating that sildenafil affected on the liver 
microsomal binding of (R)-and (S)-warfarin enantiomers by the same extent over the 
concentration range of (RS)-warfarin studied. However, the presence of a high 
concentration of sildenafil (100µM) significantly increased the unbound fraction of 
both (S)-and (R)-warfarin over the concentration range (10~50µM) of warfarin 
(P<0.05). The microsomal protein binding of (RS)-warfarin was also calculated based 
on the equation 4.4. Table 4.5 shows the unbound percent of (RS)-warfarin in rat liver 
microsomal protein.  
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Values presented are mean ±SD. Figures in parentheses indicate the number of determinations. ++P<0.01 and +++P<0.001 as compared with the 
corresponding unbound fraction values of the (S)-enantiomers. 
Group Unbound fraction of (S)-warfarin (%)   Unbound fraction of (R)-warfarin (%) 
  1.25µM         10µM 20µM 50µM 1.25µM 10µM 20µM 50µM 
Control 61.78 ± 2.5(3) 63.31 ± 1.3 (3) 67.31 ± 3.1 (3) 70.71 ± 1.2 (3)  84.63 ± 0.2 (3) ++ 85.59 ± 1.3 (3)++ 87.73 ± 2.8 (3)++ 88.9 ± 0.5 (3)++
R/S ratio 1.37 ± 0.05 (3) 1.35 ± 0.04 (3) 1.3 ± 0.06 (3) 1.26 ± 0.02 (3)      
Total 65.78 ± 4.1 (12)     86.71 ±2.2(12)+++    
         
   
         
   
R/S ratio 1.32 ± 0.06 (12)         
 
Sildenafil (10µM) 63.47 ± 1.7 (3) 64.57 ± 0.8 (3) 69.21 ± 1.6 (3) 71.26 ± 1.5 (3)  85.24 ± 0.4 (3)++ 86.82 ± 0.2 (3)++ 88.62 ± 2.2 (3)++ 92.24 ± 0.9 (3)++
R/S ratio 1.34 ± 0.03 (3) 1.34 ± 0.02 (3) 1.28 ± 0.04 (3) 1.3 ± 0.03 (3)      
Total 67.13 ± 3.6 (12)     88.23 ±2.9(12)+++
R/S ratio 1.32 ± 0.04 (12)         
 
Sildenafil (100µM) 65.73 ± 0.5 (3) 66.94 ± 0.57 (3) 69.48 ± 0.4 (3) 71.91 ± 1.1 (3)  85.49 ± 1.5 (3)++ 87.37 ± 1.4 (3)++ 91.67 ± 0.4 (3)++ 93.1 ± 0.2 (3)++
R/S ratio 1.3 ± 0.03 (3) 1.31 ± 0.02 (3) 1.32 ± 0.005 (3) 1.3 ± 0.03 (3)      
Total 68.51 ± 2.6 (12)     89.4 ± 3.3 (12)+++
R/S ratio 1.3 ± 0.02 (12)         




































































































































Figure 4.3. Graphs for in vitro effect of sildenafil on the rat liver microsomal protein  
binding of (a) (S)-warfarin, (b) (R)-warfarin and (c) ratio of unbound fraction % of 
R/S. Values presented are mean±SD of 3 determinations. 
 
 
Table 4.5. In vitro effect of sildenafil on the protein binding of (RS)-warfarin in 
pooled rat liver microsomes 
Group Unbound fraction of (RS)-warfarin (%) 
  1.25µM 10µM 20µM 50µM 
Control 72.32 ± 1.5(3) 73.67 ± 0.3 (3) 76.9 ± 2.5 (3) 79.3 ± 0.8 (3) 
Total 75.56 ± 3.2 (12)    
     
Sildenafil (10µM) 73.29 ± 1.1 (3) 75.02 ± 0.4 (3) 78.4 ± 1.3 (3) 81.15 ± 0.8 (3) 
Total 77 ± 3.6 (12)    
     
Sildenafil (100µM) 74.75 ± 0.5 (3) 76.56 ± 0.6 (3) 79.85 ± 0.4 (3) 81.89 ± 0.7 (3) 
Total 78.3 ± 3.2 (12)    
Values presented are mean ± SD. Figures in parentheses indicate the number of 
determinations 
c 
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The rat liver microsomal protein binding of sildenafil in the absence and the presence 
of warfarin was examined in pooled rat liver microsomes with the concentrations of 
warfarin at 1, 10 and 100 µM. As shown in Table 4.6 and Figure 4.5, sildenafil was 
bound to the rat liver microsomes approximately 45% and was independent of 
sildenafil concentration over the range of 5 to 50 µM studied. There was no 
statistically significant change in liver microsomal protein binding of sildenafil in the 
presence of warfarin over the concentration range of 1∼10µΜ was found (P>0.05). 
However, the present of a high concentration of warfarin (100µM) significantly 
decreased the unbound fraction of sildenafil over the concentration range (5~50µM) 
(P<0.05). 
 
Table 4.6. In vitro effect of warfarin on the protein binding of sildenafil in pooled rat 
liver microsomes  
 
Group Unbound fraction of sildenafil (%) 
  5µM 50µM 
Control  54.9 ± 0.8 (3) 55.4 ± 0.58 (3) 
Total 55.2 ± 0.67 (6)  
   
Warfarin (1µM) 54.5± 0.5 (3) 54.6 ± 0.13 (3) 
Total  54.5 ± 0.23 (9)  
   
Warfarin (10µM) 53.6± 0.94 (3) 54 ± 0.3 (3) 
Total  53.8 ± 0.55 (6)  
   
Warfarin (100µM) 52.8± 0.67 (3)+ 53.1± 0.9 (3)+
Total  52.9 ± 0.75 (9)+  
    
Values presented are mean ± SD. Figures in parentheses indicate the number of 
determinations. +P<0.05 as compared with the corresponding unbound fraction 
percent of control samples. 
 











































Figure 4.5. Graph for in vitro effect of warfarin on the rat liver microsomal protein 




A large number of workers have investigated drug-drug interactions, which result at 
least partly from the drug displacement in the protein binding. There are a few factors 
that may influence the protein binding of drugs. These include age, hepatic 
insufficiency, renal failure and drug interaction [38, 43, 57]. In the present study, the 
serum and microsomal protein bindings of warfarin in the absence and presence of 
sildenafil as well as those of sildenafil in the absence and presence of warfarin using 
pooled rat serum were investigated.  
 
The plasma protein binding studies of warfarin in either racemic or enantiomeric form 
have been performed by many workers [38, 43, 57]. As shown in Table 4.2 and 
Figure 4.1, warfarin is highly bound to rat serum protein, approximately 99.5% for 
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(S)-warfarin and 99.1% for the (R)-warfarin. Weak acidic drugs with pKa < 6.1 such 
as; naproxen and phenylbutazone are more than 95% ionized at plasma pH 7.4 and 
they are almost wholly bound to the albumin with high affinity [257]. Warfarin is a 
weak acidic drug with pKa 5.1, which is highly bound to human serum protein [261] 
as well as to rat serum protein [262, 263]. Its anticoagulant activity is directly 
proportionally to the free amount of drug in serum because the serum binding is the 
major determinant of distribution and elimination kinetics of warfarin [55, 261].  
 
In the present study, the stereospecific binding of warfarin to serum protein was 
determined instead of non-stereospecific binding. There was no significant variation 
of protein binding of (S)-or (R)-warfarin over the range of 25 ~ 100 µM racemic 
warfarin studied, yet, the protein binding values of the two warfarin enantiomers were 
obviously different (Table 4.2 and Figure 4.1). Compare to (R)-warfarin, the more 
potent (S)-isomer had higher bind affinity with the R/S ratio of 1.79±0.05. These 
results were in agreement with the findings of previous studies [57, 264]. Moreover, 
the previous studies in man also show that the two isomers of warfarin have different 
binding capacities to the serum protein and the more potent isomers; (S)-warfarin has 
higher binding capacity than (R)-warfarin [43, 46].  
 
There are several cases reported in man of the protein displacement of warfarin by 
other drugs [43, 52, 57, 103, 105, 264] as one possible source of drug-drug 
interaction. The displacement of warfarin enantiomers from their protein binding sites 
by phenylbutazone (100mg/l) causes an increase in free fraction of (S)-warfarin (0.58 
to 1.4 %) and (R)-warfarin (0.59 to 1.28 %) [43]. However, the unbound fraction 
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values of warfarin enantiomers in rat serum are not significantly changes in the 
present of either omerprazole [57] or ubidecarenone [264].  
 
Sildenafil citrate (Viagra) is the first oral administration drug for erectile dysfunction 
[265] which is relatively a new drug in the drug discovery. Therefore, only a few 
studies on the serum protein binding of sildenafil either in man [177, 191] or in rat 
[177, 191] have been reported. Our finding indicates that sildenafil is highly bound to 
rat serum protein, approximately 95%, which appears to be independent of sildenafil 
concentration over the range of 10~100 µM studied. The result is consistent with the 
reported observation [191] that sildenafil is highly bound to either rat or human serum 
protein and its binding capacity was not dependent on the sildenafil concentrations 
over the ranges of 0.01~10 µg/ml  (i.e., 0.015~15 µM) [191].   
 
There was no apparent competition between warfarin and sildenafil for the serum 
protein binding site as both drugs caused no significant change each other in the 
unbound fraction in rat serum (Tables 4.2, 4.3 and Figures 4.3, 4.4). In general, weak 
acidic drugs with pKa of 3 ~ 6 are highly ionized at plasma pH and wholly bound to 
albumin with high binding affinity, while weak basic drugs are more or less ionized at 
that pH and these drugs bind not only to albumin but also to other circulating protein 
such as lipoprotein, acidic α1-glycoprotein and γ-globulins. Thus, at plasma pH 7.4, 
the acidic drug warfarin with pKa of 5.1 is 99.5% ionized and it is mainly bound to 
albumin site I [266]. However, the weak basic drug sildenafil with pKa of 6.5 and 9.2 
is 11.2 and 98.4% ionized at that pH and it may bind not only to albumin but to other 
serum protein as well. Therefore, warfarin and sildenafil are not competitively bound 
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to serum albumin and protein binding could not be a mechanism for warfarin and 
sildenafil drug interaction in serum. 
 
Regarding to the interaction of warfarin and sildenafil in the rat liver microsomal 
protein binding, our result shows that both of warfarin and sildenafil bound to pooled 
rat liver microsomal protein with a low extent (Tables 4.4, 4.5 and Figures 4.3, 4.4) 
and the unbound fraction of (R)-warfarin was significantly higher than that of (S)-
warfarin in rat liver microsomal protein. The latter is consistent with the finding of 
Searcey et al show that warfarin binding protein isolated by cosedimentation with rat 
ribosomes, was selective for the (S)-enantiomer of warfarin [259]. There are one or 
more saturable binding sites in liver tissue for 4-hydroxycoumarin [253]. Covell et al. 
found that the hepatic warfarin binding capacity is 2.7 µg/ml and a Kd (the 
dissociation constant of warfarin-rat liver microsomal protein complex) is 1.5 ng/ml 
in liver tissue of hepatoectomized rats [267].  Scatchard analysis of in vivo steady-
state tissue levels of the (S)-enantiomer of acenocoumarol in rat liver has indicated 
that there is a single binding site for that with the binding capacity of 4nmol/g 
(0.0012µg/ml) liver tissue and Kd of 7nM (0.0022µg/ml) [268] but discords with the 
finding of Thisjssen et al that there was no difference in binding capacity of both (R) - 
and (S)-warfarin to liver microsomal protein of warfarin resistant rat. [253].    
 
The discrepancy in observations might be due to the use of different strains of rat in 
preparation of liver microsomal protein and of different microsomal preparation 
method. Additionally, filtration method was employed for the protein binding 
measurement in reported study [253], whereas equilibrium dialysis was used in this 
study.  
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Table 4.5 shows that the binding of (RS)-warfarin to rat liver microsome is dependent 
on the concentration of warfarin. Unbound fraction of racemic warfarin varied from 
72.3 to 79.3 % with an increase of racemic warfarin concentration from 1.25 to 50 
µM at the rat microsomal protein concentration of 1.6 mg/ml. The finding of Obach et 
al [83] also showed that unbound fraction of (RS)-warfarin increased from 72% to 92 
% with an increase of warfarin concentration over the same range at the human 
microsomal protein concentration of 1mg/ml. The unbound fraction of (RS)-warfarin 
in the previous study [83] was slightly higher than that in the present study due to the 
fact that the binding of warfarin is dependent on microsomal protein concentration 
[83].  
 
To date, there has been no literature data available for the microsomal protein binding 
of sildenafil. In general, the basic compounds play a greater extent of binding to 
microsome rather than the acidic and neutral compounds [84]. The present result 
agrees well with this aspect since weak basic drug demonstrated a greater binding to 
microsome compared to the weak acidic drug warfarin. (Table 4.4, 4.5 and Figures 
4.3, 4.4)  
 
The overall findings of this study show that warfarin and sildenafil affect each other 
the liver microsomal protein binding in a very different manner. The fu of (S)-and (R)-
warfarin was increased with an increasing concentration of sildenafil (displacement 
effect) as shown in Figure 4.3 and Table 4.4, whereas that of sildenafil was decreased 
with the increasing concentration of warfarin (positive allosteric effect) as shown in 
Figure 4.4 and Table 4.6. The interaction of warfarin and sildenafil was more 
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prominent when in the presence of its high molar concentration. It is noted that both 
trends are statistically significant (Spearman rank correlation, p<0.05). 
 
Both of warfarin and sildenafil have greater binding affinity to serum protein than to 
rat liver microsome. (Table 4.2 and 4.4, 4.3 and 4.6 and Figures 4.1 and 4.3, 4.2 and 
4.5). It is partly due to the fact that the protein concentration in serum (75mg/ml) is 
much higher than that in liver microsome (10 mg/ml). Therefore, only a small 




















EFFECT OF SILDENAFIL ON THE IN VITRO METABOLISM OF 
WARFARIN IN RAT AND HUMAN LIVER MICROSOMES AND 




Once drug is administered orally, it has subsequently undergone through absorption, 
distribution, metabolism and excretion (ADME) mechanisms at various rates. To 
achieve desired effect of drug, it is important to maintain the effective concentration 
of drug at receptor site with sufficient duration. As drug is constantly eliminated from 
the body, it is necessary to balance rate of drug administrative against rate of drug 
elimination to maintain the desired drug concentration in the body [269]. 
 
Metabolism is the main mechanism for elimination of many lipophilic drugs such as 
warfarin, phenytoin, chlorpromazine, propranolol, from the body and the liver is the 
major site of drug metabolism. Most of these drugs are metabolized by two phases, 
namely phase I and phase II which convert substrates (i.e., drugs) to be water soluble 
compounds to facilitate them elimination from the body [270, 271]. Phase I 
metabolism can involve reduction or hydrolysis of the drugs, but oxidation is the most 
common reaction of phase I metabolism while conjugation is that of phase II 
metabolism. Normally, Cytochrome P450 monooxygenase, azo and nitro group 
reductase, aldehyde dehydrogenase, epoxide hydrolase, monoamine oxidase, flavin 
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monoamine oxidase and non-specific esterases carry out oxidative and reductive 
reaction while nonspecific- N and O-methyl transferases, D-glucuronic acid 
transferase, glutathione transferase and sulphate transferase carry out phase II 
conjugative reaction [271].  
 
Among these enzymes, the drugs are mostly metabolized by oxidation pathway which 
mediated by cytochrome P450 (CYP450) [272]. CYP450 is a heme-containing 
superfamily enzyme found in bacteria, archaea and eukaryotes. The name 
“cytochrome P450” is derived from the fact that these are colored (chrome) cellular 
(cyto) proteins, with a heme pigments (P) which gives spectral absorbance peak of 
their carbon monoxide bound species at 450nm [273]. Animal cytochrome P450s are 
found either in the inner membrane of mitochondria or in the endoplasmic reticulum 
of cells. The hepatic microsomes are obtained by isolation of the hepatic parenchymal 
cells [274]. CYP450 enzymes are mostly expressed in the liver but also occur in other 
tissues of the body such as small intestine, lungs, placenta, and kidneys [275]. 
CYP450 which is located in the mucosa of the gastrointestinal tract takes part in 
hormone synthesis and breakdown, cholesterol synthesis, and vitamin D metabolism. 
Hepatic cytochromes P450 are extensively employed for the study of the P450 
enzymes [276]. Cytochrome P450 consists of more than 50 isozymes which contain 
closely related amino acid but differ in their protein sequence and specificity to 
substrates [277].   
 
The heme iron center is the active site of CYP 450. The iron binds to the P450 protein 
via a thiolated ligand derived from a cysteine residue. The cytochrome P450 catalyzes 
in various oxidation reactions. The most common oxidation reaction is 
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monooxygenase reaction by insertion of a single oxygen atom into the drug molecule 
while the other oxygen atom is reduced to water [271, 278].  
 
RH + O2 + 2H+ + 2e -    ROH + H2O    (5.1) 
 
Although there are many other drug metabolizing enzymes, most of CYP450 
isozymes can metabolize thousands of endogenous and exogenous compounds 
including drugs. The class of CYP450 enzymes metabolizes 90% of drugs and many 
of them can carry out various reactions [275, 279]. Some drugs are metabolized by 
only one CYP450 enzyme (e.g., metoprolol by CYP2D6) while some are by multiple 
enzymes (e.g., warfarin by CYP1A2, CYP2C9, CYP3A4, and CYP2C19). Moreover, 
many drug interactions result from the alteration of CYP450 metabolism [275, 280]. 
Some drugs induce the metabolism of CYP450 whereas some inhibit CYP450 
metabolism [139, 211]. Therefore, CYP450 represents the most important enzymes 
for the study of drug metabolism and drug-drug interaction. Hence, there is an 
increasing amount of interests in the study of CYP450 metabolism [275, 279, 281]. 
 
There are numerous reports over the metabolism study of warfarin either in human 
liver microsomes [139, 211, 282] or in rat liver microsomes [57, 139, 276, 283], but 
differences in the formation of metabolites are observed in the different studies. It 
may be due to the differences in sources of liver microsome, microsome preparation 
method and incubation method. The isomers of warfarin are slightly different in the 
metabolic pathways. It is highly metabolized in liver and only 2-5% of dose appears 
unchanged in human urine [9, 30, 77] and 5-9% in rat urine [276]. Approximately 
88% of (S)-warfarin and 85% of (R)-warfarin are metabolized to 4’-, 6-, 7- and 8-
                                                                                                                                   103
 
hydroxywarfarin in rat [64]. According to the study of Pohl et al., (1976), in rat, the 
main metabolic pathway of (S)-warfarin is 4’-hydroxylation, followed by 6- and 7-
hydroxylation while the major metabolite for (R)-warfarin is 7-hydroxywarfarin, 
followed by 6- and 4’-hydroxywarfarin [276]. However, Herman et al., (1991) 
observed that the metabolic pathways for (S)-and (R)-warfarin in rat liver microsome 
are in the same sequences of 6-, 7- and 4’-hydroxylation [284].  
 
In man, (S)-warfarin is mainly metabolized by CYP2C9 to its phenolic metabolites, 7- 
and 6-hydroxywarfarin while the major routes of (R)-warfarin termination are the 
reduction to its inactive warfarin alcohol and the CYP3A4 mediated hydroxylation to 
its phenolic metabolites [17, 79] . Approximately greater than 80% of more potent 
(S)-warfarin in racemic dose is metabolized to (S)-7-hydroxywarfarin and (S)-6-
hydroxywarfarin [70, 132]. The anticoagulant action of warfarin is mainly dependent 
on the elimination of more potent (S)-warfarin. Hence, it may alter the action of 
warfarin and may cause important drug interaction if there is a co-administered drug 
which is also extensively metabolized in liver.  
 
In recent years, there is a large amount of increasing interests in the in vitro 
metabolism study of drug interaction because it is easier to work with than the whole 
animal and it saves many of animal lives. Hepatocytes and liver microsomes are the 
commonly used to investigate metabolism of drug and metabolic drug-drug 
interactions. There are a number of published papers which studied on in vitro 
metabolism of warfarin [209] and drug interaction with the drugs, such as quinidine 
[282], fluconazole [123], omeprazole [211], and coenzyme Q [139].  
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Sildenafil citrate, 1-[[3-(6, 7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4, 3-d] 
pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate, is a selective 
inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 
5 (PDE5) and it is widely used oral drug for erectile dysfunction. It is largely 
metabolized in the liver by hepatic microsomal enzymes of CYP3A4 (major route) 
and CYP2C9 (minor route) [177]. Therefore, it may affect the action of drugs that are 
mainly metabolized by these isozymes, such as warfarin and cimetidine. However, the 
information from Pfizer shows that sildenafil has no significant effect on the 
pharmacokinetics of warfarin. But, some case report indicates that bleeding is one of 
adverse reactions associated with sildenafil [183, 285] because of its action of 
inhibiting on PDE5, which is one of phosphodiesterase located in platelet [181]. 
Pfizer clinical research unit itself has conducted a double-blind, randomized, placebo-
controlled, two-way crossover study to assess the potential interaction between orally 
administered sildenafil (50mg o.d. for 6 days) and warfarin (single dose of 40mg) in 
healthy male volunteers in 1995 [286]. They observed an increased bleeding time 
(clotting time test) in patients receiving warfarin and sildenafil. Although a reduction 
in the warfarin effect was evidenced by a statistically significant decrease in AUEC 
(area under effect-time curve) for PT (prothrombin time), this unexpected result was 
more likely to be spurious. However, this clinical study provides insufficient 
information on the effect of sildenafil on warfarin pharmacokinetics, with which one 
may assess the drug interaction liability of concurrent use of warfarin and sildenafil. 
Moreover, no further study has yet been conducted to explore the underlying 
mechanism of warfarin-sildenafil interaction, in particular pharmacokinetic aspect of 
drug interaction.  
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In vitro assessment of in vivo drug metabolism is an important approach used to select 
compounds for further development. One particular application of this approach is in 
the prediction of potential drug interactions. Therefore, in this study, the effect of 
sildenafil on the in vitro hydroxylation of warfarin enantiomers was examined using 
rat and human liver microsomes as well as cDNA-expressed human cytochrome P450 
isozymes (CYP2C9 and CYP3A4). For this purpose, the enzymatic kinetic data of 
warfarin hydroxylation were determined in attempting to quantitatively assess the 
effect of sildenafil on the formation of the phenolic metabolic of each warfarin 
enantiomers. 
 
5.2 Materials and Methods 
 
5.2.1 Chemicals and Reagents  
 
Our research group had prepared the optically pure (R) - or (S)-warfarin (optical 
purity > 99%) from racemic warfarin by fractional crystallization method [254]. 
Phenolic metabolites (4’-, 6- and 7-OH) of R- or S-Warfarin were synthesized using 
modification of previously reported methods [215, 216]. Sildenafil was obtained from 
Zhejiang Jiayuan Pharmaceutical Industry Co., Ltd, China. Chlorowarfarin, β-
nicotinamide adenine di-nucleotide phosphate sodium salt (β-NADPNa) and glucose-
6-phosphate dehydrogenase (G6PD) were obtained from Sigma-Aldrich Chemical Co. 
(St Louis, MO, USA). β-D-glucose-6-phospate sodium salt (G6P) was purchased 
from Fluka (Buchs, Switzerland).  
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Analytical grade of dibasic sodium phosphate and monobasic sodium phosphate were 
purchased from Merck KGaA (Schuchardt, Germany). Diethyl ether was obtained 
from Tedia (Fairfield, Ohio, US), acetone of HPLC grade from Labscan (Dublin, 
Ireland), acetonitrile of HPLC grade (for HPLC analysis) from Fisher Scientific (PA, 
USA) and methanol of HPLC grade (for HPLC analysis) from Tedia (Fairfield, Ohio, 
US) were purchased. All solutions were prepared using eighteen MΩ water generated 
by Milli-Q RG Millipore water purification system (Millipore Corporation, Bedford, 
MA, USA). The pH of buffer solution was measured with pH meter (EcoMet, Istek, 
Seoul, Korea) and the solution was filtered through a 0.20µm hydrophilic 
polypropylene membrane filters (Pall Corporation, Michigan, USA) and degassed in 




Six healthy and young Male Sprague-Dawley rats (~ 220 – 250g) were supplied from 
Laboratory Animal Centre, Singapore. The animals were housed in metabolic 
stainless steel cages individually in an air-conditioned room (23±1°C) and maintained 
under a 12-hr light/dark cycle for a minimum of 3 days before scarifying for 
experiment. Food and water were available ad libitum.  
 
5.2.3 Human Liver Microsomes and cDNA-expressed Human Cytochrome P450 
Isozymes 
 
Pooled human liver microsomes (Lot No. 46262) and c-DNA expressed human 
isozymes; CYP2C9 (Lot No.456218) and CYP3A4 (Lot No. 58311) were purchased 
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from Gentest (Woburn, MA, USA). All microsomes and isozymes were kept frozen at 
-80ºC until use. 
 
5.2.4. Preparation of Rat Liver Microsomes 
 
The pooled rat liver microsomes were prepared from six male Sprague-Dawley rats 
according to the published method [287]. In the preparation of liver microsome, all 
the apparatus and solution were cooled and stored in ice (or 4°C) prior to the start of 
the experiment. In addition, it was important that the temperature did not exceed 4°C 
during any stage of preparation and isolation to minimize the degradation of the tissue 
enzymes. 
 
The rats were scarified by treatment of carbon dioxide. Livers were then rapidly 
excised and immediately placed in ice-cold 0.25 M sucrose to wash off the excess 
blood and to cool the tissue, and then blotted dry, weighed and kept the liver tissues at 
-80°C until use.  
 
The tissue was thawed rapidly at 37°C water-bath and four times of liver  weight of 
0.25 M sucrose was added to the liver to make 20% (w/v) (i.e., 40ml of sucrose was 
added to 10g of liver).  The tissue was finely chopped with scissors and homogenized 
by the homogenizer (Helidoph Diax 500, Germany) until no large pieces of tissue 
were evident. Homogenizer tube was immersed in an ice bucket and excessive 
frothing was avoided, a sure sign that protein denaturation was occurring. 
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To prepare the post-mitochondrial supernatant, the tissue homogenate was centrifuged 
at 12,500g for 15mins at 2°C; the supernatant was decanted carefully and discard the 
pellet. Microsomal tissue fraction was prepared from post-mitochondrial supernatant 
by calcium precipitation method. 0.1 ml of 88mM CaCl2 solution was added per ml of 
supernatant i.e., final concentration of CaCl2 was 8mM and let it to stand on ice for 
5min with gentle swirling. The mixture was then centrifuged at 27, 000g for 15 min at 
2°C. The supernatant was discarded and the pellet was resuspended with 5ml of 0.1M 
Tris buffer (pH 7.4).  
 
The liver microsome protein concentration was determined by Bradford’s standard 
protein assay method [256] using bovine serum albumin as a standard calibrator. Then 
the microsomes were kept at -80°C until use.  
 
5.2.5 In Vitro Metabolism Study 
 
The incubations for rat liver microsomes were performed in triplicate while the 
incubations for human liver microsomes and c-DNA expressed human cytochrome 
P450 isozymes were performed in duplicate. Warfarin enantiomers were dissolved in 
0.1M Tris buffer (pH 7.4) and sildenafil was dissolved in a mixture of acetonitrile: 
water (1:1 v/v). The effect of various concentration of sildenafil on the hydroxylation 
of (S) - or (R) - warfarin enantiomers at different concentrations was carried out 
separately in rat liver microsomes, human liver microsomes and CYP450 isozymes 
(Table 5.1). 0.1 M of Tris buffer (pH 7.4) was added to the microsomal proteins to 
make a final volume of 500µl, which composed of 1.6mg, 1mg and 0.5mg protein 
concentration for rat liver microsomes, human liver microsomes and isozymes 
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respectively. 10µl of acetonitrile : milli-Q water (1:1 v/v) for control study and 10µl 
of different concentrations of sildenafil solution for interaction study were co-
incubated with warfarin enantiomers. The mixture was pre-incubated in 150rpm speed 
of shaking water bath (GFL-1083, Gesellschaft fur Labortechnnik mbH., Burgwedel, 
Denmark) at 37°C for 3 mins.  
 
To initiate the reaction, the microsomal mixture was thoroughly mixed with 500µl of 
NADPH generating system which composed of 1 mM β-NADPNa, 4 mM of G6P, 
2IU/ml of G6PD, and 8 mM of magnesium chloride (MgCl2). To prevent the 
degeneration of NADPH system, the mixture was prepared no longer than 10 minutes 
prior to use.  The reaction was allowed to proceed in 37°C shaking water bath for 30 
minutes for rat and human liver microsomes, whereas proceed for 45 minutes for 
human CYP450 isozymes. To terminate the reaction, ice-cooled acetone (600 µl) was 
added to incubation mixture and mixed thoroughly.  
 
Table 5.1. The final concentrations of substrate (warfarin) and individual co-
incubated drug (sildenafil) used in the in vitro metabolic studies. 
 Final Concentration In Incubation Mixture 






(µM) 12.5, 25, 50, 100, 200 12.5, 25, 50, 100, 200 25, 50, 100, 200 
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5.2.6. Non-Stereospecific HPLC Assay 
 
Five concentrations of warfarin metabolites were spiked into the boiled rat liver 
microsomes, human liver microsomes and c-DNA expressed CYP450 isozymes to 
prepare standard calibration samples for the metabolism study in the respective 
microsomes. The calibration curves for 4’-, 6- and 7- hydroxyl warfarin were linear 
over their respective ranges (0.08-15µM for 4’-hydroxywarfarin; 0.02-15µM for 6-
hydroxywarfarin and 0.005-3.5µM for 7-hydroxywarfarin). Calibrators as well as 
microsomal samples were then subject to liquid-liquid extraction and evaporation, as 
described in Section 3.1.2.3.1 and 3.1.2.3.2. The extract was then reconstituted with 
50µl of mobile phase solution which composed of 20mM sodium phosphate buffer 
(pH 4.5) : acetonitrile : methanol (50:40:10, v/v/v). 20µl of aliquots were then 
uploaded to HPLC for analysis.  
 
The non-stereospecific reversed phase high performance liquid chromatography with 
fluorescence detection was used to determine the phenolic metabolites of warfarin 
enantiomers in microsomal samples as described in Section 3.1.2.3.3. 
 
5.2.7. Data Analysis 
 
The individual formation rates of phenolic metabolites of warfarin enantiomers were 
calculated based on the equation (equation 6.2) and the unit was expressed as 
picomoles per milligram protein per minutes (pmol/mg protein/min).  
Time Incubation protein ofAmount 
producedmetabolite ofAmount   rateFormation ×=    (5.2) 
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Michaelis-Menten kinetics parameters for individual phenolic metabolites of warfarin 
enantiomers in the absence or presence of sildenafil were initially estimated by fitting 
Michaelis-Menten equation (equation 5.3) to the experimental data using the iterative 
nonlinear regression program WinNonlin Version 5.1 (Scientific Consulting Inc., 









max,ν        (5.3) 
where v is the formation rate of warfarin metabolites, Vmax, app is the apparent 
maximum formation rate, Km,app is the apparent substrate [either (S)-or (R)-warfarin)] 
concentration at which the reaction is half of its maximal value in the presence of the 
sildenafil, and S is the substrate concentration. In the absence of sildenafil, Vmax,app 
and Km,app is expressed as Vmax and Km.  
 
For the overall hydroxylation pathway of each warfarin enantiomer, the kinetic 
parameters were obtained by fitting the Michaelis-Menten equation to the sum of the 
formation rates of all detected phenolic metabolites (i.e. 4’-, 6- and 7-hydroxylated 
metabolites) of each enantiomer at each substrate concentration. 
 
The resultant Vmax/Km (in the absence of sildenafil) or Vmax,app/Km,app (in the presence 
of sildenafil) ratios from the one enzyme kinetic approach, which approximate to the 
intrinsic metabolic clearances under the condition of low substrate concentrations (i.e. 
[S]<<Km), were used to assess the effect of sildenafil on the hydroxylation pathways 
of warfarin metabolism in liver microsomes. 
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To quantitatively assess the effects of sildenafil on the formation of the phenolic 
metabolites of warfarin enantiomers, either the activation kinetic or inhibition kinetic 
analysis was applied. During the application of the activation or inhibition kinetic 
models, the Michaelis-Menten kinetic parameters obtained from the control 
incubation (i.e. Vmax and Km) were held constant for the corresponding hydroxylation 
pathway. A pilot study was carried out to see the effect of sildenafil on the formation 
of warfarin enantiomers. The formation rate of warfarin metabolites by liver 
microsome system appeared to be decreased in the presence of sildenafil, whereas 
(S)-4’ hydroxylation was significantly increased in the presence of 100µM sildenafil. 
Visual examination of lineweaver-Burk Plot (reciprocal plot, i.e., 1/v against 1/[S]), 
Dixon Plot (1/v against [I]) and replot of slope of reciprocal plot were carried out to 
select the inhibition model for the quantitative estimation of effect of sildenafil on 
warfarin metabolism. The preliminary result indicated that the effect of sildenafil on 
hydroxylation of warfarin in rat liver microsome is either non-essential activation 
(equation 5.4) or competitive inhibition (equation 5.5). But, the interactions which 
observed in human liver microsomes and cDNA-expressed human isozymes 
(CYP2C9 and CYP3A4) were noncompetitive (equation 5.6), competitive (equation 
5.5) and mixed-type (equation 5.7) inhibition, respectively. The effect of sildenafil on 
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 represents the dissociation constant of the enzyme-activator 
omplex, α (for Eq: 5.4) describes the affinity of the enzyme-substrate and enzyme-
presence of activator when α is less than, and β is greater than, unity. A mixed-type 
max
     (5.7) 
where ν is the formation rate of the individual phenolic metabolites of (S)-or (R)-
warfarin, S is the concentration of (S)-or (R)-warfarin, I is the inhibitor concentration 
(sildenafil concentration), A is the activator concentration (sildenafil concentration), 
Vmax and Km are the maximum formation rate and the Michaelis-Menten constant 
respectively in the absence of inhibitor or activator (for control incubation), Ki is the 
inhibition constant, KA
c
activator complexes for activator and substrate, respectively and β describes the 
breakdown of enzyme-substrate-activator complex to enzyme-activator complex and 
product. α (for Eq: 5.7) represents the factor by which Km changes when inhibitor 
occupies the enzyme.  
 
According to the nonessential activation model (Eq: 5.4), both the formation rate of 
product through the breakdown of enzyme-substrate-activator complex and the 
affinity of the enzyme-substrate (or enzyme-activator) complexes are increased in the 
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system, where α>1, β>1, and β>α, is also possible. In the latter case, the activator 
activates at low substrate concentration but inhibits at high substrate concentration. 
owever, if α>1, β>1, and β=α, the affinity of enzyme-substrate (or enzyme-
us, the potent mixed-type inhibitor is an inhibitor which has 
w Ki and α values and generally inhibits the metabolic pathway which has relatively 
or simple competitive inhibitor, the ratios of Km/Ki can be used to compare the 
 
H
activator) complexes for the activator (or the substrate) is decreased but the rate for 
product formation is increased to the same degree in the presence of the activator. As 
a result, the ratio of Vmax,app/Km,app remains unchanged. 
 
For mixed-type inhibitors (5.7), to assess the selectivity of the inhibitory effects of the 
inhibitor on the individual hydroxylation pathways, the degree of inhibition (i.e. the 
ratio of the formation rates of a particular phenolic metabolite in the presence and 
absence of the interacting drug) is dependent on S, I, Km, Ki and α. At constant S, 
when Ki and α decrease together with an increase in Km and I, the degree of inhibition 
will increase. In the condition of increasing S value, any changes in I, Km, Ki and α 
will have lesser impact on the degree of inhibition due to randomly changing of these 
constant values [288]. Th
lo
high Km value to a greater extent than those have relatively low Km values. Moreover, 
in the presence of the mixed-type inhibitors, the variations of Vmax/Km are only 
determined by I and Ki.  
 
F
inhibitory effects of the inhibitor among individual metabolic pathways. A greater 
Km/Ki ratio for the metabolic pathway is achieved as the inhibitor shows more 
selectivity towards that than the others which have lower ratio values [289].  
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To assess the selectivity of the inhibitory effects of a noncompetitive inhibitor on the 
individual hydroxylation pathways, the degree of inhibition in the presence of the 
hibitor depends only upon [I] and Ki. A classical noncompetitive inhibitor decreases 
 the Km value. When [I]=Ki, inhibitor inhibits 50% at all 
bstrate concentrations [288].  
arman rank correlation), at the 0.05 level 
f significance, was performed to determine the degree of association between two 
fil concentration and Vmax, Km or Vmax/Km ratio) using 
.3.1. Hydroxylation of Warfarin Enantiomers in the Absence of Sildenafil  
in
Vmax, but has no effect on
su
 
5.2.8 Statistical Analysis 
 
Nonparametric correlation analysis (the Spe
o
independent variables (sildena
SPSS 12.0 (SPSS Inc. Chicago, IL, USA).  
 
5.3. Results and Discussion 
5
5.3.1.1. Results  
5.3.1.1.1. In Rat Liver Microsomes 
 
With the use of non-stereospecific HPLC assay as mentioned in Section 3.1.3.3, three 
phenolic metabolites of warfarin enantiomers for either (S)-or (R)-warfarin were 
detected in rat liver microsome. The retention times of these three peaks were 
identical to the retention times of 4’-, 6- and 7-hydroxywarfarin.  In the analysis of 
(S)-warfarin, the order of formation rates of three metabolites was in decreasing order 
of 4’-OH > 6-OH > 7-OH over the entire substrate concentration (12.5~200 µM) 
used. However, for (R)-warfarin, 6-hydroxywarfarin had the highest formation rate 
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followed by 4’- and 7-hydroxywarfarin. The plot of formation rate against the 
substrate concentration in rat liver microsomes and the kinetic parameters of Vmax and 
Km derived from the metabolism study data and the corresponding Vmax/Km ratios in 
rat liver microsomes are presented in Figure 5.1 and Table 5.2, respectively. With 


































































e 4’-hydroxylated warfarin was 
.6 and 16.7 times higher than 6-and 7-hydroxylated warfarin, respectively. Vmax/Km 
tios for (R)-4’-and 6-hydroxywarfarin appeared to be close to each other, whereas 
oth were higher than that of (R)-7-hydroxywarfarin. 
Figur ichaelis-Menten plots of the formation rate (v) against the 




































                                                                                                                                   117
 
Table 5.2 Kinetics parameters phenolic metabolites from each 
warfarin enantiomer in rat liver m enafil.  
 
Kinetics 
Parameters 4’-OH 6-OH 7-OH 
for the formation of 
icrosomes in the absence of sild
(S)-warfarin (df = 3) 
Vmax 108.7 20.2 15.4 
 (95  2) (10  (13  
Km 144.3 21.3 7.7 




.2 – 116. .6 – 24.8) .6 – 18.4)
 6 – 15 .2 – 29.6)  – 9.
V 0.75 0.94 2.01 
r2 .9729 0.9165 0.9732 
(R)-  (df = 3) 
Vmax 34.7 128.2 6.3 
 (28  (125 .3) (4  
max/Km 2.19 0.39 0.056 
2 0.9182 0.9275 0.9349 
.5 – 40.1) .1 – 130 .2 – 8.4)
Km 15.9 327.4 110.8 
 (10.5 – 18) (324.3 – 330) (101.4 – 119.3) 
V
r
Figures in parentheses indicate the 95% confidence interval for parameter estimates 
nalyses. Vmax (pmol/mg protein/min), Km 
(µM), Vmax/Km (µl/mg protein/min) 
 
 
obtained from the non-linear regression a
 
 
5.3.1.1.2. In Human Liver Microsomes 
 
Incubation of the (S)-or (R)-warfarin enantiomers in human liver microsomes resulted 
in the formation of their respective 4’-, 6-, and 7-hydroxylated metabolites. In 
analysis of (S)-warfarin, the order of formation rates of three metabolites was in 
decreasing order of 4’-OH ≥ 6-OH > 7-OH at the substrate concentration of <130µM, 
but in order of 6-OH≥4’-OH>7-OH at the substrate concentration of >130µM. As in 
(S)-warfarin hydroxylation, the similar trend was observed in (R)-warfarin 
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hydroxylation, with regard to the order of metabolite formation rate at low and high 
substrate concentrations. For the former (< 75µM), 4’-hydroxywarfarin had the 
highest formation rate followed by 6- and 7-hydroxywarfarin, whereas for the latter 
(>75µM), the order of the formation rate was 6-OH > 4’-OH > 7-OH. The plots of 
formation rate against the substrate concentration in human liver microsomes and the 
kinetics parameters of Vmax and Km derived from the metabolism study data and the 
corresponding Vmax/Km ratio in rat liver microsome are shown in Figure 5.2 and Table 
5.3, respectively. Vmax/Km ratio for (S)-7-hydroxywarfarin was 2.7 and 2.1 times 
igher than those of (S)-4’-and (S)-7-hydroxywarfarin, respectively. However, 
max/Km ratio for (R)-6- and 7-hydroxywarfarin appeared to be close to each other, 























































































































Figure 5.2.Michaelis-Menten plots of the formation rate (v) against the 
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Table 5.3. Kinetics parameters for the formation of the phenolic metabolites from 
each warfarin enantiomer in human liver microsomes in the absence of sildenafil.  
 
Kinetics 
Parameters 4’-OH 6-OH 7-OH 
(S)-warfarin (df = 3) 
Vmax 108.7 20.2 15.4 
 (95.2 – 116. 2) (10.6 – 24.8) (13.6 – 18.4) 
Km 144.3 21.3 7.7 
 (137.6 – 152.5) (17.2 – 29.6) (6.8 – 9.2) 
Vmax/Km 0.75 0.94 2.01 
r2 0.9729 0.9165 0.9732 
(R)-warfarin (df = 3) 
Vmax 34.7 128.2 6.3 
 (28.5 – 40.1) (125.1 – 130.3) (4.2 – 8.4) 
Km 15.9 327.4 110.8 
 (10.5 – 18) (324.3 – 330) (101.4 – 119.3) 
Vmax/Km 2.19 0.39 0.056 
r2 0.9182 0.9275 0.9349 
Figures in parentheses indicate the 95% confidence interval for parameter estimates 
obtained from the non-linear regression analyses. Vmax (pmol/mg protein/min), Km 
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5.3.1.1.3. In cDNA-Expressed Human CYP450 Isozymes 
 
The retention times of the two peaks observed in (S)-warfarin incubation samples 
were identical to those of 6- and 7-hydroxywarfarin while the retention time of three 
peaks found in (R)-warfarin incubation samples were identical to those of 4’-, 6- and 
7-hydroxywarfarin. The order of the formation rate of phenolic metabolites of (R)-
warfarin was in decreasing order of 4’-OH > 6-OH > 7-OH while that of (S)-warfarin 
was in decreasing order of 7-OH > 6-OH. The plot of formation rate against the 
substrate concentration in CYP isozymes (Figure 5.3) and the kinetics parameters of 
Vmax and Km derived from the metabolism study data and the corresponding Vmax/Km 
ratios in rat liver microsome (Table 5.4) were presented. With respect to the Vmax/Km,, 
(S)-7-hydroxywarfarin was two times higher than that of (S)-6-hydroxywarfarin. 
However, Vmax/Km ratio of (R)-4’-hydroxywarfarin was 3.4-fold and 123.7-fold as 






































































































































Figure 5.3 Michaelis-Menten plots of the formation rate (v) against the 
concentrations of (S)-or (R)-warfarin in the absence of sildenafil in cDNA-expressed 
CYP450 isozymes, CYP2C9 and CYP3A4, respectively.  
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Table 5.4. Kinetics parameters for the formation of phenolic metabolites from each 
warfarin enantiomers in cDNA-expressed CYP450 isozymes in the absence of 
sildenafil.  
 
Kinetic Parameters 4'-OH 6-OH 7-OH 
(S)-warfarin (CYP2C9) (df=2) 
Vmax NA 17.5 36.9 
  (12.3 - 19.7) (30.3 - 40.7) 
Km NA 5.7 6.1 
  (5.1 - 6.8) (3.8 - 8.2) 
Vmax/Km NA 3.07 6.049 
(R)-warfarin (CYP3A4) (df=2) 
Vmax 416.7 106.4 9.72 
 (409.4 – 420.5) (96.8 – 110.2) (8.1 – 10.1) 
Km 124.8 108.2 355.5 
 (115.4 – 132.4) (100.1 – 115.1) (350.1 – 360.4) 
Vmax/Km 3.339 0.983 0.027 
Figures in parentheses indicate the 95% confidence interval for parameter estimates 
obtained from the non-linear regression analyses. Vmax (pmol/mg protein/min), Km 
(µM), Vmax/Km (µl/mg protein/min) 
 




Drugs in the body usually undergo the elimination process, mainly by renal excretion 
and hepatic metabolism. The basic purpose of metabolism is to transform the active 
form of parent compound to be either active or inactive form of more water soluble 
metabolites. The heme containing cytochrome P450 plays the important functional 
role in phase I oxidative process of the biotransformation process. The metabolism by 
P450 presents 55% of total elimination of dose whereas that by other metabolic 
process presents 20% [281]. CYP450 enzyme can be found in intestines, lung and 
other organs but it is most abundant in liver [290]. Moreover, the anticoagulant action 
of warfarin in rat and man is primarily terminated by CYP450-mediated hepatic 
metabolism [68, 85, 213]. The previous studies have shown that about 88% of (S)-
warfarin and 85% of (R)-warfarin are cleared via 4’-, 6-, 7- and 8-hydroxylation 
pathway in rats [64] while 80 to 88% of (S)-warfarin is cleared via 6- and 7-
hydroxylation pathways and (R)-warfarin is cleared via 4’, 6-, 7- and 10 
hydroxylation pathways in man [68, 79].  
 
The present findings obtained from the in vitro metabolism of warfarin in both liver 
microsomal systems confirm that warfarin enantiomers are transformed into their 
known inactive forms via 4’-, 6- and 7-hydroxylation pathways, but varies to a 
different extent in the formation rates of individual metabolites. 
 
In the rat liver microsomes, our data indicated that the major pathway for 
hydroxylation of (S)-warfarin was 4’-hydroxylation (4’-OH), followed by 6-
hydroxylation (6-OH) and finally 7-hydroxylation (7-OH) (Figure 5.1), which is in 
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good agreement with the finding of Zhou et al [57] and repeated study [291]. 
However, the rank order of 6-OH>4’-OH>7-OH obtained for the formation rate of 
(R)-warfarin is different from that reported in the literature (7-OH>6-OH>4’-OH) 
[57] and repeated data (4’-OH>7-OH>6-OH) [292]. The rank order of Vmax/Km for 
(S)-warfarin metabolites in this study is consistent with, whereas that for (R)-warfarin 
enantiomers is different from, the finding reported by Zhou et al [57] and unpublished 
data [291, 292], showing that Vmax/Km ratio in the decreasing order of 6-OH > 7-OH > 
4-OH and 4’-OH>6-OH>7-OH, respectively. Although the same microsomal 
preparation technique and the same organic solvent (acetonitrile for control study) 
were used for the latter [292] and the present study, the inconsistency was occurred. 
This disagreement may be mainly due to the interspecies variation in rats. However, 
the variance between the literature [57] and this study was in part attributable to the 
difference in microsomal preparation and organic solvent used. For the former, the 
standard differential centrifugation technique was used to prepare rat liver 
microsomes, whereas centrifugation technique with addition of calcium chloride 
solution was used in the present study.  Additionally, in this study, acetonitrile was 
added to the control incubation mixture (the same solvent used to dissolve the co-
incubated drug, sildenafil), but methanol was added by the former for the control 
study.  
 
The data based on human liver microsomal incubation showed that 4’-hydroxylation 
was the major pathway for (S)-warfarin hydroxylation with the highest formation rate 
among the three hydroxylation pathways. The formation rate for (S)-4’-
hydroxywarfarin was 5.4 and 7.1 times as great as that for (S)-6-and 7-
hydroxywarfarin, respectively (Figure 5.1 and Table 5.2). This finding is in good 
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agreement with the observation by Rettie et al [68], but is in discordance with the 
report by Kaminsky et al [293] and Zhou et al [211] which indicated that the 
formation rate of (S)-7-hydroxywarfarin was the highest among the three phenolic 
metabolites of (S)-warfarin. However, the present kinetic analysis indicated that the 
rank order of Vmax/Km ratio was 7-OH>6-OH>4’-OH, where Vmax/Km ratio reflects the 
slope of the v versus S plot at the condition of [S] <<Km (Figure 5.2 and Table 5.3).  
With respect to the formation rate of (R)-warfarin metabolites, 6-hydroxylation is 3.6 
and 20.3-fold higher than 4’-and 7-hydroxylation, respectively, suggesting that 6-
hydroxylation is the major hydroxylation pathway for (R)-warfarin hydroxylation.. 
However, the kinetic analysis showed that the Vmax/Km ratio of (R)-4’-hydroxylation 
was 5.6 and 39.1 times as great as that of (R)-6-and 7-hydroxylation (Table 5.3) The 
present finding with respect to 6-hydroxylation of (R)-warfarin is consistent with the 
literatures [68, 211] using human liver microsomes, but the order of formation rate of 
metabolites was different (6-OH>4-OH>7-OH versus 6-OH>7-OH>4’-OH).  The 
different human liver microsomal preparations might cause the inconsistency. 
Moreover, difference in the incubation system used might contribute to the variance 
between the studies. Acetonitrile, instead of methanol, was employed in the present 
incubation system compared to that conducted by Zhou et al [211]. According to the 
metabolites formation rate (Vmax) of (S)-warfarin, some discrepancy was observed 
between human liver microsomes and human CYP2C9 isozymes, 4’-hydroxylation 
was the major metabolic pathway in human liver microsomes (Figure 5.2 and Table 
5.3), whereas 7-hydroxylation was the major pathway in human CYP2C9 isozyme 
(Figure 5.3 and Table 5.4). In human liver microsomes, there are multiple CYP-450 
isozymes, which are responsible for 4’-hydroxylation pathway such as CYP2C8, 
CYP2C18, CYP2C19.  The discord may be due to the composition of CYP450 
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isozymes in human liver microsomes. However, the present Vmax/Km ratio of (S)-7-
hydroxywafarin was the highest in both human liver microsomes (Table 5.3) and 
CYP2C9 isozyme (Table 5.4) suggesting that 7-hydroxylation plays an important role 
for the metabolism of (S)-warfarin in vivo. This observation was in good agreement 
with the previous in vitro study reported that (S)-4-hydroxywarfarin was major 
metabolite for (S)-warfarin based on the metabolites formation rate whereas (S)-7-
hydroxywarfarin was that for (S)-warfarin based on the Vmax/Km ratio [68]. However, 
the rank order of Vmax/Km ratio for metabolic pathways of (R)-warfarin (4’-OH>6-
OH>7-OH) was the same in both human liver microsomes and CYP3A4 isozymes. 
The present finding of (R)-warfarin metabolism in human liver microsomes indicated 
that the rank order of formation rate for hydroxylation pathways was different at the 
low and high substrate concentration (Figure 5.2). This observation was confirmed by 
the previous in vitro study on the metabolism of (S)-and (R)-warfarin enantiomers in 
eleven human livers indicated that the major metabolites of (R)-warfarin was radically 
different between the samples due to different substrate concentration used [68]. 
  
Although the present study (Table 5.2), the reported study [208] (Table 5.3), and the 
repeated studies [291, 292] (Table 5.3) followed the same study protocol for the 
preparation of rat liver microsomes and for the microsomal incubation, the variance 
was observed among three sets of data. This consistency may be due to variance in rat 





Table 5.5. Reported kinetics parameters for the formation of phenolic metabolites 
from each warfarin enantiomers in rat and human liver microsomes in the absence of 
sildenafil.  
(S)-warfarin  (R)-warfarin Kinetic 
Parameters 4'-OH 6-OH 7-OH  4'-OH 6-OH 7-OH 
Ref: 
Rat Liver Microsomes 
Vmax 98.4 65.8 22.6  95.2 109 128 [208] 
 171.5 88.1 20.7  67.1 23.5 104.2 [291, 292]a
         
Km 53.3 38.1 42.5  117 122 83.9 [208] 
 40 40.7 109.8  78.5 51.6 255.4 [291, 292]a
         
Vmax/Km 1.84 1.73 0.53  0.81 0.89 1.52 [208] 
 4.25 2.16 0.189  0.855 0.455 0.408 [291, 292]a
         
Human Liver Microsomes 
Vmax 27.9 38 39.7  48.4 157 65.5 [211] 
 NA 2.18 19.6  80 15.6 8.4 [291, 292]a
         
Km 6.74 19.1 8.45  25.4 36.8 200 [211] 
 NA 10.1 12.9  153.1 36.7 169.3 [291, 292]a
         
Vmax/Km 4.13 1.99 4.7  1.91 4.27 0.33 [211] 
 NA 0.216 1.51  0.523 0.425 0.049 [291, 292]a
Vmax (pmol/mg protein/min), Km (µM), Vmax/Km (µl/mg protein/min), a: repeated study, liver 
microsomes used in the repeated study were from different rats or human livers. 
 
Likewise, this inconsistency among three sets of human liver microsomes data may be 
possibly due to inter-batches variances (batch numbers of 46262 for the present study, 
13 for the reported study [211] and 28 for repeated study [291, 292]). This conclusion 
was supported by the evidence from the two previous studies, which were conducted 
by the same research group following the same study protocol [276, 294]. One study 
showed that the mean formation rate of (S)-4’-hydroxywarfarin was 50% higher than 
that of (S)-6-hydroxywarfarin [276], whereas the other showed that the mean 








5.3.2.1.1. In Rat Liver Microsomes 
 
The changes of the formation rate of 4’-, 6- and 7-hydroxylation of warfarin 
enantiomers in presence of sildenafil in rat liver microsome were determined. The 
formation rates of phenolic metabolites of warfarin enantiomers in the absence and 
presence of sildenafil are shown in Figure 5.4 and Table 5.5. The formation rate of 
(S)-4’-hydroxywarfarin tended to be increased in the presence of increasing sildenafil 
concentration in microsomal incubation mixture.  However, the activation was not 
significant at the low concentration of sildenafil but was increased by 1-17% at high 
sildenafil concentration of 100µM. In contrast, the formation rates of (S)-6-, (S)-7-, 
(R)-4’-, (R)-6- and (R)-7-hydroxywarfairn were consistently lower in the presence of 
sildenafil with the varying degrees of 21.1-29.2%, 18.8-27%, 26.5-49.8%, 7.1-42.4% 
and 0.3-9.4 %, respectively.  
 
By visual examination of Lineweaver-Burk plot (substrate concentration versus 
formation rate), the slope for (S)-4’-hydroxywarfarin was decreased while that for all 
other phenolic metabolites was increased. The y-axis intercepts of (S)-6-, (S)-7, (R)-
4’-, (R)-6- and (R)-7-warfarin in the absence of sildenafil were identical to those in 
the presence of sildenafil at any concentration, indicating the competitive inhibitory 
model for sildenafil. This was further confirmed by the Dixon plot (inhibitor 
concentration versus 1/formation rate) where the plots at various warfarin 
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concentrations were observed to intersect at an approximate height of 1/Vmax.  The 
estimated enzymatic kinetic parameters and inhibitory constants obtained from the 
nonlinear regression using the Michaelis-Menten equation (5.5) are listed in Table 
5.6. The estimates of activation enzymatic kinetic parameters for 4’-hydroxylation 
pathway of (S)-warfarin in rat liver microsomes are shown in Table 5.6. The values of 
β, α and β/α are greater than unity i.e., β or α or β/α >1 which indicate that sildenafil 
activates at low warfarin concentration but inhibits at high warfarin concentration.  
 
A statistically significant correlation (Spearman rank correlation, P<0.01, n=4) was 
found between the sildenafil concentration and the increase in Km,app values for S-6-
hydroxylation (rs=1), overall hydroxylation of (R)-warfarin enantiomer (rs=1) and 
decrease in  Vmax,app/Km,app for all individual hydroxylation (rs=-1),  except (S)-4’-































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.4. Effect of sildenafil on the hydroxylation of warfarin enantiomers in 
pooled rat liver microsomes (A) Michaelis-Menten plots (B) Lineweaver-Burk plots, 














Table 5.6. Apparent enzymatic kinetics of the in vitro hydroxylation of warfarin 
enantiomers in rat liver microsomes in the absence and presence of sildenafil  
(S)-warfarin+Sildenafil  (R)-warfarin+Sildenafil 
Parameters 
0 a 1 a 10 a 100 a  0 a 1 a 10 a 100 a
4'-hydroxylation (df=3)        
Vmax,app 227.3 263.2 256.4 303  79.4 69.4 74.1 64.1 
Km,app 97 111.7 106.7 106.4  94.5 86.5 131.6 128.7 
 (0.996) (0.996) (0.996) (0.9958)  (0.9883) (0.992) (0.9959) (0.9809) 
Vmax,app/Km,app 2.343 2.356 2.403 2.848  0.840 0.802 0.563 0.498 
R/S ratio 0.36 0.34 0.23 0.17      
          
6-hydroxylation(df=3)        
Vmax,app 84 84.7 80.6 68.5  138.8 133.3 129.9 135.1 
Km,app 106.6 109 115 121.5  148.7 145.7 150 177.2 
 (0.9982) (0.9982) (0.9968) (0.9991)  (0.9916) (0.99) (0.9788) (0.9754) 
Vmax,app/Km,app 0.788 0.777 0.701 0.564  0.933 0.915 0.866 0.762 
R/S ratio 1.18 1.18 1.24 1.35      
          
7-hydroxylation(df=3)        
Vmax,app 45.9 39.8 48.5 59.9  17.7 17.9 17.7 17.7 
Km,app 322 285.2 375 575.5  49.1 50.6 50.4 59 
 (0.9984) (0.9982) (0.9982) (0.9988)  (0.9966) (0.9966) (0.9964) (0.9891) 
Vmax,app/Km,app 0.143 0.140 0.129 0.104  0.360 0.354 0.351 0.300 
R/S ratio 2.53 2.53 2.72 2.88      
          
Overall hydroxylation(df=3)        
Vmax,app 344.8 344.8 333.3 285.7  238.1 238.1 227.3 208.3 
Km,app 105.5 107.4 105.2 82.9  114.2 117 125.6 132.1 
 (0.997) (0.9969) (0.9967) (0.997)  (0.9932) (0.9937) (0.991) (0.984) 
Vmax,app/Km,app 3.268 3.210 3.168 3.446  2.085 2.035 1.810 1.577 
R/S ratio 0.64 0.63 0.57 0.46      
Figures in parentheses indicate the coefficient of determination (r2) for the nonlinear 
regression of v versus S curves. V max (pmol/mg protein/min), Km (µM) and Vmax/Km (µl/mg 
protein/min). a: The final concentration (µM) of sildenafil in the incubation mixture 
 136
Table 5.7. Estimates of kinetics parameters for the hydroxylation of warfarin 
enantiomers in the presence of sildenafil in pooled rat liver microsomes. 
Kinetics 
Parameters 4'-OH 6-OH 7-OH 
Overall 
Hydroxylation 
(S)-warfarin     
Inhibition Type Non-essential act a Comp. b Comp. b No apparent effect observed 
 Ki (µM)  244.1 (15) 228.7 (35)  
α 1.29    
β 1.33    
β/α 1.03    
 Ka 1.63    
 df 17 17 17  
 r2 0.991 0.958 0.9957  
     
(R)-warfarin     
Inhibition Type Comp. b Comp. b Comp. b Comp. b
 Ki (µM) 154.3 (12) 336.5 (38) 379.5 (52) 240.3 (37) 
 df 17 17 17 17 
 r2 0.9735 0.9829 0.9933 0.9868 
Figures in parentheses indicate the coefficient of variation (CV%) for estimates 
obtained by fitting of the corresponding inhibition model to the formation rate data. a: 
Non-essential activation; b: Competitive inhibition; c: Mixed-type inhibition 
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5.3.2.1.2. In Human Liver Microsomes 
 
The effect of sildenafil on the in vitro metabolism of warfarin enantiomers in human 
liver microsomes was also assessed by measuring  the changes of the formation rates 
of 4’-, 6- and 7-hydroxylation of warfarin enantiomers in the presence of sildenafil. 
The formation rates of phenolic metabolites of warfarin enantiomers in the absence 
and presence of sildenafil are shown in Figure 5.5 and Table 5.7. The formation rates 
of (S)-4’, (S)-6-, (R)-4’, (R)-6, (R)-7-hydroxywarfarin, overall (S)-and (R)-warfarin 
were consistently decreased in the presence of increasing sildenafil concentration in 
microsomal incubation mixture with the varying degree of 18.7-78.1%, 22.1-56.2%, 
30-77.2%, 32-52%, 7-31.4%, 14.8-56.5% and 32.7-70.2%, respectively.  The effect of 
sildenafil on the formation rate of (S)-7-hydroxywarfarin was magical. In the presence 
of increasing sildenafil concentration, the formation rate of (S)-7-OH was decreased 
at low substrate concentration (<100µM) with the varying degree of 8.7-24.5%, yet, 
that was increased with the varying degree of 1.8-12.6% at high substrate 
concentration (>100µM) (Figure 5.5).  
 
To determine the inhibitory model of sildenafil on warfarin enantiomers, preliminary 
visual examination of Lineweaver-Burk Plots (Figure 5.5 B), Dixon plot (Figure 5.5 
C) and re-plot of the slopes obtained from the Lineweaver Burk plots (Figure 5.5 D) 
was carried out, indicating the non-competitive inhibitory model for sildenafil on (S)-
4’-hydroxylation, with the slopes having similar x-intercept with increasing y-
intercept for increasing sildenafil concentration. The y-axis intercept of (R)-7-
hydroxywarfarin in the absence of sildenafil was identical to that in the presence of 
sildenafil at any concentration, suggesting the competitive inhibitory model for 
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sildenafil. Furthermore, for (S)-6-, (R)-4’- and (R)-6-hydroxywarfarin, neither the x-
axis intercepts nor the y-axis intercepts were identical in the presence of any 
concentration of sildenafil. Therefore, the inhibitory model of sildenafil on (S)-6-, (S)-
7, (R)-4’, (R)-6 and overall (R)-hydroxylation was mixed-typed. The estimated 
enzymatic kinetic parameters and inhibitory constants obtained from the nonlinear 
regression using the Michaelis-Menten equations (5.5, 5.6 and 5.7) are listed in Table 
5.8.  
 
The apparent kinetic parameters for the individual hydroxylation pathways as well as 
the overall hydroxylation of (S)-and (R)-warfarin enantiomers in human liver 
microsomes in the absence or presence of sildenafil are summarized in Table 5.7. The 
values of Vmax,app and Km,app for all hydroxylation pathways were either randomly 
changed or remained unchanged. A statistically significant correlation (Spearman 
rank correlation P<0.01, n=4) was found between the sildenafil concentration and the 
decrease in Vmax,app  values for (S)-4’-hydroxylation (rs= -1) and increase in Km,app 
values for (S)-4, (S)-7-, (R)-4’-, (R)-7-hydroxylation and overall hydroxylation of  
(R)-warfarin enantiomer (rs=1) as well as decrease in Vmax,app/Km,app for all individual 
hydroxylation and overall hydroxylation of (R)-warfarin enantiomer (rs=-1) and 7-


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.5. Effect of sildenafil on the hydroxylation of warfarin enantiomers in 
pooled human liver microsomes; (A) Michaelis-Menten plots, (B) Lineweaver-Burk 





Table 5.8.  Apparent enzymatic kinetics of the in vitro hydroxylation of warfarin 
enantiomers in human liver microsomes in the absence and presence of sildenafil  
(S)-warfarin+Sildenafil  (R)-warfarin+Sildenafil 
  
Parameters 0a 1a 10a 100a  0a 1a 10a 100a
4'-hydroxylation (df=3)        
Vmax,app 108.7 99 95.2 87  34.7 35.3 36.1 28.4 
Km,app 144.3 111.7 103.7 337.2  15.9 22.6 47.9 91.3 
 (0.9729) (0.9804) (0.9726) (0.8778)  (0.6224) (0.7671) (0.8584) (0.9441) 
Vmax,app/Km,app 0.753 0.886 0.918 0.258  2.182 1.562 0.754 0.311 
R/S ratio 2.90 1.76 0.82 1.21      
6-hydroxylation(df=3)        
Vmax,app 20.2 16.4 13.1 15.1  128.2 285.7 161.3 238.1 
Km,app 21.3 13.8 12.4 74.2  327.4 1036.6 731.8 1234.4 
 (0.8165) (0.7807) (0.7964) (0.8623)  (0.9991) (0.9993) (0.9982) (0.9998) 
Vmax,app/Km,app 0.948 1.188 1.056 0.204  0.392 0.276 0.220 0.193 
R/S ratio 0.41 0.23 0.21 0.95      
7-hydroxylation(df=3)        
Vmax,app 15.4 16.2 15.8 17.3  6.3 6.1 6.6 6.3 
Km,app 7.7 9.4 9.8 17.3  110.8 114.9 144.1 168.6 
 (0.9732) (0.9883) (0.9987) (0.9559)  (0.9724) (0.9794) (0.9898) (0.9957) 
Vmax,app/Km,app 2.000 1.723 1.612 1.000  0.057 0.053 0.046 0.037 
R/S ratio 0.03 0.03 0.03 0.04      
Overall hydroxylation(df=3)        
Vmax,app 122 119 87.7 158.7  117.6 116.3 119 80.6 
Km,app 63.2 55.2 25.7 133.8  58.8 77.1 126.7 153.4 
 (0.8753) (0.8716) (0.8948) (0.9116)  (0.9716) (0.9791) (0.9844) (0.9991) 
Vmax,app/Km,app 1.930 2.156 3.412 1.186  2 1.57 0.93 0.53 
R/S ratio 1.04 0.70 0.27 0.44      
Figures in parentheses indicate the coefficient of determination (r2) for the nonlinear 
regression of v versus S curves. V max (pmol/mg protein/min), Km (µM) and Vmax/Km (µl/mg 
protein/min). a: The final concentration (µM) of sildenafil in the incubation mixture. 
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Table 5.9. Estimates of kinetics parameters for the hydroxylation of warfarin 
enantiomers in the presence of sildenafil in pooled human liver microsomes.  
Kinetics 




    
Inhibition type Non-comp a Mixed-type b Mixed-type b Mixed-type b
Ki (µM) 79 (20) 36.2 (15) 307.2 (70) 177.3 (40) 
α   2.5 0.3 
df 17 17 17 17 
r2 0.9172 0.8142 0.9439 0.8492 
     
(R)-warfarin     
Inhibition type Mixed-type b Mixed-type b Comp c. Mixed-type b
Ki (µM) 23.9 (10) 194.3 (30) 340.5 (35) 78 (18) 
α 21.1 2.6  3.8 
df 17 17 17 17 
r2 0.7988 0.9756 0.9831 0.9643 
Figures in parentheses indicate the coefficient of variation (CV%) for estimates 
obtained by fitting of the corresponding inhibition model to the formation rate data. a: 








5.3.2.1.3. In cDNA-Expressed Human CYP450 Isozymes 
 
The (S)-6-and (S)-7-hydroxywarfarin were detected in the incubation of (S)-warfarin 
with CYP2C9 isozyme while (R)-4’-, (R)-6- and (R)-7-hydroxywarfarin were found 
in the incubation of (R)-warfarin with CYP3A4 isozyme. The respective formation 
rates of (S)-warfarin in CYP2C9 and of (R)-warfarin in CYP3A4 in the absence and 
the presence of sildenafil are shown in Figure 5.6 and Table 5.9. Of individual 
hydroxylation of (S)-warfarin, Vmax,app  values remained unchanged in the presence of 
any concentration of sildenafil, whereas Km,app values were consistently increased.  
However, the Vmax,app values for (R)-4- and (R)-6-hydroxylation were consistently 
decreased  in the presence of sildenafil with the varying degree of 65-91%, 85.6-94% 
while Km,app values  for those were either randomly or consistently increased in the 
presence of sildenafil. The values of Vmax,app and Km,app for (R)-7-hydroxylation were 
randomly changed. Sildenafil decreased the Vmax,app/Km,app ratios for all individual 
hydroxylation pathways as well as overall hydroxylation pathways of both (S)-and 
(R)-warfarin enantiomers (Table 5.9).  
 
The visual examination of Lineweaver-Burk plot for (S)-6-, (S)-7 and (R)-7-
hydroxywarfarin revealed that the y-intercepts of the slopes for either the absence of 
sildenafil or the presence of sildenafil in incubation mixture were identical, indicating 
competitive inhibition by sildenafil on the formation of these metabolites. Sildenafil 
appeared to inhibit non-competitively on (R)-4’-hydroxylation, with the slopes having 
similar x-intercept with increasing y-intercept for increasing sildenafil. Furthermore, 
for (R)-6-hydroxywarfarin, neither the x-axis intercepts nor the y-axis intercepts were 
identical in the presence of any concentration of sildenafil in the incubation with 
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CYP3A4 isozyme. Therefore, the inhibitory model of sildenafil for (R)-6 
hydroxylation was mixed-typed. The estimated enzymatic kinetic parameters and 
inhibitory constants obtained from the nonlinear regression using the Michaelis-
Menten equations (5.5, 5.6 and 5.7) are listed in Table 5.10.  
 
A statistically significant correlation (Spearman rank correlation, P<0.01, n=4) was 
found between the sildenafil concentration and the decrease in Vmax,app  values for (R)-
4’-, (R)-6-hydroxylation and overall hydroxylation of (R)-warfarin (rs=-1), increase in 
Km,app values for (S)-6-, (S)-7-hydroxylation and overall hydroxylation of (S)-warfarin 
(rs=1), as well as decrease in Vmax,app/Km,app for all individual hydroxylation and 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.6. Effect of sildenafil on the hydroxylation of (R)-and (S)-warfarin 
enantiomers in cDNA-expressed human CYP450 isozymes, CYP3A4 and CYP2C9, 
respectively. (A)Michaelis-Menten plots, (B) Lineweaver-Burk plots, (C) Dixon plots, 
(D) plots of sildenafil concentration vs. slope from Lineweaver-Burk plots 
 
Table 5.10. Apparent enzymatic kinetics of the in vitro hydroxylation of (S)-and (R)-
warfarin enantiomers in cDNA-expressed CYP450 isozymes, CYP2C9 and CYP3A4, 
respectively. 
(S)-warfarin+Sildenafil  (R)-warfarin+Sildenafil 
Parameters 
0a 1a 10a 100a  0a 1a 10a 100a
4'-hydroxylation (df=3)        
Vmax,app NA NA NA NA  416.7 400 151.5 82.6 
Km,app NA NA NA NA  124.8 210.7 146.7 246.7 
      0.997 0.986 0.958 0.862 
Vmax,app/Km,app NA NA NA NA  3.339 1.898 1.033 0.335 
R/S ratio NA NA NA NA      
          
6-hydroxylation(df=3)        
Vmax,app 17.5 17.7 17.6 17.6  106.4 95.2 24.3 18.9 
Km,app 5.7 7.4 8.9 12.4  108.2 173.5 133.8 342 
 (0.799) (0.878) (0.884) (0.914)  (0.995) (0.983) (0.996) (0.985) 
Vmax,app/Km,app 3.070 2.392 1.978 1.419  0.983 0.549 0.182 0.055 
R/S ratio 0.32 0.23 0.09 0.04      
          
7-hydroxylation(df=3)        
Vmax,app 36.9 36.6 37.2 37  9.72 11.1 15.4 9.8 
Km,app 6.1 7.6 10.1 23  355.5 490.9 814 603.7 
 (0.984) (0.995) (0.994) (0.999)  (0.996) (0.986) (0.999) (0.994) 
Vmax,app/Km,app 6.049 4.816 3.683 1.609  0.027 0.023 0.019 0.016 
R/S ratio 0.00 0.00 0.01 0.01      
          
Overall hydroxylation(df=3)        
Vmax,app 54.1 53.8 54.1 54.9  526.3 500 128.2 107.5 
Km,app 6.1 7.6 9.5 18.2  121.1 202.5 58.7 264.7 
 (0.964) (0.981) (0.984) (0.990)  (0.996) (0.985) (0.964) (0.887) 
Vmax,app/Km,app 8.869 7.079 5.695 3.016  4.346 2.469 2.184 0.406 
R/S ratio 0.49 0.35 0.38 0.13      
 Figures in parentheses indicate the coefficient of determination (r2) for the nonlinear 
regression of V versus S curves. V max,app (pmol/mg protein/min), Km,app (µM) and 




Table 5.11. Estimates of kinetics parameters for the hydroxylation of (S)-and (R)- 
warfarin enantiomers in the presence of sildenafil in cDNA-expressed human 
isozymes; CYP2C9 and CYP3A4, respectively. 
Kinetics Parameters 4'-OH 6-OH 7-OH Overall Hydroxylation 
(S)-warfarin (CYP2C9)     
Inhibition Type NA Comp. a Comp. a Comp. a
Ki (µM) NA 131.5 45.2 61.8 
df  13 13 13 
r2  0.873 0.963 0.961 
     
(R)-warfarin (CYP3A4)     
Inhibition Type Non-Comp. b Mixed-Type c. Comp. a Mixed-Type c. 
Ki (µM) 32.5 17.5 263.4 20.1 
α  3.5  4.6 
df 13 13 13 13 
r2 0.909 0.981 0.984 0.91 
Figures in parentheses indicate the coefficient of variation (CV%) for estimates 
obtained by fitting of the corresponding inhibition model to the formation rate data. a: 






Sildenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific 
phosphodiesterase type 5 (PDE5) and it is widely used oral medication for erectile 
dysfunction (ED) in recent years. It is predominantly cleared from the body by hepatic 
metabolic pathways which are mediated by CYP3A4 (major pathway) and CYP2C9 
(minor pathway) [177]. Both of CYP3A4 and CYP2C9 are also responsible for the 
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metabolism of (R)-warfarin and (S)-warfarin respectively [13].  Therefore, CYP450 
based drug-drug interaction may occur between warfarin and sildenafil. 
 
The finding of in vitro warfarin metabolism in rat liver microsomes shows that 
sildenafil acts as a competitive inhibitor for the (S)-6-, (S)-7, (R)-4, (R)-6, (R)-7-
hydroxylation and the overall hydroxylation of (R)-warfarin. Sildenafil was a weak 
non-essential activator for (S)-4’-hydroxylation when a very high concentration of 
(S)-warfarin (> 100 µM) and sildenafil (100 µM) was present in the incubation 
mixture (Figure 5.4 and Table 5.7). However, there was no apparent effect of 
sildenafil on the 4’-hydroxylation of (S)-warfarin in the presence of the low substrate 
(≤100 µM warfarin) and interacting drug (10µM sildenafil). Of (S)-warfarin 
enantiomer, sildenafil has a similar inhibitory effect on the 6- and 7-hydroxylation in 
rat liver microsomes with Ki value of 244.1 and 228.7 µM, respectively. The Ki value 
of the 4’-hydroylation is about half of that of the 6-and 7-hydroxylation, of (R)-
warfarin. The estimated Ki value coupled with the Km/Ki ratio points out that the 
inhibitory effect of sildenafil is selectively towards the 4’-hydroxylation of (R)-
warfarin. In addition, regardless of sildenafil concentration, sildenafil appeared to 
decrease Vmax,app/Km,app ratios for (S)-6- and (R)-4’-hydroxylation and the overall 
hydroxylation of (R)-warfarin with a greater extent as compared to its effect on their 
respective antipodes, whereas the Vmax,app/Km,app ratios for 7-hydroxylation of two 
enantiomers of warfarin were decreased to the same extent in the presence of 
sildenafil  (Table 5.6). The large Ki values (> 100 µM) observed for all hydroxylation 
pathways (Table 5.7) suggest that sildenafil is a weak inhibitor of the hydroxylation of 
warfarin enantiomers in rat liver microsomes.  
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The results from the in vitro warfarin metabolism in human liver microsomes (Figure 
5.5 and Table 5.7) demonstrates that sildenafil has an inhibitory effect on the 
hydroxylation pathways of both (S)-and (R)-warfarin. Sildenafil plays as a non-
competitive inhibitor for 4’hydroxylation and a mixed-typed inhibitor for 6- and 7-
hydroxylation, of (S)-warfarin, while it acts as a mixed-type inhibitor for 4’- and 6-
hydroxylation and a competitive inhibitor for 7-hydroxylation, of (R)-warfarin (Table 
5.8). As in rat liver microsomes, the inhibitory effect of sildenafil is selectively 
towards to (R)-4’-hydroxylation with the smallest Ki value of 23.9 µM, which was 8.1 
and 14.2 times as low as that of (R)-6 and (R)-7-hydroxylation, respectively. 
Comparison of the Ki values (Table5.9) indicates that sildenafil has a relatively 
stronger inhibitory effect on (S)-6-hydroxywarfarin formation (36.2µM) among the 
three hydroxylation pathways of (S)-warfarin studied. Sildenafil appeared to decrease 
the Vmax,app/Km,app ratios for the (R)-4-, (S)-6-hydroxlation and the overall 
hydroxylation of (R)-warfarin with a greater extent in concentration-independent 
manner as compared to those for their respective antipodes, whereas those ratios for 
the 7-hydroxylation of the two enantiomers of warfarin were decreased to the same 
extent in the presence of sildenafil. Moreover, the Ki value for the overall 
hydroxylation of (R)-warfarin is 2.2 times smaller than that of (S)-warfarin, indicating 
that the inhibitory effect of sildenafil on (R)-warfarin hydroxylation is more potent 
than that on (S)-warfarin in human liver microsomes.  
 
Discrepancy in the inhibitory potency of sildenafil between rat and human liver 
microsomes was observed. The inhibitory effect of sildenafil on the hydroxylation of 
warfarin enantiomers in human liver microsomes was more potent than that in rat 
liver microsomes. Moreover, the differential effect of sildenafil on the (S)-4’-
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hydroxylation between rat and human liver microsomes was noted (Table 5.7 and 
5.9). The discrepancy may be in part attributable to the structural differences between 
rat and human liver microsomal enzymes [295, 296]. It has been proposed for species 
differences in the effect of chemical inhibitors on in vitro drug metabolism [297] as 
follows: (1) the active enzymatic site different amongst different species; (2) 
metabolism is catalyzed by different isoforms in different species; and (3) the 
inhibition is not via direct competition at the active site, and the inhibitory site is 
different between the species. It is well established that there are great differences in 
the metabolic fate of drugs in different animal species. The comparative patterns of 
drug metabolism have been reviewed by a number of authors [298-300]. Quinn et al 
[300] observed that there were marked species differences in the metabolism of 
hexobarbital, which were correlated well with the observed differences in duration of 
action of the barbiturate in various species. An additional important reason is species 
variation in enzyme induction. Phenylbutazone pretreatment stimulated 6β-, 7α-and 
16α-hydroxylation of testosterone in rats but had no effect on the 7α-hydroxylation of 
testosterone in dogs [301].  
 
In man, various forms of isozymes perform the biotransformation of active forms of 
warfarin enantiomers into their inactive forms of metabolites by different pathways  
[78]. Isozymes do not have substrate specific properties and can oxidize different 
kinds of substrates as well as can transform only one substrate into different products 
[270]. According to the report by Pfizer, sildenafil is predominantly metabolized by 
CYP3A4 and CYP2C9, in man [177]. In the presence of sildenafil, both of CYP2C9 
and CYP3A4 isozyme-mediated hydroxylation of (S)-and (R) enantiomers of warfarin 
were decreased (Figure 5.6 and Table 5.9).  Sildenafil plays as a competitive inhibitor 
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on the (S)-6-, (S)-7, (R)-7-hydroxylation and the overall hydroxylation of (S)-
warfarin. However, it is a non-competitive inhibitor for (R)-4-hydroxylation and a 
mixed-typed inhibitor for (R)-6-and overall hydroxylation of (R)-warfarin. The 
relatively low Ki value couples with Km/Ki values shows that of (R)-warfarin, the 
inhibitory effect of sildenafil is selectively towards to the 6-hydroxylation in CYP3A4 
isozyme. Moreover, of (S)-warfarin, the inhibitory effect of sildenafil on the 7-
hydroxylation is more potent than that on the 6-hydroxylation pathway. Comparison 
of the Ki value for the overall hydroxylation between (R)-warfarin and (S)-warfarin 
indicates that sildenafil inhibits the CYP3A4-mediated hydroxylation of the former 
with a greater extent than the CYP2C9-mediated hydroxylation of the latter 
 
Due to inter-batches variation, either in rat or human liver microsomes, the variance 
in the inhibitory effect of sildenafil was observed between the present and repeated 
study. For the former (Table 5.7), sildenafil had no apparent effect (Figure 5.7 A), but 
for the latter (Table 5.13 and 5.14), it exhibited some inhibitory effect, on the 4’-
hydroxylation of (S)-warfarin (Figure 5.7 B) in the presence of the low substrate and 
inhibitor concentration in rat liver microsomes. Moreover, the inhibitory effect of 
sildenafil on the overall hydroxylation of (S)-warfarin was slightly better than that of 
(R)-warfarin for the latter (Table 5.15 and 5.16), but the opposite trend was noted for 
























































































































Figure 5.7. Michaelis-Menten plots for effect of sildenafil (≤10µM) on the 4’- 
hydroxylation of (S)-warfarin enantiomer (≤100µM) in rat liver microsomes (A) the 






Table 5.12.  Apparent enzymatic kinetics of the in vitro hydroxylation of warfarin 
enantiomers in rat liver microsomes in the absence and presence of sildenafil 
(repeated study) 
 (S)-warfarin+Sildenafil  (R)-warfarin+Sildenafil 
Parameters 0a 1a 10a 100a  0a 1a 10a 100a
4'-hydroxylation      
Vmax,app 172 185 186 191  67.1 68 77.5 73 
Km,app 40 38.4 34.9 28.6  78.5 52.1 52.2 38.5 
Vmax,app/Km,app 4.300 4.818 5.330 6.678  0.855 1.305 1.485 1.896 
R/S ratio 0.20 0.27 0.28 0.28      
          
6-hydroxylation      
Vmax,app 88.1 65.8 57.5 50  23.5 23 21.6 21.7 
Km,app 40.7 36.8 32.8 28.5  51.6 54.8 61.1 92.6 
Vmax,app/Km,app 2.165 1.788 1.753 1.754  0.455 0.420 0.354 0.234 
R/S ratio 0.21 0.23 0.20 0.13      
          
7-hydroxylation      
Vmax,app 20.7 20 18 15  104.2 104.2 104.2 104.2 
Km,app 109.8 112.5 110 112  255.4 326.8 434.1 824.7 
Vmax,app/Km,app 0.189 0.178 0.164 0.134  0.408 0.319 0.240 0.126 
R/S ratio 2.16 1.79 1.47 0.94      
          
Overall hydroxylation      
Vmax,app 357.1 294.1 285.7 384.6  135.1 147.1 185.2 131.6 
Km,app 63.5 48.3 48.5 65.2  60.5 74 94.3 63.6 
 0.997 0.9969 0.9967 0.997  0.9932 0.9937 0.991 0.984 
Vmax,app/Km,app 5.624 6.089 5.891 5.899  2.233 1.988 1.964 2.069 
R/S ratio 0.40 0.33 0.33 0.35      
V max (pmol/mg protein/min), Km (µM) and Vmax/Km (µl/mg protein/min). a: The final 
concentration (µM) of sildenafil in the incubation mixture. 
 159
Table 5.13. Estimates of kinetics parameters for the hydroxylation of warfarin 
enantiomers (>100µM) in the presence of sildenafil (>10µM) in pooled rat liver 
microsomes (repeated study) 
Kinetics 
Parameter 4'-OH 6-OH 7-OH 
Overall 
Hydroxylation 
(S)-warfarin     
Inhibition type Non-essential act a Uncomp. b Noncomp. c No apparent effect observed 
Ki (µM) NA 240.6 240.3 NA 
α 0.88 NA NA NA 
β 1.11 NA NA NA  
β/α 1.28 NA NA NA 
Ka 0.721 NA NA NA 
     
(R)-warfarin     
Inhibition Type Non-essential act a Comp. d Comp. d No apparent effect observed 
Ki (µM) NA 103 49  
α 0.64 NA NA NA 
β 1.25 NA NA NA 
β/α 1.95 NA NA NA 
Ka 6.41 NA NA NA 
a: Nonessential activation when a very high concentration of warfarin (>100µM) and 
sildenafil (100µM) was used in incubation, b: uncompetitive inhibition, c: 




Table 5.14. Estimates of kinetics parameters for the hydroxylation of warfarin 
enantiomers (≤100µM) in the presence of sildenafil (≤10µM) in pooled rat liver 
microsomes (repeated study) 
Kinetics Parameter (S)-4'-hydroxylation Overall (S)-warfarin hydroxylation 
(S)-warfarin   
Inhibition type Mixed-type a Mixed-type a
Ki (µM) 270 709.2 
α 0.23 0.1 
   
a: Mixed-type inhibition 
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Table 5.15. Apparent enzymatic kinetics of the in vitro hydroxylation of warfarin 
enantiomers in human liver microsomes in the absence and presence of sildenafil 
(repeated study)[292, 293] 
(S)-warfarin+Sildenafil  (R)-warfarin+Sildenafil  
Parameters 0a 1a 10a 100a  0a 1a 10a 100a
4'-hydroxylation          
Vmax,app NA NA NA NA  80 84.7 84.7 87 
Km,app NA NA NA NA  153.1 192.2 221.9 272.9 
Vmax,app/Km,app NA NA NA NA  0.523 0.441 0.382 0.319 
R/S ratio NA NA NA NA      
6-hydroxylation         
Vmax,app 2.18 2.19 2.29 2.19  15.6 14.6 14 14.2 
Km,app 10.1 10.6 12.4 14.6  36.7 35.5 39.4 44.8 
Vmax,app/Km,app 0.216 0.207 0.185 0.150  0.425 0.411 0.355 0.317 
R/S ratio 1.97 1.99 1.92 2.11      
7-hydroxylation         
Vmax,app 19.6 18.6 17.9 17.5  8.4 10.1 8.4 10.3 
Km,app 12.9 14.1 16.6 23.4  169.3 235.2 247.1 454.6 
Vmax,app/Km,app 1.519 1.319 1.078 0.748  0.050 0.043 0.034 0.023 
R/S ratio 0.03 0.03 0.03 0.03      
Overall hydroxylation         
Vmax,app 21.7 20.7 20.2 19.2  116.3 113.6 95.2 103.1 
Km,app 12.6 13.6 16 20  132.3 150.6 131.1 173.5 
Vmax,app/Km,app 1.722 1.522 1.263 0.960  0.879 0.754 0.726 0.594 
R/S ratio 0.51 0.50 0.58 0.62      
V max (pmol/mg protein/min), Km (µM) and Vmax/Km (µl/mg protein/min). a: The final 




Table 5.16. Estimates of kinetics parameters for the hydroxylation of warfarin 
enantiomers in the presence of sildenafil in pooled human liver microsomes (repeated 
study)[291, 292]  
Kinetics 
Parameters 4'-OH 6-OH 7-OH 
Overall 
Hydroxylation 
(S)-warfarin     
Inhibition Type NA Comp a Comp a Comp a
Ki (µM) NA 243.4 122.2 144.5 
     
(R)-warfarin     
Inhibition Type Comp a Comp a Comp a Comp a
Ki (µM) 257 51 85 156.7 
     
a: competitive inhibition, NA=not available data 
 
Based on the overall in vitro metabolism results obtained, it is concluded that 
sildenafil selectively inhibits the overall hydroxylation of (R)-warfarin in both rat and 
human liver microsomes. This finding is consistent with the fact that both of sildenafil 
and (R)-warfarin are mainly metabolized by CYP3A4 and the former has more potent 
effect on the metabolism of the latter than that of (S)-warfarin. However, the 
regioselectivity and intensity of the inhibitory effect of sildenafil on the other 
hydroxylation pathways of warfarin enantiomers are different between two species. 
Sildenafil exhibits a weak inhibitor of CYP450 enzyme in rat liver microsomes 
because of the large Ki values for all metabolic pathways (greater than 100 µM) and 
of no apparent effect on the overall hydroxylation of (S)-warfarin. Sildenafil exhibits 
a far lesser inhibitory effect on the metabolism of warfarin in rat liver microsomes 
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than that in human liver microsomes due to the fact that Ki values for most of the 
hydroxylation pathways of either (S)-or (R)-enantiomer of warfarin in the latter are 
much lower than those in the former. In addition, the Ki values for sildenafil-liver 
microsomal protein are considerably higher than the estimated maximum liver 
sildenafil concentration of 14.4µM in rat after oral administration of a single dose of 
sildenafil 0.25mg [191] , but are less than that of 41.1µM in man after oral 
administration of a single dose of sildenafil 50mg  [191] when active transport (A=8) 
is  taken into consideration.  
 
Furthermore, the present in vitro metabolism data in rat liver microsomes was in good 
agreement with in vivo data for the metabolic drug interaction of warfarin and 
sildenafil in rat (unpublished data*), showing that sildenafil weakly inhibits on the 
metabolism of both (S)-and (R)-warfarin, and has a relatively high inhibitory effect on 
(R)-warfarin. With this regards, the present in vitro result from human liver 
microsomes could be a predictor of the effect of sildenafil on the clearance of 














APPLICATION OF IN VITRO DATA TO PREDICT IN VIVO 
CLEARANCE AND DRUG INTERACTION 
 
6.1. Prediction of In Vivo Hepatic Clearance from the In Vitro Data 
6.1.1. Introduction 
 
The interest on the synthesis or manufacturing of chemicals or new drugs has been 
growing in recent years. The early evaluation of pharmacokinetics must be done in 
order to get the optimal pharmacokinetic and pharmacological properties in drug 
discovery. The pharmacokinetics and drug metabolism play as important determinants 
of the in vivo drug interaction [302] because drug-drug interaction is mostly caused by 
one drug activating or inhibiting on the plasma protein binding or metabolism of 
another drug [303] . Therefore, the evaluation of pharmacological and toxicological 
properties is crucial during drug discovery, yet, it is not possible to investigate in man 
during the early state of drug development. Thus, the evaluation of these properties is 
examined in laboratory animals and in vitro system before testing in man [304]. As in 
vivo pharmacokinetic studies are time-consuming, high-expense, and labor-intensive, 
an in vitro approach for the qualitative and quantitative prediction of in vivo 
parameters is desirable as a primary screen [305].  
 
Liver is a major site for termination of the activity of many endogenous and 
exogenous compounds because of residing of many of metabolizing enzymes, which 
involve the disposition and metabolism of compounds, in the endoplasmic reticulum 
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of the liver [306]. Therefore, many investigators have investigated drug metabolism 
using various liver fractions; such as hepatocytes, and liver microsomes [307].  
 
The oral anticoagulant, warfarin is rapidly and highly absorbed from the 
gastrointestinal tract and assumed that it has complete bioavailability [308]. However, 
its bioavailability may vary from one brand to others due to different dissolution rates 
by different formulations [309]. Warfarin is highly plasma protein bound drug and it 
is mostly distributed to the liver.  It is cleared from the body by metabolism [85]. In 
rat, approximately 86 to 90% of more potent (S)-warfarin is cleared via 4’-, 6-, 7-, and 
8-hydroxylation pathway [64] while 80-85% via 6- and 7-hydroxylation pathway in 
man [79]. 
  
Furthermore, warfarin is known to be a low extraction drug with predominantly 
hepatic clearance [63, 64]. The hepatic clearance of such a low extraction drug like 
warfarin is influenced by plasma protein binding, and intrinsic clearance CLint [310].  
 
This study aims to predict the vivo hepatic clearance of warfarin using in vitro 
intrinsic clearance data obtained from the in vitro metabolism study of warfarin 
enantiomers in rat and human liver microsomes, together with the data of in vitro 
plasma protein binding, microsomal binding and in vivo metabolites information. 
Furthermore, the predicted results were compared to the observed data of in vivo 







6.1.2.1. In Vitro Metabolism Data  
 
The apparent intrinsic clearance values, obtained on the basic of the substrate 
concentration added into the microsomal incubation, for individual (Clint,app,j, where j 
is a particular pathway) and overall hydroxylation (Clint,app) of warfarin enantiomers in 
rat and human liver microsomes are summarized in Table 7.1. Unbound fraction of 
warfarin enantiomers in pooled rat serum and microsome was investigated in our 
previous studies presented in which the detailed assay procedures were described in 
Section4.3.2 and 4.3.1, respectively. However, unbound fraction of warfarin 
enantiomers in human plasma and human microsomal binding value of racemic 
warfarin, and microsome-serum partitioning value were obtained from the literature 
[43].   
 
6.1.2.2. In Vivo Data  
 
The fraction of enantiomeric dose which is converted to particular metabolite and 
recovered from urine (fm,j) in rats and man was retrieved from the literatures [57, 77]. 
To estimate the contribution of each hydroxylation pathway to the overall metabolism 
of warfarin enantiomers, a correction factor f’m,j was used. The factor f’m,j were 
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Table 6.1. Information on the in vitro intrinsic /K lism 
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  osom osom zymes
(S)-warfarin   (CYP2C9) 
4'-Hydroxylation 2.3 0.8  
6-Hydroxylation 0.78 0.95 3.1 
ion 0.  
tion 
(CYP3A4) 
7-Hydroxylat 14 2 6 
Overall Hydroxyla 3.3 1.93 8.9 
    
(R)-warfarin   
4'-Hydroxylation 0.84 2.2 3.34 
6-Hydroxylation 0.93 0.39 0.98 
7-Hydroxylation 0.36 0.06 0.03 
2.1 2 4.3 Overall Hydroxylation 
a: Using rat liver microsomes with 0.5% acetonitrile in the incubation mixture.  
osomes with 0.5% acetonitrile in the incubation mixture. 
c: Using human cytochrome P-450 isozymes, CYP2C9 for (S)-warfarin and CYP3A4 for (R)-
arfarin incubation, respectively, with 0.5% acetonitrile in the incubation mixture. 
b: Using human liver micr
w
 
6.1.2.3. Data Analysis 
 
In Vitro intrinsic clearance is the cornerstone for extrapolation of in vitro enzyme 
kinetics of drug metabolism to in vivo intrinsic clearance. Under the conditions of low 
substrate (S-or R-warfarin) concentrations ([S]<<Km), in vitro true intrinsic clearance 
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(Clint) is theoretically a ratio of the Michaelis-Menten parameters (Vmax/Km) estimated 
on the basis of the free drug concentration at the enzymatic site [307]. Thus, Clint can 
be estimated from one based on the total drug concentration at the enzymatic site 
using Clint=Clint,app/fu,mic, where fu,mic is the unbound fraction at the enzymatic site. 
CLint,app values obtained from the individual hydroxylation pathways of warfarin 
metabolism in hepatic microsomes were expressed as CLint,app,j, where the subscript j 
indicates a particular hydroxylation pathway. The apparent intrinsic clearance for the 
overall hydroxylation of warfarin enantiomers (Clint,app) were estimated on the basic of 
the kinetic parameters obtained by fitting the Michaelis-Menten equation to the sum 
of the formation rates of those three phenolic metabolites of each enantiomer at each 
bstrate concentration added into the microsomal incubation, assuming that except 
 study), i.e. CL’int(ml/min/kg) = 
.3 x CLint (µl/mg protein/min); or of 45mg microsomal protein per gram liver wet 
su
4’-,6- and 7-hydroxylation the other metabolic pathways are too minor to be taken 
into account. 
 
Additionally, CLint,app, expressed on a per milligram microsomal protein basis, was 
normalized to reflect the in vivo intrinsic clearance (CL’int) on a per kilogram body 
weight basis. In the present study, normalization was done using the values of 28mg 
microsomal protein per gram liver wet weight for  46.2g liver wet weight per 
kilogram rat body weight (determined in the present
1
weight for 20 g liver wet weight per kilogram human body weight [83], i.e. 
CL’int(ml/min/kg) = 0.9 x CLint (µl/mg protein/min). 
 
Moreover, drugs are mostly cleared by metabolic pathway and liver is the main site of 
drug metabolism [311]. Therefore, hepatic clearance is considerable important factor 
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in drug discovery. The clearance is influenced by three independent variables such as 
hepatic blood flow (QH), unbound fraction of the drug (fu), the intrinsic clearance 
(CLint) [307]. The two models to predict in vivo hepatic clearance have been 
stablished [82]. In the present study, the extrapolation of the in vitro hepatic 
clearance data to in vivo data using the reported two models, the well-stirred model 
(eq: 7.2) and the parallel tube model (eq: 7.3), w
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kg was used for 
rat [83]. Furthermore, the
microsomes (Cmic) and serum (Cu) is defined as the microsomal-serum partitioning 
value (P ). If the free drug concentration of warfarin enantiomers in microsomes is 
equal to that in serum, the P value could be estimated as follows: 
H value of 20 ml/min/kg was used for man while 60 ml/min/













==        (6.4) 
 
fCC /
T e basis of the independently 
etermined serum protein and microsomal unbound fraction values. The Pm/s value 
could also be measured by the di
fu/fu,mic  with Pm/s  into the of equation (6.2) and (6.3) yields, 
heoretically, the ratio of fu/fu,mic could be calculated on th
d





























⎛ ⎟⎟⎠⎞⎜⎜⎝⎛ ••− jmfQH jappCLsPm ,' ,int,/
The f
−•= HpH eQCL , 1       (6.6) 
rosomal protein concentration-dependent in man[83]. 
hus, the fu,mic values for each warfarin enantiomer used in this study was calculated 
nd the reported fu,mic value. Since there was no reported Pm/s value 
av at fu/fu,mic ratio for 
mated by the following 
quation.  
u,mic values from racemic warfarin retrieved from the literature appeared to be 
substrate concentration –and mic
T
from its corresponding fu value based on the ratio of the unbound fraction of racemic 
warfarin a
ailable for rats, the Pm/s value for rat was calculated from the r
racemic warfarin based on the ratio of the reported human Pm/s value and fu/fu,mic 
ratio for racemic warfarin [83].  
 













here FE is the average fold error for each prediction method; CLH,p,pred,j is the 
      (6.7) 
w
predicted plasma/serum hepatic clearance value; CLH,p,pred,obs is the observed in vivo 
hepatic clearance data retrieved from the literatures. In addition, the fold error for 
















       (6.8) 
 50% below) would have a value of 2 and 
udy, a prediction method with a FE ≤ 2 was considered 
icted hepatic clearance values for warfarin enantiomers estimated from in 
 intrinsic clearance are listed together with the observed in vivo hepatic clearance 








successful [312].  
so forth. Thus, in the present st
Using this approach, underpredictions are of equal value to overpredictions. A method 
which predicts all observed values perfectly would have a value of 1; one that makes 
























Table 6.2.A. Comparison of in vivo plasma hepatic clearance values with the predicted values based on in vitro intrinsic clearance data.(present 
study) 
 Rat   Human  Human CYP-450 isozyme 
 (S)-warfarin     (R)-warfarin (S)-warfarin (R)-warfarin  (S)-warfarin (CYP2C9) 
(R)-warfarin 
(CYP3A4) 
fu,serum 0.005    0.009 0.005a 0.006a 0.005a 0.006a
fu,mic 0.65    
      
       
4'- hydroxylation 
0.87 0.53b 0.64b 0.53b 0.64b
Pm/s 0.037c 0.037c 0.033 0.033 0.033 0.033
CL H,p,in vivo (ml/min/kg)d 0.15 0.23  0.054 0.044 0.054 0.044
f'm, reported 0.4 0.21  N.A N.A  N.A N.A 
CL'int(ml/min/kg) 3.05 1.1  0.68 1.96  0.68 1.96 
CLH,p predict (ml/min/kg)         
Well Stirred Model         
without microsomal 
binding 0.038 (3.9) 0.028 (5.0)       
with microsomal binding 0.058 (2.6) 0.033 (4.4)  NA NA  NA NA 
Using Pm/s value 0.280 (1.8) 0.117 (1.2)  NA NA  NA NA 
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(Continue) 
Parallel Tube Model         
without microsomal 
binding 0.038 (3.9) 0.028 (5.0)       
with microsomal binding 0.058 (2.6) 0.033 (4.4)  NA NA  NA NA 
Using Pm/s value 0.281 (1.8) 0.117 (1.2)  NA NA  NA NA 
6- hydroxylation 
f'm, reported 0.16 0.22  0.18 0.31  0.18 0.31 
CL'int(ml/min/kg) 1.02 1.21  0.85 0.35  2.8 0.89 
CLH,p predict (ml/min/kg)         
Well Stirred Model         
without microsomal 
binding 0.033 (4.6) 0.049 (4.7)  0.024 (2.3) 0.007 (6.5)  0.077 (1.4) 0.017 (2.6) 
with microsomal binding 
        
without microsomal 
binding 0.033 (4.6) 0.049 (4.7)  0.024 (2.3) 0.007 (6.5)  0.077 (1.4) 0.017 (2.6) 
with microsomal binding 0.050 (3.0) 0.057 (4.1)  0.045 (1.2) 0.011 (4.2)  0.146 (2.7) 0.026 (1.7) 
Using Pm/s value 0.242 (1.6) 0.203 (1.2)  0.158 (2.8) 0.037 (1.2)  0.506 (8.4) 0.093 (2.0) 
 
0.050 (3.0) 0.057 (4.1)  0.045 (1.2) 0.011 (4.2)  0.145 (2.7) 0.026 (1.7) 
Using Pm/s value 0.238 (1.6) 0.199 (1.2)  0.152 (2.8) 0.036 (1.2)  0.452 (8.4) 0.089 (2.0) 




f'm, reported 0.4 0.49  0.74 0.13  0.74 0.13 
CL'int(ml/min/kg) 0.19 0.47  1.8 0.05  5.44 0.02 
CLH,p predict (ml/min/kg)         
Well Stirred Model         
without microsomal 
binding 0.002 (65.1) 0.009 (26.5)  0.012 (4.4) 0.002 (19.0)  0.037 (4.4) 0.001 (39.5) 
with microsomal binding 0.004 (42.3) 0.010 (23.0)  0.023 (2.3) 0.004 (12.1)  0.069 (2.3) 0.002 (25.2) 
Using Pm/s value 0.017 (8.8) 0.036 (6.4)  0.080 (1.5) 0.013 (3.4)  0.243 (1.5) 0.006 (7.2) 
Parallel Tube Model         
without microsomal 
binding 0.002 (65.1) 0.009 (26.5)  0.012 (4.4) 0.002 (19.0)  0.037 (4.4) 0.001 (39.5) 
with microsomal binding 0.004 (42.3) 0.010 (23)  0.023 (2.3) 0.004 (12.1)  0.069 (2.3) 0.002 (25.2) 
Using Pm/s value 0.017 (8.8) 0.036 (6.4)  0.080 (1.5) 0.013 (3.4)  0.242 (1.5) 0.006 (7.2) 
Overall hydroxylation 
f'm, reported 0.96 0.92  0.94 0.65  0.94 0.65 
CL'int(ml/min/kg) 4.2 2.7  1.7 1.8  7.98 3.91 
CLH,p predict (ml/min/kg)         
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Well Stirred Model         
without microsomal 
binding 0.022 (6.8) 0.026 (8.7)  0.009 (5.8) 0.006 (2.6)  0.043 (1.3) 0.036 (1.2) 
with microsomal binding 0.034 (4.4) 0.030 (7.6)  0.017 (3.1) 0.010 (1.7)  0.080 (1.5) 0.057 (1.3) 
Using Pm/s value 0.163 (1.1) 0.109 (2.1)  0.061 (1.1) 0.036 (2.1)  0.278 (5.1) 0.198 (4.5) 
Parallel Tube Model         
without microsomal 
binding 0.022 (6.8) 0.026 (8.7)  0.009 (5.8) 0.006 (2.6)  0.043 (1.3) 0.036 (1.2) 
with microsomal binding 0.034 (4.4) 0.030 (7.6)  0.017 (3.1) 0.010 (1.7)  0.080 (1.5) 0.057 (1.3) 
Using Pm/s value 0.164 (1.1) 0.109 (2.1)  0.061 (1.1) 0.036 (2.1)  0.279 (5.1) 0.199 (4.5) 
         
FE         
Well Stirred Model 5.1 5.1  2.4 4  2.4 4.2 
without microsomal 
binding 9.4 8.6  3.9 6.9  1.4 5.0 
with microsomal binding 6.1 7.4  2.1 4.4  1.7 3.8 
Using Pm/s value 2.3 2.1  1.7 2.1  5.8 4.0 
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(Continue)         
Parallel Tube Model 5.1 5.1  2.4 4  2.4 4.3 
without microsomal 
binding 9.4 8.6  3.9 6.9  1.4 5.0 
with microsomal binding 6.1 7.4  2.1 4.4  1.7 3.8 
Using Pm/s value 2.3 2.1       
         
 
Figures in parentheses indicate the FEj. 
a:  Unbound fraction values were obtained from Ref: [315],  
b:  fu,mic value for each warfarin enantiomer in man was calculated from (fu,mic for racemic warfarin)×(fu for individual warfarin enantiomers)/(fu 
for racemic warfarin). The fu and fu,mic values for racemic warfarin in man were from Ref: [84]. 
c:  The rat Pm/s value was calculated as (human Pm/s value)×(rat fu/fu,mic ratio for racemic warfarin)/(human fu/fu,mic ratio for racemic warfarin). 
d:  In vivo rat CLH,p values for warfarin enantiomers were calculated by CLH,P=CL-CLr (CL and CLr values based on serum were from Ref: [58], 
where CL is the total clearance, CLr is the renal clearance. In man, since the renal clearance of warfarin enantiomers is so minor that it is usually 
ignored, the CL values based on plasma, which were obtained from [315] were used as CLH,P  values. 
e: Rat data for the calculation of f’m values were obtained from Ref: [58] and [78], respectively. 
N.A represents not available data. 
 





Table 6.2.B. Comparison of in vivo plasma hepatic clearance values with the 
predicted values based on in vitro intrinsic clearance data.( repeated study). 
 Rat  Human 
 (S)-warfarin (R)-warfarin 
fu,serum 0.005 0.009  0.005a 0.006a
 (S)-warfarin (R)-warfarin 
fu,mic  0.53b 0.64b
Pm/s 0.037c 0.037c
CL H,p,in vivo (ml/min/kg)d
0.65 0.87 
 0.033 0.033 
0.15 0.23  0.054 0.044 
4'- hydroxylation 
f'm, reported 0.4 0.21  N.A N.A 
CL'int(ml/min/kg)  
CLH,p predict (ml/min/kg)   
 
0.070 (2.2) 
with microsomal binding NA 
Using Pm/s value 
 
NA 
Using Pm/s value 0.192 (1.2) 
5.6 1.1   
   
Well Stirred Model     
without microsomal binding 0.047 (4.9)    
0.107 (1.4) 0.054 (4.3)  NA 
0.511 (3.4) 0.191 (1.2)  NA NA 
Parallel Tube Model     
without microsomal binding 0.070 (2.2) 0.047 (4.9)    
with microsomal binding 0.107 (1.4) 0.054 (4.3)  NA 
0.513 (3.4)  NA NA 
6- hydroxylation 
f'm, reported 0.16 0.22  0.18 0.31 
CL'int(ml/min/kg) 
CLH,p predict (ml/min/kg) 
  
Using Pm/s value 
 
without microsomal binding 0.007 (6.0) 
 
Using Pm/s value  
2.81 0.59  0.194 0.38 
     
Well Stirred Model    
without microsomal binding 0.090 (1.7) 0.024 (9.6)  0.005 (9.9) 0.007 (6.0) 
with microsomal binding 0.138 (1.1) 0.028 (8.3)  0.010 (5.2) 0.011 (3.9) 
0.635 (4.2) 0.098 (2.3)  0.036 (1.5) 0.039 (1.1) 
Parallel Tube Model     
0.090 (1.7) 0.024 (9.6)  0.005 (9.9) 
with microsomal binding 0.138 (1.1) 0.028 (8.3) 0.010 (5.2) 0.011 (3.9) 
0.661 (4.4) 0.099 (2.3) 0.036 (1.5) 0.040 (1.1) 
7- hydroxylation 
f'm, reported 0.13 0.4 0.49  0.74 
CL'int(ml/min/kg) 
CLH,p predict (ml/min/kg) 
0.013 (4.1) 
Using Pm/s value 0.023 (6.6) 
0.25 0.53  1.04 0.045 
     
Well Stirred Model      
without microsomal binding 0.003 (49.1) 0.010 (23.4)  0.007 (7.7) 0.002 (22.0) 
with microsomal binding 0.005 (31.9) 0.011 (20.3)  0.003 (14.1) 
0.040 (5.7)  0.046 (1.2) 0.011 (4.0) 
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Parallel Tube Model      
without microsomal binding 
0.005 (31.9) 0.003 (14.1) 
Using Pm/s value 0.046 (1.2) 
0.003 (49.1) 0.010 (23.4)  0.007 (7.7) 0.002 (22.0) 
with microsomal binding 0.011(20.3)  0.013 (4.1) 
0.023 (6.6) 0.040 (5.7)  0.011 (4.0) 
Overall hydroxylation 
f'm, reported 0.96  0.65 0.92 0.94 
CL'int(ml/min/kg) 2.91 1.56 
CLH,p predict (ml/min/kg) 
0.033 (7.0) 
Using Pm/s value 
Parallel Tube Model    
 0.010 (6.0) 
0.033 (7.0) 0.016 (3.4) 
Using Pm/s value 0.282 (1.9) 0.055 (1.0) 0.053 (1.1) 
   
FE   
7.32  0.79 
     
Well Stirred Model      
without microsomal binding 0.038 (3.9) 0.028 (8.1)  0.008 (6.5) 0.010 (6.0) 
with microsomal binding 0.059 (2.6)  0.016 (3.4) 0.015(3.8) 
0.281 (1.9) 0.117 (2.0)  0.055 (1.0) 0.053 (1.1) 
  
without microsomal binding 0.038 (3.9) 0.028 (8.1) 0.008 (6.5) 
with microsomal binding 0.059 (2.6)  0.015 (3.8) 
0.117 (2.0)  
   
   
Well Stirred Model 4.0 5.8 3.4  4.5 
without microsomal binding 7.9 
Using Pm/s value  
4.8 5.9  3.7 4.0 
5.1 9.7  9.2 
with microsomal binding  4.2 5.9 
Using Pm/s value 3.7 2.4  1.2 1.7 
5.1 9.7  9.2 
with microsomal binding 3.3 8.5  4.2 5.9 
3.7 2.4 1.2 1.7 
Parallel Tube Model 
without microsomal binding 7.9 
3.3 8.5 
Figures in parentheses indicate the FEj. 
a:  Unbound fraction values were obtained from Ref: [313],  
b:  fu,mic value for each warfarin enantiomer in man was calculated from (fu,mic for racemic 
warfarin)×(fu for individual warfarin enantiomers)/(fu for racemic warfarin). The fu and fu,mic 
values for racemic warfarin in man were from Ref: [83]. 
c:  The rat Pm/s value was calculated as (human Pm/s value)×(rat fu/fu,mic ratio for racemic 
warfarin)/(human fu/fu,mic ratio for racemic warfarin). 
d:  In vivo rat CLH,p values for warfarin enantiomers were calculated by CLH,P=CL-CLr (CL 
and CLr values based on serum were from Ref: [57], where CL is the total clearance, CLr is 
the renal clearance. In man, since the renal clearance of warfarin enantiomers is so minor that 
it is usually ignored, the CL values based on plasma, which were obtained from [313] were 
used as CLH,P  values. 
e: Rat data for the calculation of f’m values were obtained from Ref: [57] and [77], 
respectively. 





Many studies have been performed the prediction of in vivo drug clearance from in 
vitro metabolism data [84, 248, 307, 314]. There are a few established methods which 
are used in the predictions, such as the well-stirred model [82, 315, 316], the parallel-
tube mode [82], the distributed model [317, 318] and the dispersion model [319-321]. 
In general, there are slightly differences in calculated CLH values among the models 
especially in the prediction of low-clearance drugs. Some of studies have investigated 
that the influence of parameters; such as hepatic blood flow, serum protein binding, 
microsomal protein binding, in the prediction of in vivo clearance to perform the best 
suited model for that purpose [82, 83, 322]. The in vitro enzymatic kinetic data used 
in the previous studies [83, 84] are based on the decreased in the amount of racemic 
warfarin rather than the formation of individual metabolites. In the present study, the 
prediction was made based on the in vitro intrinsic clearance data which estimated 
from the corresponding in vitro individual hydroxylation data of rat and human liver 
microsomes. 
 
In the present study, the prediction was made based on the fu alone, fu incorporated 
with fu,mic and Pm/s values in the prediction models. In rats, the predictions of CLH,p 
values based on fu alone resulted in significant underpredictions of CLH,p values with 
the FEj values of (3.9~65.1) for both (R)-and (S)-warfarin enantiomers. When fu,mic 
values were incorporated in the prediction models, the predictions of CLH,p values for 
warfarin enantiomers in rats were generally improved, although some 
underpredictions still remained (with FEj values of 2.6~42.3). Based on the reported 
human Pm/s value (0.033) and the calculated fu/fu,mic ratio (0.0094) for racemic warfarin 
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[83], the estimated rat Pm/s value was 0.037. When Pm/s value instead of fu/fu,mic  ratio, 
the predictions of the CLH,p values for both warfarin enantiomers were dramatically 
improved with FE value of 2.3 versus 9.4 and 6.1 for (S)-warfarin, and 2.1 versus 8.6 
and 7.4 for (R)-warfarin, irrespective of the prediction models used. This finding was 
in agreement with the literature studies using the in vitro approach to predict the in 
vivo clearance of warfarin [83]. Obach et al demonstrated that the prediction of in vivo 
clearance of (RS)-warfarin based on either the well-stirred model or parallel-tube 
model, when integrated with either fu/f u,mic or Pm/s ratio gave a better prediction of in 
vivo hepatic clearance of drugs including warfarin than that integrated only with fu 
alone [83]. However, this prediction was made on racemic warfarin only.  Such 
information on warfarin enantiomers is still lacking. Since warfarin enantiomers are 
remarkable differences in the pharmacokinetics and pharmacodynamic properties, 
individual kinetic prediction was made on the (S)-and (R) enantiomers of warfarin.  
 
Prediction made on the event in rats show that the most accurate prediction of CLH,p 
values with the actual in vivo CLH,p values was obtained when Pm/s value was used. Of 
all the hydroxylation pathways evaluated for each warfarin enantiomer, the most 
accurate prediction on the CLH,p values for warfarin enantiomers were based on the 
apparent intrinsic clearance values for the overall hydroxylation of (S)-warfarin and 
the 4’-and 6-hydroxylation of both warfarin enantiomers, using Pm/s values with their 
respective FEj values of no greater than 2, irrespective of the models used (Table 6.2). 
The finding suggests that determination and inclusion of the Pm/s value is important in 
the process of extrapolation of the in vitro intrinsic clearance data of warfarin 
enantiomers to the in vivo hepatic clearance data in rats.  
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As in rats, the prediction of CLH,p in man based on Pm/s value was generally performed 
better than that based on fu alone or fu/fu,mic with the FE values of 1.7 versus 3.9 and 
2.1 for (S)-warfarin, and 2.1 versus 6.9 and 4.4 for (R)-warfarin, either in the well-
stirred or parallel-tube model. The most accurate predictions of human CLH,p for 
warfarin enantiomers were  based on the CLint,app,j value for the (R)-6 hydroxylation 
(FEj=1.2), (S)-7-hydroxylation (FEj=1.5), overall (S)-warfarin hydroxylation 
(FEj=1.1) using either the well-stirred or the parallel-tube model integrated with the 
Pm/s value and on that for (S)-6-hydroxylation (FEj=1.2), overall (R)-warfarin 
hydroxylation (FEj=1.7) using either prediction model integrated with the fu/fu,mic 
value.  
 
In contrast to the predictions of CLH,p based on the rat and human CLint,app,j  data, the 
predictions based on human CYP-450 isozyme data integrated with fu alone or fu/fu,mic 
ratio were generally performed better than those based on Pm/s value (FE values of 1.4 
and 1.7 versus 5.8 for (S)-warfarin) Table (6.2. A). However, the prediction based on 
fu/fu,mic ratio was relatively better than those integrated with fu alone or Pm/s values (FE 
values of 3.8 versus 5 and 4 for (R)-warfarin. There are a few forms of isozymes 
participating in biotransformation of drug in man. Since the prediction was only based 
on CLint,app,j of (S)-warfarin in CYP2C9 isozyme and CLint,app,j of (R)-warfarin in 
CYP3A4 isozyme, there may have the variance in accuracy of the prediction based on 
human CLint,app,j data and CYP-450 CLint,app,j data.   
 
The overall observation shows that the relatively accurate prediction of in vivo hepatic 
clearance from in vitro data could be obtained based on the in vitro intrinsic clearance 
of either individual hydroxylation pathways or the overall hydroxylation integrated 
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with Pm/s value using either the  well-stirred or parallel-tube model. The prediction, 
based on the CLint,app data from repeated study shows that the prediction of CLH,p 
based on Pm/s value was generally performed better than that based on fu alone or 
fu/fu,mic, except for the prediction of CLH,p for (S)-warfarin in rats (Table 6.2.B).  The 
most accurate prediction for the repeated study was  based on the CLint,app,j value from 
human liver microsomal incubation for the (S)-6 hydroxylation (FEj=1.5), (S)-7-
hydroxylation (FEj=1.2), overall (S)-warfarin hydroxylation (FEj=1.0), R-6-
hydroxylation (FEj=1.1), overall (R)-warfarin hydroxylation (FEj=1.1) and that from 
rat liver microsomal incubation for (R)-4’-hydroxylation using either the well-stirred 
or the parallel-tube model integrated with the Pm/s value, whereas on that from rat 
liver microsomal incubation for (S)-4’-hydroxylation (FEj=1.4), (S)-6warfarin 
hydroxylation (FEj=1.1) using either prediction model integrated with the fu/fu,mic 
value.  
 
Hence, it is concluded that in vitro intrinsic clearance based on fu/fu,mic or Pm/s value 
can be employed to predict the in vivo plasma hepatic clearance of warfarin 
enantiomers using the well-stirred or parallel-tube model. Moreover, this approach 
can be extended to predict the in vivo drug interaction with warfarin from the in vitro 
metabolic drug interaction data.  
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6.2. Prediction of  Drug interaction of Warfarin and Sildenafil from In Vitro 





Cytochrome P450 enzymes are mostly responsible for drug metabolism and these 
enzymes are particularly occurred in the endoplasmic reticulum of the liver. Hence, 
investigators employ animal microsomes in the study of in vitro metabolism study to 
extrapolate in vivo parameters. CYP450-dependent drug interaction based on 
inhibition mechanism can be classified into reversible inhibition, quasi-irreversible 
inhibition and irreversible inhibition [323]. Of these inhibitions, reversible inhibition 
is the most frequently occurred in drug-drug interaction study and it can be further 
categorized as a competitive, noncompetitive or uncompetitive inhibition. A 
Combination drug therapy for the treatment of a disease is very common in the recent 
decades.  As a result, the patient has a high risk of suffering from an adverse drug-
drug interaction [303]. In the case of a drug with low therapeutic index such as 
warfarin, drug-drug interaction could lead to a life-threatening reaction. As the 
metabolism-based drug-drug interactions are mostly occurred, these are widely 
interested by researchers and have been investigated in various ways. In addition, in 
vitro approach for the prediction of in vivo pharmacokinetic parameters becomes as a 
desirable primary investigation due to the fact that successful prediction of in vivo 
drug metabolism is not only to save animals, time and expense during the drug 
discovery [248] but also reduction of potential risks involved in conducting human in 
vivo study [249].  
 183
competitive inhibition is the most facile prediction in drug interaction studies [324]. 
With the knowledge of the in vitro inhibition constant (Ki) values for any drug which 
is a substrate/inhibitor of a cytochrome P450 isoform, it is theoretically possible to 
assess the likelihood of interactions [323, 325].The inhibitory constant Ki value is 




6.2.2.1. In Vitro Data 
 
To assess the enzyme kinetics of warfarin-sildenafil drug interaction, in vitro 
metabolic drug interaction of warfarin with sildenafil was investigated. The in vitro 
enzymatic kinetic analysis for warfarin-sildenafil interaction was performed as 
Warfarin is included in the world top 200 prescribed drugs in 2006 [223] although it 
possesses some other unfavorable properties of high protein binding, CYP450-
dependent metabolism, and low therapeutic index [13]. As such, drug interaction 
involving warfarin could lead to life-threatening major bleeding [326]. Hence, the 
drug interactions of warfarin with more than 250 therapeutic agents have been 
investigated [327]. Sildenafil is also widely prescribed drug in the US [328] and its 
pharmacokinetic properties are similar to warfarin such as high plasma protein 
binding and CYP450-dependent metabolism [177]. In this study, in vivo drug 
interaction of warfarin and sildenafil drug interaction was predicted using the in vitro 
metabolic drug interaction data of these drugs and some other in vivo data which were 
retrieved from the literatures.  
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described in Section 5.2.5. The resultant enzyme kinetic data in the absence and 
presence of sildenafil were used in this estimation of in vivo warfarin-sildenafil drug 
interaction and the data are summarized in Table 6.3.  
 
Table 6.3. Estimate kinetics parameters for the hydroxylation of warfarin enantiomers 
in the presence of sildenafil. 
  Ki (µM) 
  RLM 
a HLM b CYP450 isozyme c
(S)-warfarin    (CYP2C9) 
4'-hydroxylation NA 
244.1 36.2 131.5 
7-hydroxylation 228.7 307.2 45.2 
Overall hydroxylation NA 177.3 61.8 
    
(R)-warfarin    (CYP3A4) 
NA 79 
6-hydroxylation 
4'-hydroxylation 23.9 32.5 154.3 
6-hydroxylation 336.5 194.3 17.5 
7-hydroxylation 379.5 340.5 263.4 
Overall hydroxylation 240.3 78 20.1 
a: pooled rat liver microsomes, b: pooled human liver microsomes, c: human cytochrome 
P450 isozymes, Ki represents inhibition constant, NA represents not available data (α value is 
not available for the simple competitive inhibition unless the inhibition is of mixed type). 
 
 
6.2.2.2. In Vivo Data 
 
The in vivo pharmacokinetic information of sildenafil was retrieved from the literature 
to estimate the maximum concentration of the unbound sildenafil in rat or human 
liver. The information is presented in Table 6.4. Furthermore, the rat in vivo clearance 
data for warfarin enantiomers with or without sildenafil were obtained from the 
previous in vivo study of warfarin and sildenafil in rats done by the previous graduate 
student in the same lab. The degree of inhibition of sildenafil on the total and hepatic 
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clearance of warfarin enantiomers in rats was evaluated based on these in vivo 
clearance data. The data were presented in Table 6.5 A and 6.5 B.  
 
Table 6.4. Information for estimating the maximum concentration of the unbound 










µmol F Ref. 
Rat 0.4 Single oral dose 0.024 0.05 3 0.4 2.15 0.23 [191] 
Man 3.7 75 Single oral dose 0.22 0.04 1.2 2.26 0.38 [191] 
D=Dose; fu,i=unbound fraction in serum; Ka=absorption rate constant; F=bioavailability; Ka 
was calculated using the equation Tmax=[1/(Ka-K)]y Ln(Ka/K) 
 
Prediction of the degree of inhibition in the in vivo hepatic clearance and total 
clearance of warfarin enantiomers was calculated based on the following equations: 
 































⎛ −+•=       (6.10) 
 
where CL’ and CL are the total clearance of warfarin in the presence and absence of 
sildenafil, respectively; CL’H and CLH are the hepatic clearance of warfarin in the 
presence and absence of sildenafil, respectively; fH is the fraction of hepatic clearance 
in total clearance; fm,j is the fraction of the enantiomeric dose that is converted to a 
particular metabolite, j; which was calculated by equation (6.1);  fu and f’u are the 
unbound fraction of warfarin enantiomers in the plasma in the absence and presence 
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of sildenafil, respectively. Due to the lack of data for the effect of sildenafil on the 
plasma protein binding of warfarin enantiomers in man, we assumed f’u/fu=1. 
Combing Equation (6.9) and (6.10) yields: 
H





H fCLffffCL −+⎟⎟⎞⎜⎜⎛ ⎟⎞⎜⎛•+−•= 1'1'' ,,      (6.11) 
In the presence of a competitive inhibitor, the intrinsic clearance of the warfarin can 
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where Cu,i is the unbound inhibitor concentration at the enzymatic site; Ki is inhibitory 
constant.  
 
But, Km value is much larger than Cu in the in vivo study. Hence, equation (6.12) can 
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For the presence of mixed-type inhibitor, the intrinsic clearance can be estimated by 
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But, the equation was simplified to the same equation which used for simple 
competitive inhibition because Km value is much larger than Cu in the in vivo study.  
To evaluate the degree of an decrease in the in vivo hepatic clearance (CL’H/CLH) and 
total clearance (CL’/CL) of warfarin enantiomers in the presence of sildenafil, 
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max,,max,,      (6.17) 
where A is factor for assumed active transport; fu,i is the unbound fraction of sildenafil 
in plasma, Ci,max is the maximum concentration of sildenafil in plasma; Ka is first 
order absorption rate; D is dose; F  is bioavailability of sildenafil; Q  is hepatic 
plasma flow (34.2 and 11.4 ml/min/kg for rats and man respectively)[312]. 
 
6.2.3. Results  
 
Since the renal clearance of warfarin is negligible in both rats and man, it can be 
assumed to remain unchanged in the metabolism-based warfarin-drug interactions. 
The estimation of in vivo warfarin-sildenafil interaction was carried out by 
a H,P
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incorporating the in vitro enzyme kinetics data and some of in vivo data retrieved 
from the literature. The results obtained from in vitro metabolism study in rat liver 
microsomes (Figure 5.4 and Table 5.7), human liver microsomes (Figure 5.5 and 
Table 5.9) and human CYP450 isozymes (Figure 5.6 and Table 5.11) show that 
sildenafil has an inhibitory effect on all the hydroxylation pathways of warfarin 
enantiomers in rat and human liver microsomes, except on the 4’-hydroxyaltion and 
overall hydroxylation of (S)-warfarin in rat liver microsomes.  In rat liver microsome, 
sildenafil inhibits on the overall hydroxylation of (S)-warfarin with very low extent 
due to its activation effect on (S)-4’-hydroxylation. By incorporating the enzymatic 
kinetic data of the in vitro warfarin-sildenafil drug interaction with the in vivo kinetic 
information of the sildenafil retrieved from the literature [191], the magnitude of drug 
interaction with warfarin in the in vivo situation was projected. The predicted degree 
of inhibition on the in vivo clearance (including both hepatic and total clearance) of 
the two enantiomers of warfarin in rat and man in the presence of sildenafil is shown 
in Table 6.5.A.  
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Table 6.5(A). Prediction of the degree of inhibition in the in vivo hepatic and total 
clearance of (S)-and (R)-warfarin by sildenafil in rats and man. 
a: Data were obtained with use of Cu,i,max,liver were calculated without assumptive active 
transport. (A=1) 
b: Data were obtained with use of Cu,i,max,liver were calculated with assumptive active transport. 
(A=8) 
 
Rat   Human  CYP450 isozyme 
 CL’H/CLH  CL’H/CLH CL’/CL  CL’H/CLHCL’/CL CL’/CL 
(S)-warfarin         
Observed in vivo 
datac NA 0.96 0.98  NA NA  NA 
     
 
NA 
   
6-Hydroxylation 0.99a (1.04) 0.99a (1.02)  0.97a 0.97a  0.99a 0.99a
 0.99b (1.03) 0.99b (1.01)  0.91b 0.91b  0.96b 0.96b
  
7-Hydroxylation 0.99a (1.04) 0.99a (1.02)  0.98a 0.98a  0.92a 0.93a
 0.98b (1.02) 0.98b (1.00)  0.90b 0.92b  0.67b 0.66b
 0.97a 0.97a  0.92a 0.93a
 NA NA  0.82b 0.83b  0.63b 0.64b
        
(R)-warfarin  
    
4’-Hydroxylation NA NA NA NA  NA NA 
 NA NA  NA  NA NA 
      
       
         
Overall 
Hydroxylation NA NA 
 
       
Observed in vivo 
data c 0.93 0.96 NA  NA NA  NA 
     
4’-Hydroxylation 0.99a (1.07) 0.99a (1.04)  
 0.98b (1.06) 0.98b (1.02) 
     
6-Hydroxylation 0.99a (1.07) 0.99a (1.04)  0.99a 0.99a  0.93a 0.93a
 0.99b (1.07) 0.99b (1.03)  0.95b 0.95b  0.78b 0.80b
 
7-Hydroxylation 0.99a (1.07) 0.99a (1.03)  0.99a 0.99a  0.99a 0.99a




a (1.06) 0.99a (1.03)  0.96a 0.96a  0.89a 0.88a
 0.95b (1.01) 0.95b (1.01)  0.78b 0.80b  0.57b 0.60b
    
NA NA  NA NA 
 NA NA  NA NA 
    
        
       
c: Unpublished data (Data was obtained from the previous in vivo drug interaction study of 
warfarin and sildenafil in rats; Eli Chan and Chen Xin) 
NA=No data available 
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Table 6.5(B). Prediction of the degree of inhibition in the in vivo hepatic and total 
clearance of (S)-and (R)-warfarin by sildenafil in rat and man (repeated study) 
 Rats  Human 
 CL'H/CLH  CL'H/CLH CL'/CL CL'/CL 
(S)-warfarin      
Observed in vivo datac 0.98    0.96 
    
4-Hydroxylation* 0.99a (1.04) 0.99a (1.02)  NA 
 0.98b (1.02) 0.98b (1.00) NA 
   
6-Hydroxylation 0.99a (1.04) 0.99a (1.02)  0.99a 0.99a
 0.99b (1.03) 0.99b (1.01)  0.97b 0.98b
  
7-Hydroxylation 0.99a (1.04) 0.99a (1.02)  0.97a 0.97a
 0.98b (1.02) 0.98b (1.00)  0.81b 0.82b
 
Overall Hydroxylation* 0.99a (1.04) 0.99a (1.02)  0.97a 0.97a





   
    
     
     
(R)-warfarin      
Observed in vivo datac 0.96  0.93   
     
4-Hydroxylation NA NA 
 NA 
 
6-Hydroxylation 0.99a (1.07) 0.99a (1.04)  0.97a 0.97a
 0.98b (1.05) 0.97b (1.01)  0.86b 0.87b
7-Hydroxylation 0.98a (1.06) 0.98a (1.03)  0.99a 0.99a
 0.89b (1.05) 0.90b (1.07)  0.96b 0.96b
    
NA  0.97a 0.98a
NA NA  0.87b 0.87b
  
 
 NA NA 
NA  NA NA 
     
      
  
Overall Hydroxylation NA 
 
    
a: Data were obtained with use of Cu,i,max,liver were calculated without assumptive active 
transport. (A=1) 
b: Data were obtained with use of Cu,i,max,liver were calculated with assumptive active transport. 
(A=10) 
c: Unpublished data (Eli Chan and Chen Xin) 
NA=No data available 
*data were calculated based on inhibitory effect of sildenafil at low concentration of warfarin 




For warfarin-sildenafil interaction in rats, the prediction on the degree of inhibition in 
the in vivo hepatic and total clearance of both (S)-and (R)-warfarin in rats was 
performed based on the results of the in vitro metabolic drug interaction of warfarin 
and sildenafil from both the present and repeated studies. The predicted degree of 
inhibition of oral clearance by sildenafil was in good agreement with the observed 
values obtained from the in vivo studies (Table 6.5), indicating that sildenafil weakly 
affects either the hepatic and/or total clearance of warfarin enantiomers in rat possibly 
due to its lower tissue concentrations in the liver (Cu,i,max,liver = 14.4 µM, when active 
transport, A=8, was assumed) compared to the Ki values (Table 6.3) obtained from the 
in vitro study.  
 
In the present study, regardless of the individual or overall hydroxylation pathways 
based, the predictions on the degree of decrease of hepatic and total clearance of (S)-
and (R)-warfarin were overestimated when no active transport (A=1 in equation 6.17) 
was taken into consideration (Table 6.5.A). When active transport was assumed 
(A=8), the prediction was generally improved. The most accurate predications for the 
degree of inhibition of sildenafil on hepatic (CL’H/CLH) and total clearance (CL’/CL) 
of (S)- warfarin were based on (S)-7-hydroxylation (FEj=1.02 for CL’H/CLH and 
FEj=1.00 for CL’/CL) while those for (R)-warfarin were based on overall 




For the repeated study, as shown in Table 6.5 B, the most accurate prediction for the 
inhibition degree of sildenafil on the hepatic and total clearance of (S)-warfarin was 
based on overall hydroxylation (FEj=1.02 for CL’H/CLH and FEj=1.00 for CL’/CL), 
but those for (R)-warfarin were based on (R)-6-hydroxylation (FEj=1.05 for 
CL’H/CLH and FEj=1.01 for CL’/CL) when active transport (A=8) was assumed.  
 
 
To our knowledge, the in vivo clearance data for warfarin in the presence of sildenafil 
in man was not available. Due to the lack of information, the accuracy of the 
predictability of this in vitro approach could not be evaluated for man. Based on the 
prediction, in man, the total clearance values of (S)-warfarin and (R)-warfarin are 
expected to be decreased by 8~20% and 13~20%, respectively, whereas the decrease 
in hepatic clearance are estimated to be decreased by 10~21% for (S)-warfarin and 14 
~22% for (R)-warfarin, when co-administered with 50mg of sildenafil. It is 
worthwhile to note that sildenafil has a more potent inhibitory effect in man than in 
rats.  
 
An important assumption in our predictive approach is that only hepatic first-pass 
metabolism is affected by the interacting drug. However, it is known for 
substrates/inhibitors of CYP2C9 and CYP3A4, significant first-pass metabolism may 
also occur in the epithelium of the small intestine. Since CYP2C9 and CYP3A4 are 
the cytochrome P450s isozymes responsible for the clearance of (S) and (R)-warfarin, 
respectively as well as for that of sildenafil, the influence of sildenafil on the 
clearance of warfarin enantiomers may be underestimated if sildenafil is able to affect 
the CYP3A4-mediated hydroxylation of warfarin in gastrointestinal tract.  
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Although the in vitro hepatic microsomal system can be used to predict the likelihood 
of most of the metabolic warfarin–drug interactions since the major metabolic 
pathway of the metabolism of the more potent (S)-warfarin is via hydroxylation in 
both rats and man, the in vitro approach was not a good choice for some interacting 
drugs, such as 5-fluorouracil, which affect the metabolism of warfarin via other 
mechanism, such as altering the expression of hepatic cytochrome P450 [329, 330]. In 
this case, only the in vivo study in animals can help to forecast the likelihood of the 
drug interactions.  
 
In summary, a useful approach was employed in this study to quantitatively predict in 
vivo warfarin-sildenafil interactions involving the alterations of the metabolism and in 
vitro serum and liver microsomal protein binding of warfarin enantiomers data. 
However, some uncertainties still remain regarding to the estimation of the effective 
concentrations of inhibitions at the site of interaction. Better insights into this aspect 
are crucial for improving the accuracy in the forecasting drug-drug interactions. 
Moreover, clinical study of these two drugs should be investigated to evaluate for the 
better understanding on warfarin and sildenafil drug interaction. Our in vitro data can 
also be used to evaluate the extent to which this in vitro data is predictive of the actual 




CONCLUSION AND FURTHER STUDY 
 
According to the reported case studies, there may have serious drug interaction 
between warfarin and sildenafil [200] and concurrent use of anticoagulant and 
sildenafil can lead to increase the patient’s International Normalized Raito (INR) 
[201]. The interaction can be occurred due to the fact that both warfarin and sildenafil 
are highly bound to plasma protein binding as well as both of them are cleared from 
the body by the Cytochrome P450 enzymes dependent metabolic pathway. Moreover, 
warfarin possesses very low therapeutic index. As such properties of warfarin, it has a 
high possibility to interact with other drugs. Based on these assumptions, we 
investigated metabolic drug interaction between warfarin and sildenafil in this study.  
 
The displacement of one drug to the protein binding site of other drug can increase the 
free fraction of the other drug which can lead to potentiate its action.  Thus, we have 
examined the interaction of warfarin and sildenafil in the serum protein binding. The 
result indicates that warfarin and sildenafil have no influence on each other in the 
serum protein binding. However, we observed that both of warfarin and sildenafil are 
rarely bound to liver microsome. Each of them hardly effect on the microsome 
binding of another drug at low concentration. However, the displacement effect of 
sildenafil on liver microsomal protein binding of both (S)-and (R)-warfarin was 
observed at high sildenafil concentration and positive allosteric effect was found at 
high warfarin concentration.  
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The results from in vitro metabolism study suggest that sildenafil exhibits more potent 
inhibitory effect on the hydroxylation of warfarin enantiomers in human liver 
microsomes. However, in rat liver microsomes, it acts as a weak inhibitor for the 
hydroxylation of either (S)-or (R)-warfarin. The inhibitory effect of sildenafil is 
selectively towards on (R)-warfarin hydroxylation in both rat and human liver 
microsomes.  
 
Finally, based on the in vitro data, the prediction of the effect of sildenafil on the 
clearance of warfarin was investigated. It is noted that sildenafil has some inhibition 
effect on the oral clearance of warfarin. Therefore, the precaution must be taken when 
warfarin and sildenafil are administered concurrently in patients.  
 
In the present study, in vitro models provided encouraging results with respect to 
predicting metabolic pharmacokinetic drug interactions of warfarin with sildenafil in 
man. In this regard, in vitro drug interaction studies will mainly be helpful in 
narrowing down the number of clinical studies that must ultimately be performed if 
they are conducted in the early stage of drug interaction studies.  
 
To date, there has not been published data for the clinical study for the interaction of 
warfarin and sildenafil. Based on the present in vitro metabolism data, further studies 
can be conducted in man to obtain the most definitive data on the probability and 
magnitude of warfarin interaction with sildenafil. In addition, the further study can be 
conducted on the in vitro metabolism study using other in vitro models, such as 
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